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The purpose of the study was to characterize and compare demographic and clinical 
characteristics, treatment patterns (i.e., medication adherence, persistence, addition, and 
switching), and healthcare utilization and cost (i.e., all-cause and epilepsy-related) associated with 
refractory or non-refractory epilepsy. The study used Texas Medicaid claims data from 09/01/07-
12/31/13. Prescription and medical service claims of eligible patients analyzed over a 30-month 
study period comprised of a 6-month pre-period (baseline) and a 24-month follow-up period 
(annual increments). Patients eligible for the study: 1) were between 18-62 years of age, 2) had a 
prescription claim for an antiepileptic drug (AED) during the identification period (03/01/08-
12/31/11) with no baseline use of an AED and no prophylactic use of an AED at follow-up, and 
3) had evidence of epilepsy diagnosis during the study period. Additionally, patients had to be 
continuously enrolled in Texas Medicaid with no dual eligibility for Medicare and Medicaid. The 
index date for both the cohorts was the date of the first AED claim. Dependent variables included: 
treatment patterns, healthcare utilization and cost. The primary independent variable was group 





patients were categorized as “refractory” (i.e., three or more AEDs, excluding diazepam, in the 
identification period) and “non-refractory” (i.e., less than three AEDs in the identification period). 
The covariates included age, gender, race/ethnicity, type of epilepsy, type of index AED, baseline 
CCI, number of psychiatric comorbidities and presence of non-psychiatric comorbidities at follow-
up, baseline pill burden, presence of baseline all-cause inpatient visits, baseline number of all-
cause outpatient visits, and baseline all-cause total cost. Using a retrospective matched-cohort 
design, patients in the refractory cohort were matched 1:1 to patients in the non-refractory cohort 
using propensity scoring. The matched cohorts were compared for treatment patterns and 
healthcare utilization and costs using multivariate conditional regression models and non-
parametric methods. 
Of the 10,599 eligible patients, 2,789 (26.3%) patients in the refractory cohort were matched 
1:1 to patients in the non-refractory cohort for a total of 5,596 patients. Mean (± SD) age of the 
patients in the matched cohort was 38.0 (± 13.1) years, and the cohort was comprised of a higher 
proportion of females (56.0%), Caucasians (41.9%), patients with other convulsions (77.2%), and 
those with claims for sodium channel blockers (35.4%). A higher proportion of patients with 
refractory epilepsy were initiated on combination AEDs (26.5% vs. 10.7%), followed by GABA 
analogues (12.0% vs. 10.2%), and calcium channel action agents (7.7% vs. 3.4%) compared to 
patients with non-refractory epilepsy. During the second year of follow-up, patients with refractory 
epilepsy had a higher mean (± SD) (2.1 [± 1.5] vs. 1.8 [± 1.4]) number of psychiatric comorbidities, 
and a higher proportion (51.3% vs. 41.4%) of patients had one or more non-psychiatric 
comorbidities compared to patients with non-refractory epilepsy. Regarding treatment patterns, 
compared to patients with non-refractory epilepsy, patients with refractory epilepsy were 3.6 times 





(HR=0.653; 95% CI=0.608-0.702; p<0.0001) lower hazard rate of discontinuation of AEDs during 
the second-year of follow-up, after controlling for covariates. Among those patients on two or 
more AEDs, patients with refractory epilepsy were 3.7 times (OR=3.723; 95% CI=2.902-4.776; 
p<0.0001) more likely to add an alternative AED and 3.6 times (OR=3.591; 95% CI=3.010-4.284; 
p<0.0001) more likely to switch to an alternative AED during the first-year of follow-up, after 
controlling for covariates. Regarding healthcare utilization and costs during the second year of 
follow-up, compared to patients with non-refractory epilepsy, patients with refractory epilepsy had 
a significantly higher number of all-cause outpatient visits (p<0.0001) and pharmacy claims 
(p<0.0001), higher epilepsy-related inpatient hospital and emergency department (ED) visits 
(p<0.0001), outpatient visits (p<0.0001), and pharmacy (p<0.0001) claims, after controlling for 
covariates. Consequently, these patients incurred higher costs for all-cause outpatient visits 
(p=0.0190) and pharmacy claims (p<0.0001), and higher costs for epilepsy-related inpatient 
hospital and ED visits (p<0.0001), outpatient visits (p<0.0001), and pharmacy (p<0.0001) claims, 
after controlling for covariates. Although a majority of the estimates were higher than the second 
year of follow-up, a similar trend in results was observed during the first-year of follow-up. 
In conclusion, findings from this study provide evidence for the dynamic patterns of AED 
use in clinical practice and provide current estimates of the resource utilization and costs associated 
with Texas Medicaid patients with refractory epilepsy. Management of epilepsy extends beyond 
the control of seizures and encompasses improvement in overall burden of the disease. As the costs 
in the second year were lower than in the first year, timely identification and early treatment 
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HVFA Health Care Financing Administration 
AAN American Academy of Neurology 
AES American Epilepsy Society 
OXC Oxcarbazepine 
FDA Food and Drug Administration 
SC Sodium Channel blockers 
G Gamma-aminobutyric acid analogs 
SV2 Synaptic Vesicle protein 2A binding 
M Multiple mechanisms 
MMAS Morisky Medication Adherence Scale 
MPR Medication Possession Ratio 
BDI-II Beck Depression Inventory-II 
NDDI-E Neurologic Disorders Depression Inventory-Epilepsy 
PHQ-GAD 7 Patient Health Questionnaire-Generalized Anxiety Disorder7 





CCI Charlson Comorbidity Index 
GCN Generic Code Number 
NDC National Drug Code 
AHFS American Hospital Formulary Service 
PDC Proportion of Days Covered 
ICD-9-CM The International Classification of Diseases, 9th Revision, 
Clinical Modification 
CPT Current Procedural Terminology 
HCPCS Healthcare Common Procedure Coding System 
GEE Generalized Estimating Equation 
ZIP Zero-Inflated Poisson regression 
GLM Generalized Linear Models 
















Chapter 1 Introduction 
1.1 Background 
Epilepsy is the fourth most common neurological condition after migraine, stroke, and 
Alzheimer’s disease with a prevalence of 2.2 million cases and an annual incidence of 150,000 
new cases per year in the United States (U.S.).1,2 The age-adjusted prevalence of epilepsy ranges 
from 5 to 7.1 cases per 1,000 persons, while the age-adjusted incidence of epilepsy ranges from 
16 to 51 cases to 100,000 person-years. Also, the prevalence of epilepsy is higher in males than in 
females, while the age-adjusted prevalence is higher for African-Americans (8.2 cases per 1,000 
persons) as compared to Caucasians (5.4 cases per 1,000 persons).3 
In 1995, the average annual direct cost for epilepsy prevalent cases was $1,072 per case, 
while the per member per year direct cost for the treatment of epilepsy in 2009 was estimated at 
$8,206.4,5 Potential drivers for the high and increasing burden of epilepsy include costs associated 
with injury, hospitalization, and adverse effects on a patient’s mental health, which include 
anxiety, depression, and other cognitive impairment. The indirect costs drivers include epilepsy-
related absenteeism, disability, and impaired quality of life.  
Epilepsy treatment consists of vagal nerve stimulation, surgery, and pharmacotherapy. Due 
to the limited effectiveness of the first two options, pharmacotherapy is the foremost epilepsy 
treatment paradigm.6 A 1984 Scottish prospective study of 525 newly-diagnosed epilepsy patients, 
aged 9 to 93 years, reported that about half (47%) of the patients became seizure-free while 
receiving their first antiepileptic drug (AED), and 13% became seizure-free with the first 





have seizure remission with less than three trials of AED regimens, while the remaining 40% of 
patients are considered refractory or drug-resistant and are candidates for additional AED trials or 
epilepsy surgery (Figure 1.1).8 Further, about 1% of refractory patients may become seizure-free 
with a second alternative monotherapy, and 3% may become seizure-free with two AEDs.7 
Figure 1.1: Strategies for Managing Newly Diagnosed Epilepsy  
 
Source: Brodie et al. (2001)8 
The International League Against Epilepsy (ILAE) commission defines drug-resistant 
epilepsy (DRE) (often used inter-changeably with “uncontrolled,” “medically 
refractory/intractable,” or “pharmacoresistant”) as “failure of adequate trials of two tolerated and 
appropriately chosen and used AED schedules (whether as monotherapies or in combination) to 
achieve sustained seizure freedom.”9 Replicating the ILAE definition in population studies, the 
prevalence of refractory epilepsy in the U.S. population ranges from 1.7% to 29%.10-14 Estimates 
of DRE are heavily based on patient self-reported data from literature and expert panels. Very few 
studies have evaluated the utilization of AEDs using administrative claims databases while 





cost of care for establishment of epilepsy control in patients with refractory epilepsy is significant. 
The cost drivers include frequent hospitalizations and emergency department (ED) visits, longer 
hospital lengths of stay, and more neurologist, diagnostic imaging and other outpatient visits. 
Moreover, patients with refractory epilepsy are at an increased risk of fractures, head injuries, 
status epilepticus, motor-vehicle accident-related injuries, and sudden death.13 The risk of sudden 
death among patients with refractory epilepsy is about 1.1 to 5.9 per 1,000 person-years with a 
cumulative probability of death of 8.7% at 6 years as compared to patients without refractory 
epilepsy.15-17  
Previous studies by Manjunath et al. (2012), Chen et al. (2013), and Cramer et al. (2014) 
used commercial claims to quantify the economic burden of refractory epilepsy in adults.11,13,18,19 
Manjunath et al. assessed the burden among the Medicaid populations in Florida, Iowa, Kansas, 
Missouri, and New Jersey, and reported high health care utilization and costs for the patients with 
refractory epilepsy.13 With more than half of Medicaid recipients living in poverty and having 
physical or cognitive limitations, refractory epilepsy is particularly debilitating for these patients.13 
In patients with refractory epilepsy, when monotherapy fails, a small percentage of patients 
(14%) become seizure-free by switching to an alternative monotherapy.8,20 Also, previous studies 
have hypothesized that small differences in between-product bioavailability from switching 
between brand-name and generic versions of AEDs, even within the narrow bounds of allowable 
variation that determine bioequivalence, can lead to adverse clinical outcomes. Studies have 
reported recurrence of seizures, high switchback rates from generic to brand name AEDs, and 
subsequent high health resource utilization due to antiepileptic drug substitutions.21-23 As a result, 





 Choosing an alternative AED from the many AEDs available is often a problem for the 
practicing physician. The drug selection may differ due to such things as formulary restrictions 
and an individual’s reaction to medications. However, determining the optimal combination of 
AEDs is an area that is not yet well defined. Previous studies have illustrated the clinical efficacy 
of adding an AED over placebo or no treatment in patients with epilepsy; however, direct 
comparison between individual trials has not been possible due to baseline differences in the 
population. The concept of “rational polytherapy” has gained increased attention in epilepsy. 
Rational polytherapy indicates that AED combinations with different mechanisms of action 
(MOAs) are more effective than AED combinations with similar MOAs.20,25,26,27 In light of the 
limited evidence to support the optimal combination of AEDs, refractory epilepsy treatment 
patterns in real world clinical practice need to be evaluated.  
Data from a national survey indicate that 18% of the individuals with epilepsy were 
covered by Medicaid in the U.S. in 1994.28 There is concern that patients on Medicaid may not be 
adherent to their regimen, which is associated with serious outcomes. A quarter of patients with 
epilepsy covered by Medicaid during the period from January 1997 to June 2006, in Florida, Iowa, 
and New Jersey were non-adherent to their AED regimen.29 The lifetime prevalence of epilepsy in 
the state of Texas was reported to be 1.7% in 2005.30 About 16% of Texans are enrolled in the 
Medicaid program.31 Given the limited resources of the enrollees, the clinical burden of refractory 
epilepsy on the patients and the economic burden on the state need to be quantified. Also, previous 
studies have assessed epilepsy-related healthcare utilization before the U.S. Food and Drug 
Administration (FDA) approval of third-generation AEDs (e.g., rufinamide, retigabine/ezogabine, 
clobazam, lacosamide, and eslicarbazepine acetate were approved after 2008).10,24,29,32 In the 





medications, it is imperative to evaluate the treatment patterns and associated economic outcomes 
in recent times. 
1.2 Study Aim 
To better understand refractory epilepsy in Medicaid patients, this study uses Texas Medicaid 
medical and prescription claims data to characterize and compare the demographic and clinical 
characteristics, treatment patterns (consisting of medication adherence and persistence, and adding 
or switching to alternative therapy), and healthcare utilization and costs associated with patients 
who have refractory or non-refractory epilepsy. 
1.3 Study Relevance 
Findings from this study about treatment patterns, resource utilization, and healthcare costs 
using real world data can be useful in filling a missing gap in the currently published literature. 
Evidence on patterns of AED use in clinical practice may contribute to the understanding of seizure 
control, and may thereby reduce subsequent epileptic events and costs. Likewise, the results of the 
analyses can help identify unmet needs in the epileptic population by improving seizure control, 
promoting better medication use behavior, and reducing economic burden. The results can also 





Chapter 2 Literature Review 
Chapter Overview 
This chapter is divided into two sub-sections: epilepsy and refractory epilepsy. The first 
sub-section describes the epidemiology, management, economic, and humanistic burden of 
epilepsy. The second sub-section includes a detailed discussion on the definition, prevalence, and 
economic burden of refractory epilepsy. This chapter concludes with a discussion of AED 
treatment patterns and the impact of comorbid conditions on refractory epilepsy. Finally, it 
discusses Texas Medicaid, summarizes the literature, and lists the objectives and hypotheses of the 
study.  
2.1 Epilepsy 
2.1.1 Definition, Classification and Etiology of Epilepsy 
There is an ongoing debate regarding the classification of epilepsy as a disease or a 
syndrome.33,34 The Commission of the ILAE describes an epileptic syndrome as “an epileptic 
disorder characterized by a cluster of signs and symptoms customarily occurring together; which 
include the type of seizure, etiology, anatomy, precipitating factors, age of onset, severity, 
chronicity, diurnal, and circadian cycling, and sometimes prognosis.” Thus, epileptic syndrome 
involves more than just the seizure type. In contrast, epilepsy disease is described as “a 
pathological condition with a single, specific, well-defined etiology.” This disease-syndrome 
distinction depends on the context of use.34 For simplicity and consistency, the ILAE and the 
International Bureau for Epilepsy (IBE) define epilepsy as “a disorder of the brain characterized 
by an enduring predisposition to generate epileptic seizures and by the neuro-biologic, cognitive, 





least one epileptic seizure, described as “a transient occurrence of signs and/or symptoms due to 
abnormal excessive or synchronous neuronal activity in the brain.”35,36 
Based on the mode of seizure onset, seizures are mainly classified as generalized and focal 
seizures. Generalized seizures originate at a point and rapidly distribute in bilateral networks of 
the brain, which include the cortical and subcortical structures. The clinical manifestation of these 
seizures may vary from mild alterations in consciousness to convulsions. Generalized epileptic 
seizures are further categorized as: tonic-clonic seizures, absence seizures, myoclonic seizures, 
clonic seizures, tonic seizures, and atonic seizures. Tonic-clonic seizures, also known as grand mal 
seizures, are characterized by loss of consciousness and stiffening of the body followed by 
contraction of the muscles; absence seizures, also known as petit mal seizures, include brief lapses 
in awareness; myoclonic seizures involve sudden muscular contractions; clonic seizures consist of 
alternating successions of contractions and relaxations of a muscle; tonic seizures are depicted by 
an onset of increased muscle tone; and atonic seizures are characterized by a sudden loss of muscle 
tone. In contrast to generalized seizures, focal seizures originate within networks limited to a single 
hemisphere. These seizures may manifest with or without impairment of consciousness or 
awareness depending on the disruption in brain activity. Seizures can also be categorized as 
belonging to the unknown type.35,37 Table 2.1 summarizes the classification of seizures as adopted 














Table 2.1: Classification of Seizures 
Generalized seizures 
     Tonic–clonic (in any combination)  
     Absence 
           Typical 
           Atypical 
           Absence with special features 
                  Myoclonic absence 
                  Eyelid myoclonia  
      Myoclonic 
            Myoclonic  
            Myoclonic atonic  
            Myoclonic tonic 
       Clonic  
       Tonic  
       Atonic 
Focal seizures  
Unknown 
        Epileptic spasm 
 
Seizure that cannot be clearly diagnosed into one of the preceding categories is considered 
unclassified until further information allows their accurate diagnosis. This is not considered a 
classification category. 
Source: Berg et al. (2010)
35 
The underlying cause of epilepsy may be genetic, structural, or unknown. Epilepsy may be 
a symptom of a known genetic deficit or an environmental external factor that may contribute to 
the expression of the disease. Structural or metabolic conditions such as stroke, trauma, infection, 
or tuberous sclerosis may increase the risk of developing epilepsy. The etiology of epilepsy may 







2.1.2 Epidemiology of Epilepsy 
Epilepsy affects about 1% of adults in the U.S.38 National estimates of the prevalence of 
epilepsy are scarce. The earliest report by the Centers of Disease Control and Prevention (CDC) 
found the overall prevalence of epilepsy to be 4.7 cases per 1,000 persons during 1986 – 1990.39 
Recent estimates from a composite of studies conducted in the U.S. (1978 – 2005) suggest that the 
incidence of epilepsy is bimodal, with peak incidence rates in young children and older adults, 
while the number of people with epilepsy at any point in their lifetime increase as age increases.37 
Figure 2.1 depicts the prevalence of epilepsy by age (1978-2005). 
Figure 2.1: Prevalence of Epilepsy by Age in the U.S. (1978-2005)  
 
 
Source: England et al. (2012)37 
 
Children and adolescents have seizures due to genetic or unknown causes, while severe 
head injury, stroke, and tumor are frequently considered as triggers of seizures in adults. Unlike 



















differently to medications and have different side effects. As a result, they typically need more 
frequent dose adjustments. Moreover, as brain development is rapid in the initial years of life, 
children require regular monitoring to assess the impact of seizures and treatment on cognition and 
learning abilities that reflect ongoing maturational changes. Also, the frequency of seizures 
experienced by children is much higher than those experienced by adults. As a result, the 
neuropsychological compromise seen in children is much more widespread than in adults.40 This 
heterogeneity makes it a challenge to study epilepsy in children, and most studies using 
administrative claims data have focused on understanding the etiology and burden of epilepsy in 
adults.  
If a patient is being treated for epilepsy, and the most recent seizure occurred within two 
and five years, the patient is characterized as having active epilepsy.41 Data from the National 
Health Interview Survey (NHIS) indicated that about 1.9% of adults with annual family income 
levels less than or equal to $34,999 had active epilepsy in 2010.38 In the Ohio Medicaid program, 
the prevalence of active epilepsy was 13.2 cases per 1,000 persons, and the incidence was 362 
cases per 100,000 person-years from 1992 – 2006.42 According to a report by the ILAE, IBE, and 
the World Health Organization (WHO), the low-income population in the U.S. carries a 
disproportionate amount of epilepsy burden, and deserves attention for its health care needs and 
supportive services.43 
Patients with epilepsy are at a higher risk of mortality than the general population. The 
causes of death in patients with epilepsy include internal causes, such as cardiovascular and 
cerebrovascular diseases, neoplasms, and pneumonia, and external causes, such as suicide, 





patients with epilepsy have a 1.6-11.4 times greater mortality rate than patients without epilepsy.44 
Also, the rate of sudden unexplained death in epilepsy (SUDEP) is reported to be nearly 24 times 
higher than the general population expected death rate, with a standardized mortality ratio of 23.7% 
and overall incidence of 0.35 cases per 1,000 person-years.15-17 SUDEP is defined as sudden, 
unexpected, non-traumatic, and non-drowning death in patients with epilepsy. In the U.S., about 
2,000 deaths occur each year due to SUDEP. The years of potential life lost to SUDEP is 73,000 
per year, which outweighs the values for multiple sclerosis, Alzheimer’s disease, and Parkinson’s 
disease.44 The rates of SUDEP and epilepsy-related mortality are estimated to be higher in adults 
than in children.45 
2.1.3 Treatment of Epilepsy 
The therapies commonly used to prevent seizures include pharmacotherapy, diet changes, and 
brain surgery. Vagus Nerve Stimulation (VNS) is another option, when other treatments are not 
effective.  
2.1.3.1 Pharmacotherapy 
Medications used to treat seizures can be grouped by two classifications; generation and 
mechanism of action (MOA). 
2.1.3.1.1 Generations of Antiepileptic Drugs 
Pharmacotherapy consisting of AEDs available before 1980 are classified as “first-
generation,” those available after 1993 are classified as “second-generation,” and those available 





have better safety and tolerability profiles.48,49 AEDs classified as first, second, and third 
generation are listed in Table 2.2, while Table 2.3 displays the most common AED regimens used 
in adults listed by year of introduction.48,50 
Table 2.2: List of Antiepileptic Drugs 
Generation Generic Name Brand Name 
First Generation Phenobarbital Luminal® 




Carbamazepine Carbatrol®, Epitol®, Equetro®, 
Tegretol® 
Valproate/valproic acid Depakote®, Depakene®, Stavzor® 
Clonazepam Klonopin® 




Gabapentin Gabarone®, Gralise®, Neurontin® 
Fosphenytoin Cerebyx® 
Diazepam Diastat® 




Third Generation Lacosamide Vimpat® 













Suggested titration Suggested range of 
average target dose (total 











50–100 mg every 3–5 days; beyond 
200 mg in 25–30 mg steps 
200–300 mg; bid, tid Idiosyncratic rash; rarely 
pseudolymphoma; peripheral 
neuropathy; Stevens-Johnson 









250 mg daily every 4-7 days 500 mg; qd Rarely idiosyncratic rash; Stevens-




1 g or less in 4-6 divided doses daily 
 
2-3 g daily 
 
Blood problems; liver problems; 
swollen glands; lupus; serious rash 
Carbamazepine  
(1963) 
200 mg every 3 days 600–1200 mg; bid or tid Idiosyncratic reactions; rarely 
Stevens-Johnson syndrome; 












Suggested titration Suggested range of 
average target dose (total 





500 mg every 3–7 days 600–1500 mg; bid slow 
release, tid 
Teratogenicity; rarely acute 
pancreatitis; hepatotoxicity; 
thrombocytopenia; encephalopathy; 
polycystic ovarian syndrome 
Clonazepam 
(1975) 




150 mg every 3–7 days 800–1800 mg; bid, tid Idiosyncratic rash; hyponatraemia 
Zonisamide 
(1990) 
25 mg 300 mg; bid Rash; rarely blood dyscrasias 
Lamotrigine  
(1991) 
Monotherapy: 25 mg for 2 weeks, 50 
mg for the next 2 weeks, then 
increases of 50–100 mg/week.  
Add-on in the presence of Valproic 
acid: 25 mg every other day for 2 
weeks, 25 mg/day for the next 2 
weeks, then increases of 25–50 
mg/week. 
Add-on in the presence of enzyme-
inducing AEDs: 50 mg for 2 weeks, 
100 mg for the next 2 weeks, then 
increases of 50–100 mg/week. 
100–400 mg; qd, bid Idiosyncratic rashes; rarely 
Stevens-Johnson syndrome; Toxic 
epidermal necrolysis; liver failure; 










Suggested titration Suggested range of 
average target dose (total 









300 mg every 1-3 days 900–2400 mg; bid, tid Paradoxical increase in seizures 
Fosphenytoin 
(1996) 
Expressed as phenytoin sodium 
equivalents. 1.5 mg of fosphenytoin 
sodium is equivalent to 1 mg 
phenytoin sodium.  
Loading dose of 15-20 mg PE/kg 
administered at 100-150 mg PE/min 
4–6 mg PE/kg/day in 
divided doses 
 





Rectal get dose of 0.2 mg/kg of body 
weight to treat no more than five 
episodes per month and no more than 
one episode every 5 days. 
 
A second dose, when 
required, may be given 4-12 
hours after the first dose. 
 
Sedation; agitation; chest pain; rash 
Topiramate 
(1995) 
25 mg for 1–2 weeks; beyond 100 
mg, 25–50 mg per week 
100–400 mg; bid 
 




















Suggested titration Suggested range of 
average target dose (total 









Monotherapy: 100 mg twice daily 
increased at weekly intervals to 150-
200 mg twice daily. 
Adjunctive therapy: 50 mg twice 
daily increased at weekly intervals to 
100-200 mg twice daily. 
200-400 mg; qd Dizziness; nausea; vomiting 
Rufinamide 
(2008) 
400-800 mg per day administered in 
two equally divided doses increased 
by 400-800 mg every other day until 
a maximum daily dose of 3200 mg in 
two equally divided doses. 
3200 mg; qd Dizziness; nausea; diplopia; ataxia 
Vigabatrin 
(2009) 








150 mg per day 
 













Suggested titration Suggested range of 
average target dose (total 





2 mg once daily 4-12 mg; qd Dizziness; somnolence; fatigue; 
irritability; falls; nausea; weight 
gain; vertigo; ataxia; headache; 





400 mg once daily increased to 800 
mg once daily after one week. 
 
800-1200 mg; qd Dizziness; headache; diplopia 
AED = Antiepileptic drug 
qd = quaque die (once a day); bid = bis in die (twice a day); tid = ter in die (three times a day) 
Source: Schmidt, 2009; Druga-FDA; Brodie et al. (2011); Duncan et al. (2006); Lason et al. (2006); Rho et al. (1994); Bazil et al. (2003); Uthman, (2000); 





2.1.3.1.2 Mechanism of Action of Antiepileptic Drugs 
Table 2.4 lists the MOA of AEDs based on the foremost targets at therapeutic 
concentration.51 Figure 2.2 depicts the main targets of AEDs.52 The most common targets among 
AEDs are sodium channels. The voltage-dependent sodium channels generate both normal action 
potentials and seizures. Antagonists of sodium channels prolong the time of the channel 
inactivation during epileptic discharges. Inactivation leads to conformational changes from an 
open channel to a non-conducting state. Carbamazepine, derivatives of carbamazepine (i.e., 
eslicarbazepine acetate, oxcarbazepine), phenytoin, fosphenytoin, ethotoin, lamotrigine, and 
rufinamide bind to the fast-inactivated state of the voltage-gated sodium channel through isoforms 
such as Nav1.1–Nav1.4, Nav1.6, and Nav1.7. In contrast, lacosamide binds to the slow-inactivated 
state of the voltage-gated sodium channels through isoforms Nav1.5, Nav1.8, and Nav1.9, which 
reduces the channel conductance.51,53 
Benzodiazepines, barbiturates, vigabatrin, and tiagabine target the synaptic Gamma-
aminobutyric acid (GABA) transmission. Diazepam, clonazepam, clobazam, phenobarbital, and 
primidone work as GABAA receptor agonists. Activation of GABAA receptor generates fast 
inhibitory postsynaptic potentials, which inhibit seizures. GAT-1, a GABA transporter, 
participates in GABA uptake and is the target for the efficient antiepileptic drug tiagabine. 
Vigabatrin is an irreversible GABA transaminase inhibitor. Inhibition of GABA transaminase, an 
enzyme that carbolizes GABA, increases the GABA level in brain tissue and leads to an elevated 
seizure threshold.51,53  





foremost mechanism of action of gabapentin, pregabalin, and ethosuximide is blockage of calcium 
channels; gabapentin and pregabalin block the high-voltage-activated calcium channel of the P/Q-
type, and ethosuximide blocks the low-voltage-activated calcium channel of the T-type. This 
prevents synchronized depolarization of neurons, resulting in seizure control.51,53 Valproic 
acid/sodium valproate, felbamate, topiramate, and zonisamide have multiple MOAs. The 
mechanism of valproic acid is not fully known. It may act through a combination of mechanisms 
involving sodium flux, potassium channel inhibition, and modulation of GABA levels. Felbamate 
has dual actions in inhibiting N-methyl-D-Aspartate (NMDA) and potentiating (GABA) brain 
mechanisms.54 Topiramate prolongs inactivation of sodium channels, acts as a GABAA agonist, 
and a non-NMDA glutamate rector antagonist. Perampanel is an antagonist of the glutamate 
receptor. Zonisamide blocks sodium channels and T-type calcium channels, binds to the GABA 
receptor, and facilitates dopaminergic neurotransmission.51,55 
Levetiracetam binds to stereoselective sites on synaptic vesicles in the central nervous 
system, inhibits N-type calcium channels, and reverses inhibition of GABA and glycine-gated 
currents. Retigabine/ezogabine acts as a potassium channel agonist. Specifically, retigabine binds 
to a hydrophobic amino acid pocket and stabilizes the neuronal Kv7 channels in an open 
conformation preventing epileptic discharges. Kv7, a subfamily of the voltage-dependent 
potassium channels, regulates the response of neurons to excitation and forms a potent inhibitory 






Table 2.4: Mechanism of Action of Antiepileptic Drugs based on the Foremost Targets at 
Therapeutic Concentration 
Antiepileptic druga Target Mechanism 
Carbamazepine1, Eslicarbazepine 
Acetate2, Oxcarbazepine2, Phenytoin1, 









Lacosamide3 Blockade by stabilizing slow-
inactivated state 








Blockade of GABA 
transporter-1 






Blockade of high voltage-
activated channel (P/Q-type) 
Ethosuximide1 Blockade of low voltage-
activated channel (T-type)           
Sodium Valproate/Valproic Acid1, 
Felbamate2, Topiramate2, Perampanel3, 
Zonisamide2 
Multiple actions  
 
Various actions on multiple 
targets 
Levetiracetam2 SV2A actions Modulation of SV2A 
Retigabine/Ezogabine3 Potassium 
channel activity 
Opens Kv7 potassium 
channels 
GABA = Gamma-aminobutyric acid 
SV2A = Synaptic vesicle protein 2A 
aGeneration (see Table 2.2) 1 = First generation; 2 = Second generation; 3 = Third generation 


















Figure 2.2: Main Targets of Antiepileptic Drugs 
 
GABA = Gamma-aminobutyric acid 
Source: Duncan et al. (2006)52 
 
2.1.3.2 Vagus Nerve Stimulation 
VNS was first approved for use in 1997 as an adjunctive therapy in reducing seizure 
frequency in adults and adolescents (>12 years) with partial onset seizures not controlled by AEDs. 
VNS may also be used in treating generalized epilepsy.56,57  
The neurocybernetic prothesis (NCP) system of the VNS is an implantable pulse-generator 
surgically implanted into the upper left chest with the lead tunneled under the skin and wound 
around the left vagus nerve in the neck area. The VNS causes enhancement of inhibition by 
interrupting the events proceeding and leading to a seizure, thus preventing a seizure.56 Generally, 
implantation of a VNS device requires less than two hours and patients are discharged within 24 
hours. The follow-up visits among patients with VNS are similar to the regular visits among 





2.1.3.3 Surgery  
In patients who fail to achieve seizure remission with the use of AEDs, surgery may be 
used as a remediable option.59 The surgical intervention is determined by diagnostic tests that 
involve the use of electroencephalography (EEG), magnetic resonance imaging (MRI), positron-
emission tomography, single-photon-emission computed tomography, and neuropsychological 
testing.60 In the past, video EEG monitoring was performed on an inpatient basis with several days 
of continuous monitoring required to record a sufficient number of seizures, resulting in an 
expensive pre-surgical evaluation.61 In recent times, outpatient EEG recording with home-
monitoring systems, and the use of MRI and other modern diagnostic techniques, have made pre-
surgical evaluation less expensive. Few surgical procedures commonly performed to treat epilepsy 
include Anterior temporal lobectomy, amygdalohippocampectomy, neocortical resection, 
lesionectomy, multiple subpial transections, hemispherectomy and large multilobar resections, and 
corpus callosotomy.59 An estimated 70% and 25% of appropriately selected candidates may be 
seizure-free with temporal and frontal resection, respectively.62  
Despite the advances, surgery is often underutilized in patients with epilepsy in the U.S.63 
Data from the Nationwide Inpatient Sample (NIS) hospital discharge database (1990 - 2008) 
showed that the hospitalizations for lobectomy significantly (p<0.01) reduced from 6.9% during 
1990 – 1994 to 4.3% during 2004 – 2008.  Also, patients with Medicaid had notably lower rates 







2.1.4 Economic and Humanistic Burden of Epilepsy 
The impact of epilepsy is multi-faceted, affecting the economic, clinical, and humanistic 
outcomes of patients. In the case of economic burden, patients with epilepsy have higher healthcare 
utilization and costs than patients without epilepsy.4,5,64-66 In 1995, the average direct cost for 
epilepsy prevalent cases in the U.S. derived using population claims data was $6,429 per case over 
a 6-year period, and the annual direct cost of the 2.3 million extrapolated prevalent cases was $1.7 
billion. Indirect costs consisting of morbidity- and mortality-related costs accounted for 85% 
($10.8 billion) of the total healthcare costs.4 Data pooled from the 1996 – 2004 Medical 
Expenditure Panel Survey (MEPS) estimated the excess total medical expenditures for those with 
epilepsy at $4,523 (2004 dollars), with a mean unadjusted total expenditure estimated at $9,181 
(95% CI=$7,889 to $10,473) and the annual economic impact of epilepsy of the 2.1 million cases 
at $9.6 billion (95% CI=$6.7 billion to $12.4 billion) composed of medical expenditures and 
informal care.66 Among privately insured U.S. patients between 1999 through 2005, the direct 
annual cost for patients with epilepsy was $10,258 (2005 dollars) per patient with epilepsy-related 
costs of $2,057. Also, the annual indirect cost for employees with epilepsy was $3,192  (2005 
dollars).64 Kurth et al. (2010) assessed the health care resource utilization of patients using the 
Thomas-Reuters insurance database from 2005-2007, and found that patients with active epilepsy 
averaged 10 physician visits per year, 24 diagnostic tests or procedures per year, more than 30 
drug dispensings per year, and more than one ED visit per year.65 In 2009, the estimated direct 
health plan paid cost ($, per member per year) in the U.S. for treatment of epilepsy was $8,206.5  
Thus, there is heterogeneity in the estimates reported by previous studies. In summary, in 





the annual indirect cost comprising of morbidity- and mortality-related cost was estimated at 
$328,481 per-patient  (i.e., morbidity-related cost of $10,057 and mortality related-cost of 
$318,424).4 In 2005, the annual total direct cost was estimated at $10,258 per-patient and the 
annual indirect cost comprising of informal care days provided by family members was estimated 
at $3,192 per-patient.4,64 Further, the 1995 annual total direct cost of the 2.3 million cases with 
epilepsy was estimated at $1.7 billion, while the 2004 annual total direct cost of the 2.1 million 
cases with epilepsy was estimated at $9.5 billion.4,66  The direct cost estimates reported in 1995 
are conservative as the projections reflect the treatment patterns available through the mid-1990s. 
Newer therapies, such as VNS and the second- and third-generation AEDs available in recent 
years, were not included.  The epilepsy-related cost was estimated at $9,181 per-patient, in 2004, 
in a general population using survey data, while in 2005, it was estimated at $2,057 per-patient, in 
a privately insured population using claims data.64,66 Thus, direct comparison of these estimates 
are not possible due to differences in the patient population, type of costs included in the study, 
and methods used to quantify the burden. 
According to the WHO, disability due to epilepsy accounts for approximately 1% of the 
global burden of disease.67 The negative effects of epilepsy extend beyond the duration of 
individual seizures.68 Potential drivers for the high burden of epilepsy include injury, 
hospitalization, mortality, and adverse effects on a patient’s mental health, including anxiety, 
depression, and other cognitive impairment. The substantial indirect costs associated with epilepsy 
include medically-related absenteeism, disability, and affected quality of life. Epilepsy may affect 
the physical, social, neuropsychological, and psychological functioning of patients, and, thus, 





















2.2 Refractory Epilepsy 
2.2.1 Definition and Classification of Refractory Epilepsy 
Despite advances in epilepsy pharmacotherapy, about one-third of patients are drug-
resistant or refractory. These patients often receive polytherapy and additional AED trials are 
needed to identify optimal therapy. Figure 2.4 outlines the treatment outcomes of patients.  
Figure 2.4: Response with Antiepileptic Drug 
 






Early working definitions used to operationalize DRE (i.e., refractory epilepsy) among 
pediatrics and adults, evaluated seizure remission by assessing tolerability of drugs, and followed 
patients for 12-18 months (Table 2.5).7,70-72 Note that all three of the studies focused on pediatric 
patients and only one included adults. All the three diagnostic criteria had favorable observer 
agreement and were credible over long-term follow-up. In other words, as the length of follow-up 
increased, the outcome (i.e., refractoriness) became more apparent.73 
 
Table 2.5: Definitions of Drug-Resistant Epilepsy 
Author Patient population Definition 
Camfield and Camfield, 
199670  
Pediatrics Patients with an average of two or more 
seizures in each 2-month period during 
the last year of observation, despite 
treatment with at least three AEDs as 
monotherapy or polytherapy 
Kwan and Brodie, 20007 Pediatrics and adults Patients who had seizures without a 
seizure free status (i.e., lack of seizures 
of any type for a minimum of 1 year 
while receiving the same dose of AED 
or while not taking any medication) 
were considered to be refractory 
Berg, 200671,72 Pediatrics Failure of two medications for seizure 
control or failure of one for seizure 
control and two others for intolerable 
side effects, and at least one seizure per 
month on average over an 18-month 
period. A child could have up to but no 
more than a 3-month seizure-free period 









Recognizing the need to standardize DRE definitions and shorten the length of follow-up 
to diagnose refractoriness, the ILAE Commission on therapeutic strategies provided a two–
hierarchical level framework to define DRE in 2010.9 Level 1 is comprised of a broad 
categorization of outcomes to each therapeutic intervention (whether pharmacologic or non-
pharmacologic) and includes a minimum dataset needed for determining the outcomes. The 
categories of outcomes include “seizure-free,” “treatment failure,” and “undetermined,” which are 
further subdivided into three groups based on outcomes with respect to adverse effects (A: no 
occurrence; B: occurrence; and C: undetermined occurrence of adverse events) (Table 2.6). 
Capturing this information often aids clinicians in determining interventions.  
Table 2.6: Scheme for Categorizing Outcome(s) of a Drug Intervention for Epilepsy 
Seizure control Occurrence of adverse 
effects 
Outcome category 
1. Seizure-free A. No  





2. Treatment failure A. No  





3. Undetermined  A. No  














The minimum dataset required to determine whether the trial of an intervention is informative 
in an individual patient, as stated by the ILAE, includes: 
 Nature of the intervention (e.g., type of drug)  
 Mode of application (e.g., formulation, dose, dosing interval, and patient compliance)  
 Duration of exposure 
 Occurrence of seizures and adverse effects during the trial period 
 Whether there was any effort to optimize dose 
 Reason(s) for discontinuation (if applicable) 
o Unsatisfactory seizure control 
o Adverse effects 
o Long-term seizure freedom 
o Psychosocial reasons, for example, planning for pregnancy  
o Administrative reasons, for example, lost to follow up 
o Financial issues, for example, cannot afford treatment  
o Patient/caretaker preference  
o Other reasons  
Level 2 provides a core definition of DRE, which is defined as “failure of adequate trials 
of two tolerated and appropriately chosen and used AED schedules (whether as monotherapies or 
in combination) to achieve sustained seizure freedom.” This classification of DRE is valid for a 
given point in time and does not imply that a patient would never become seizure-free on further 
titrations of AEDs. After careful deliberation of the available evidence from prospective and 





definition to represent a testable hypothesis and to prevent delay in the evaluation.  In addition, 
consideration is also given to frequency of seizures and duration of follow-up.  
Using the scheme of level 1 (Table 2.6), drug resistance is defined as having a Category 2 
outcome for trials of at least two AEDs (monotherapy or in combination) without a Category 1 
outcome on the drug(s) currently taken. A patient may have a Category 1 outcome if seizure-free 
for a minimum of three times the longest pretreatment inter-seizure interval or for 12 months, 
whichever is longer.9  
The ILAE definition has been established as a valid and reliable measure to define 
refractory epilepsy in comparison to clinically significant constructs. Comparison of the ILAE 
definition with previously established definitions by Berg, Kwan and Brodie and Campfield and 
Campfield showed the highest interobserver (κ = 0.77 vs. κ = 0.56 vs. κ = 0.58 vs. κ = 0.69) and 
intraobeserver (κ = 0.82 vs. κ = 0.81 vs. κ = 0.82 vs. κ = 0.72) reliability. Also, the Phi correlation 
between the ILAE definition and the definitions by Berg (Φ = 0.75), Campfield and Campfield (Φ 
= 0.81) and Kwan and Brodie (Φ = 0.93) were high. This corroborates that the ILAE definition 









2.2.2 Prevalence Estimates of Refractory Epilepsy 
Applying the ILAE definition to clinical practice, the prevalence of refractory epilepsy 
ranges from 1.7% to 33% (Table 2.7).10-13,74,75 The estimates of the prevalence of refractory 
epilepsy have not been consistent due to differences in population selection, terminology, and 
characterization of epilepsy.  
Two studies conducted in Spain and Canada used the ILAE definition to classify refractory 
epilepsy. In 2012, a prospective study in Spain among 508 children less than 14 years of age treated 
for epilepsy reported the prevalence of refractory epilepsy as 10% (95% CI=7,13), 19% (95% 
CI=15,23) and 23% (95% CI=19,27) at two, six, and ten years after diagnosis, respectively.75 
Similarly, a 2014 retrospective chart review in an adult Canadian epilepsy center at Saskatchewan 
followed 250 patients with severe epilepsy (i.e., refractory epilepsy) with a mean (± standard 
deviation (SD)) duration of epilepsy of 22.6 (±14.0) years. The study estimated the point 
prevalence of refractory epilepsy at 33%.74 
Three studies conducted in the U.S. used working definitions of refractory epilepsy to 
operationalize refractoriness. These retrospective studies used population-based administrative 
claims data to characterize the patients. Manjunath et al. (2012) used a restrictive definition to 
develop a selection algorithm to replicate the levels of the ILAE definition using public and private 
insurance claims data. In addition to the ILAE criteria, this study also included restrictions 
regarding time for changes (i.e., 30 days) and requiring an ED visit or hospitalization. The study 
used Medicaid claims (1997 – 2009) for five states (Florida, Iowa, Kansas, Missouri, New Jersey), 
and private insurance claims data (1999 – 2008) from the Ingenix employer database. The study 





therapy (switch to a different compound or addition of an adjunctive compound) occurring at least 
30 days apart, followed by at least one epilepsy-related ED visit or hospitalization during the next 
365 days. An interval of at least 30 days between each AED therapy was used as a proxy to ensure 
that the AED changes occurred due to inadequate treatment and not due to tolerability issues. Any 
change in AED therapy occurring within 30 days was assumed to occur due to tolerability issues. 
The inclusion criterion requiring an epilepsy-related ED visit or hospitalization following an AED 
change restricted the study to patients with severe seizures (i.e., requiring ED visit or 
hospitalization). Thus patients who may have had drug changes but managed on an outpatient basis 
(i.e., not requiring ED visit or hospitalization) were not included, thus refractory epilepsy 
prevalence was likely underestimated. The study found the prevalence of refractory epilepsy to be 
3.2% in the 110,312 eligible Medicaid sample, and 1.7% in the 36,529 eligible employer 
population.13 The study’s more restrictive sample identification criteria may explain the relatively 
low prevalence estimates. 
Chen et al. (2013) evaluated the prevalence of refractory epilepsy in patients with partial 
epilepsy observed in the U.S. Thomson Medstat MarketScan commercial insurance database from 
2004 - 2008. Refractoriness was defined based on having three lifetime AEDs observed in the 
dataset. Patients were included in the refractory group on receiving the third AED. Since the onset 
of seizures could not be determined from the data, the study used a less restrictive definition that 
did not require patients to have an ED visit or hospitalization following the third AED therapy. 
Using this definition, the study reported the prevalence of refractory epilepsy to be 11% among 
the 79,149 eligible patients with partial epilepsy on commercial insurance in the U.S.10 Using the 
same U.S. Thomson Reuters MarketScan commercial database, Cramer et al. used a modified 





added AEDs to an existing regimen during the year of observation, were classified as refractory. 
Addition of AED(s) was defined as at least three months of baseline therapy, followed by at least 
three months with both baseline and additional AED(s). The study did not include patients who 
switched AED therapy, as a switch was more likely to represent intolerance to an AED. In contrast, 
adding an AED was suggestive of poor control of seizures and need of greater intensity of 
treatment. Though the definition of refractory epilepsy is restrictive, the study reported a 
prevalence of 15.2% among the 10,107 eligible patients with epilepsy on commercial insurance in 
2008, which is higher than the prevalence reported by Manjunath et al. in 2008.11 Also, using the 
same definition of refractory epilepsy (i.e., patients who added AEDs to an existing regimen during 
the year of observation), the authors reported a prevalence of 19.4% among children less than 12 
years of age with partial epilepsy.19 The prevalence of refractory epilepsy among children is higher 














Table 2.7: Prevalence of Refractory Epilepsy 
Author Patient population Definition Prevalence estimates 
Ramos-Lizana et 
al. (2012)75 
Children <14 years of age (n=508) 
with newly diagnosed epilepsy 
observed at a tertiary referral center 
in Spain 
Failure of adequate trials of two tolerated and 
appropriately chosen and used AED schedules 
(whether as monotherapy or in combination) to 
achieve seizure freedoma 
10%, 19%, and 23% of the 
patients treated for epilepsy 
at two, six and ten years after 
diagnosis, respectively 
Manjunath et al. 
(2012)13 
Adults ≥18 years of age with 
epilepsy on Medicaid (n=110,312) 
and private insurance (n=36,529) in 
the U.S. 
Patients with at least two consecutive changes 
in AED therapy (switch to a different 
compound or addition of an adjunctive 
compound) occurring at least 30 days apart, 
followed by at least one epilepsy-related 
emergency department visit or hospitalization 
during the next 365 days 
3.2% of the Medicaid, and 
1.7% of the employer 
population with epilepsy 
identified in a data collection 
period of 12 and 8 years, 
respectively 
Chen et al. 
(2013)10 
Adults <65 years of age with 
partial epilepsy on commercial 
insurance (n=79,149) in the U.S.  
Patients with three lifetime AEDs 
11% of the patients with 
partial epilepsy identified in a 
data collection period of 4 
years 
Cramer et al. 
(2014)11 
Adults ≥18 years of age with 
partial epilepsy on commercial 
insurance  (n=10,107) in the U.S. 
Patients adding additional AED(s) with at least 
three months of baseline therapy, followed by 
at least three months with both baseline and 
additional AED(s) 
15.2% of the patients with 
epilepsy identified in a data 
collection period of 4 years  
Cramer et al. 
(2014)19 
Children <12 years of age with 
partial epilepsy on commercial 
insurance (n=2,172) in the U.S. 
Patients adding additional AED(s) with at least 
three months of baseline therapy, followed by 
at least three months with both baseline and 
additional AED(s) 
19.4% of the patients with 
epilepsy identified in a data 
collection period of 4 years 
Tellez-Zenteno 
et al. (2014)74 
Adults diagnosed with epilepsy 
(n=250) at a Canadian epilepsy 
center 
Failure of adequate trials of two tolerated, 
appropriately chosen and used AED schedules 
to achieve sustained seizure freedoma 
33% of the patients 
diagnosed with epilepsy with 
a mean epilepsy duration of 
22.6 (±14.0) years 
aILAE = International League Against Epilepsy; AED = Antiepileptic drug 





2.2.3 Risk Factors of Refractory Epilepsy 
 
There is varying risk of refractory epilepsy by age group. Findings from epidemiological 
studies suggest an increase in the prevalence of epilepsy with increasing age.37 Disease burden, 
polytherapy, susceptibility to drug-drug interactions and intolerable side effects, and age-related 
physiological changes may increase the risk of pharmacoresistance in older patients.76 Age is an 
independent risk factor for the onset of epilepsy. Studies have shown patients who develop 
epilepsy at a later age are less likely to become refractory than younger patients.77,78 Likewise, 
patients developing epilepsy at an early age may become refractory at a later age, after a period of 
remission.79 
According to published studies, there are gender differences in the risk of epilepsy with 
males reported to have a higher overall risk of developing epilepsy than females.3 This difference 
has been reported to vary by epilepsy type. Males are more prone to develop partial or focal 
epilepsy due to the higher prevalence of lesions in men. On the other hand, females are more likely 
to develop generalized epilepsy due to structural and functional changes in the cerebral networks.80 
With regards to race, African Americans have been reported to have a higher risk of epilepsy as 
compared to whites or any other race. Also, a study reported lower likelihood of epileptic surgery 
and poor epilepsy control among African Americans in comparison to Caucasians.81  
Regarding epilepsy type, most research has reported that localization-related seizures or 
partial seizures are more common than generalized seizures in patients with refractory epilepsy. 
About 60% - 70% of patients with refractory seizures suffer from partial epilepsy. Studies have 
shown a higher probability of achieving remission in patients with generalized seizures as 
compared to patients with partial seizures. Patients with partial seizures who have already failed 





seizures.82,83 In addition, patients with multiple seizures also have worse outcomes in adults with 



















2.2.4 Economic Burden of Refractory Epilepsy 
Previous literature has evaluated the healthcare resource utilization and costs of patients 
with stable epilepsy, with a few studies estimating the overall and epilepsy-related healthcare 
resource utilization and costs of patients with refractory epilepsy. These studies found significant 
epilepsy-related and non-epilepsy related direct medical cost of care for reestablishment of 
epilepsy control in patients with refractory epilepsy.85 However, direct comparison of the cost 
estimates reported by the studies is challenging due to the heterogeneity in the studies. Table 2.8 
provides a summary of the direct cost estimates of refractory epilepsy. Most of the estimates of 
the economic burden of refractory epilepsy are based on patient self-reported data from literature 
and expert panels.14,86-89 The studies conducted outside the U.S. used national reimbursement rates 
over varying time periods to compute the healthcare utilization and costs of patients.86-89 In the 
U.S., the first study on refractory patients by Murray et al. (1996) modeled the prevalence rates 
and estimated the healthcare costs using the 1994 Red Book Prices, the 1994 Health Care 
Financing Administration (HCFA) Medicare program physician and laboratory standard rates 
based on the consensus of a physician panel.14 Three other studies conducted in U.S. settings used 
commercial claims to assess the treatment patterns of patients in clinical practice.10,11,13 The cost 
estimates of the studies differed due to the varying definitions and data sources used to characterize 
refractory epilepsy. The subsequent paragraphs discuss the non-U.S. and U.S. studies in detail. 
Among non-U.S. studies, three prospective and one retrospective study evaluated the costs 
of treating patients with refractory epilepsy.86-89 A 2002 Italian study by Tetto et al. evaluated and 
compared the cost of 525 children and adults with epilepsy differing in disease severity from the 
Italian National Health Service (INHS) perspective. The study derived the costs of AEDs by 





drug consumed over a one-year follow-up period, while the costs of hospital admissions were 
extrapolated from the corresponding diagnosis-related groups (DRG). Refractory epilepsy, which 
was defined as physician-reported relapsing seizures within 1-2 years of diagnosis that could not 
be improved by further treatment changes or surgery, was reported in 20.4% of the patients. The 
study found the costs of outpatient, hospital services as well as treatment costs to be significantly 
different for refractory epileptic adults and children as compared their non-refractory counterparts. 
The average total annual cost for a patient with refractory epilepsy in 2002 was estimated at €2,198 
(U.S.$2,054), consisting of costs associated with outpatient visits (€165) (U.S.$154), drug 
treatments (€1,398) (U.S.$1,306), and hospital admissions (€636) (U.S.$594) (Note: no standard 
deviations were provided).89  
Another non-U.S. prospective study by Boon et al. (2002) at a Belgian hospital quantified 
the epilepsy-related direct medical costs incurred by 84 patients with refractory seizures. The costs 
of AEDs were based on the official reimbursement rates published in the 1999 Medication 
Compendium of the Belgian Health Authority. Similarly, the costs of clinical visits, hospital 
admissions, and laboratory tests were calculated using fixed reimbursement rates. The study 
sample consisted of pre-surgical candidates (5-71 years) with a mean duration of epilepsy of 21 
years, of which 29% of the patients were assigned AED polytherapy using expert opinion of a 
multi-disciplinary team involving noninvasive tests and neurophysiological examinations. The 
study found the mean annual epilepsy–related direct medical costs to be U.S.$2,421 (range = $387 
- $7,409) per person after an average follow-up of 25 months (range = 12 - 48 months). The average 
cost of hospital admissions was U.S.$870 (range = 0$ - $6,310), cost of clinic visits was U.S.$93 
(range = $22 - $132), cost of AEDs was U.S.$1,218 (range = $110 - $2,285), and cost of laboratory 
tests was U.S.$241 (range = $110 - $441).86 When compared to the previous study, the average 





Hamer et al. (2006) evaluated the all-cause direct and indirect costs of refractory epilepsy 
in a German epilepsy center over a three-month period. Direct costs included direct medical costs 
of providing inpatient, outpatient, ancillary treatment, and diagnostic procedure services; direct 
non-medical costs of providing assistive or protective equipment; and dental care for side effects 
of AED, which were obtained from the official German price list of drugs and the charges listed 
in the official doctor’s fee scale. Indirect costs due to a patient’s early retirement and productivity 
losses were calculated using the human capital method. The study sample consisted of a 
“convenience sample” of 101 adults, with disease duration of 18.1 (±15.3) years, recruited from 
the outpatient clinic of a tertiary epilepsy center consisting of patients who were not newly 
diagnosed and were not presenting with their first seizure. The study estimated the mean (±SD) 
total costs of refractory epilepsy in Germany (2003 €) at €2,610 (±4,200) (U.S.$3,183 (±5,122)) 
per patient.  Direct costs contributed 39% (€1,010 (±1,600) (U.S.$1,232 (±1,951)) to the total costs, 
while the remaining indirect costs (€1,610 (±3,460) (U.S.$1,963 (±4,220)) were mainly attributed 
to losses due to early retirement (€780 (±2,690) (U.S.$951 (±3,280))).87 When compared to the 
previous studies, the three-month average direct cost ($1,232) extrapolated to annual costs 
($4,928) was higher owing to the inclusion of patients more advanced in their disease trajectory 
(i.e., with a mean disease duration of 18.1 (±15.3) years).86,87,89  
Sancho et al. (2008) conducted a cost of illness study to estimate the previous 12-month 
healthcare and non-healthcare resource use of 762 adult outpatients with refractory epilepsy in 
Spain. Direct health costs including hospital stays, medical visits, tests, and pharmacological and 
non-pharmacological treatments were obtained from the official Pharmacist Colleges General 
Council catalogue and from the Soikos Institute and multiplying by the number of resources used. 
Direct non-healthcare costs consisting of transportation and other out of pocket expenses were 





extrapolating it to one-year costs. Indirect cost consisting of productivity losses was calculated 
using the human capital method. Refractory epilepsy was defined as failure of at least three drugs, 
in monotherapy or combination therapy, to provide seizure control, with overall treatment duration 
of at least one year, and at least one seizure during the previous three months.  The prevalence of 
refractory epilepsy among patients attending general clinics was 18.5% and 36.0% among patients 
in specialized clinics. The total annual mean cost per-patient was estimated at €6,838 (±8,100) 
(U.S.$9,910 (±11,745)). Direct healthcare, non-healthcare and indirect costs accounted for 72.8% 
(€4,977 (±6,490) (U.S.$7,217 (±9,411)), 3.7% (€255 (±1,275) (U.S.$370 (±1,849)) and 23.6% 
(€1,618 (±4,527) (U.S.$2,346 (±6,564) of the total cost. When compared to previous studies, the 
mean annual direct costs (U.S.$7,217 (±9,411)) were higher due to methodological differences in 
extrapolating costs, and higher health expense consumption per capita in Spain, which differs from 
other countries.88  
Among U.S. studies, a 1996 study by Murray et al. was the first study to report the 
economic burden of refractory epilepsy among adults in the U.S. Direct costs included diagnostic 
procedures, laboratory tests charges, hospital physician service charges, surgery charges, AED-
associated costs, costs of AED-associated adverse reactions, and costs associated with 
breakthrough seizures, which were determined from the 1994 Red Book Prices, the 1994 HCFA 
Medicare program physician and laboratory standard rates and expert panels. The indirect costs 
consisting of decreased productivity or loss of income for the patient, and decreased or lost 
earnings to the caretaker were calculated based on literature and a physician panel. The study 
defined refractory epilepsy based on model parameters estimated using literature and by a panel 
of three physicians with expertise in the field of epilepsy, chosen by a review of published literature 
involving authors of manuscripts discussing refractory epilepsy or quality of life issues. The study 





5% of the patients with generalized seizures in the incidence cohort (consisting of 84,755 new 
adult epilepsy cases) as well as in the prevalence cohort (consisting of 1,155,746 cases of adult 
epilepsy). The estimated total health care cost for prevalent cases was $11,745 per patient per year 
(1994 dollars), and $12,962 per patient per year (1994 dollars) for incident cases. Direct costs were 
found to be $2,817 per patient per year for prevalent cases and $4,116 per patient per year for 
incident cases. The high costs of treating incident cases was attributed to the additional medical 
resource use in diagnosis and management of the patients. The indirect costs were estimated at 
$8,929 per patient per year for prevalent cases, and $8,846 per patient per year for incident cases.14  
Manjunath et al. quantified the economic burden of patients with refractory epilepsy in the 
U.S. and compared it to patients whose epilepsy was well controlled. The economic burden 
consisted of all-cause and epilepsy-related direct healthcare resource utilization and costs among 
privately insured patients (1999 – 2008) identified from the Ingenix employer database and 
patients on Medicaid (1997 – 2009) for five states (Florida, Iowa, Kansas, Missouri, New Jersey), 
and indirect costs consisting of work days lost due to short- and long-term disability and sick leaves 
for the private insurance patients. The healthcare resource utilization included hospitalizations, 
length of hospital stays, ED visits, outpatient visits, neurologist visits, other services, and AED 
and non-AED prescriptions. The study defined uncontrolled epilepsy (i.e., refractory epilepsy) as 
patients with at least two consecutive changes in AED therapy (switch to a different compound or 
addition of an adjunctive compound) occurring at least 30 days apart, followed by at least one 
epilepsy-related ED visit or hospitalization during the next 365 days (Table 2.9). The study found 
the prevalence of uncontrolled epilepsy to be 3.2% in the 110,312 eligible Medicaid patients, and 
1.7% in the 36,529 eligible employer population in the U.S. Patients with uncontrolled epilepsy 
on private insurance had $14,582 (95% CI = $12,019 to $17,097) (2009 dollar) higher average 





(2009 dollars) higher average annual direct costs as compared to patients with well-controlled 
epilepsy. The major drivers of the high healthcare resource utilization among both private insured 
employees and those on Medicaid included prescriptions of AEDs and non-AEDs, 
hospitalizations, outpatient visits, and neurologist visits. Also, patients with uncontrolled epilepsy 
had longer hospital stays and two times the number of fractures and injuries than patients with 
well-controlled epilepsy. In the case of productivity losses, privately insured employees with 
uncontrolled epilepsy had 2.5 times higher workday losses, with associated indirect costs of $2,857 
(2009 dollars).13 
Chen et al. assessed the economic burden of direct healthcare utilization and costs for 
refractory epileptic patients with partial onset seizures observed in the U.S. Thomson Medstat 
MarketScan Commercial Insurance database from 2004 - 2008. The direct healthcare utilization 
and costs included all-cause and epilepsy-related inpatient admissions, ED visits, outpatient visits, 
diagnostic tests, and AED and non-AED prescriptions for each calendar year converted to 2008 
dollars. Refractory epilepsy was defined based on having three lifetime AEDs. The study reported 
the prevalence of refractory epilepsy to be 11% among the 79,149 eligible patients in the U.S. The 
study found the average annual all-cause total ($33,613 vs. $19,085), inpatient ($11,780 vs. 
$6,076), outpatient ($13,431 vs. $8,637), and pharmacy costs ($8,402 vs. $4,372) to be 
significantly higher for refractory patients as compared to non-refractory patients. In the case of 
epilepsy-related costs, the average annual total ($10,804 vs. $4,032), inpatient ($4,621 vs. $1,384), 
outpatient ($904 vs. $391), and pharmacy costs ($5,280 vs. $2,256) were significantly higher for 
refractory patients as compared to non-refractory patients.10  
A 2014 study by Cramer et al. compared the economic burden of patients with refractory 





Commercial database for a period from 2007 - 2009. The economic burden (2009 dollar) was 
comprised of all-cause and epilepsy-related inpatient hospitalizations, days of stay among patients 
with inpatient hospitalizations, ED visits, physician office visits, and AED and non-AED 
prescriptions. The study defined uncontrolled epilepsy (i.e., refractory epilepsy) as patients who 
added AEDs to an existing regimen during the year of observation. Addition of AED(s) was 
defined as at least three months of baseline therapy, followed by at least three months with both 
baseline and additional AED(s). The study reported a prevalence of 15.2% among the 10,107 
eligible patients in 2008. Patients with uncontrolled epilepsy were more likely to be hospitalized 
for any diagnosis (18.3% vs. 9.8%) and for epilepsy-related diagnoses (15.7% vs. 7%), had higher 
mean of all-cause (12 vs. 9) and epilepsy-related physician office visits (3.6 vs. 2.2), and were 
more likely to have a brain imaging (34.4% and 18.5%) as compared to patients with stable 
epilepsy. Also, patients with uncontrolled epilepsy had higher all-cause ($23,238 (±42,894) vs. 
$13,839 (±31,355)) and epilepsy-related ($12,399 ($25,773) vs. $5,511 (±11,730)) total costs per 
patient-per year (PPY) as compared to patients with stable epilepsy. Of the total all-cause costs, 
$15,842 (±$40,999) vs. $9,214 (±$2,457) PPY were for medical services and $7,247 (±$6,411) vs. 
$4,349 (±$5,085) PPY were for AEDs in patients with uncontrolled epilepsy as compared to 
patients with well-controlled epilepsy, respectively. Of the total epilepsy-related costs, $7,257 
(±$25,202) vs. $2,751 (±$11,029) PPY were for medical services and $5,142 (±$4,110) vs. $2,760 
(±$3,361) PPY were for AEDs in patients with uncontrolled epilepsy as compared to patients with 
well-uncontrolled epilepsy, respectively.11 
In conclusion, among privately insured employees in the U.S., the average all-cause annual 
direct costs of refractory patients ranged from $23,238 (±$42,894) to $24,853 (±$81,299) in 2009, 
and $33,613 (Note: no standard deviations provided) in 2008, while the average all-cause annual 





2009 and $19,085 (Note: no standard deviations provided) in 2008.10,11,13 When comparing 
refractory and non-refractory patients among Medicaid patients from Florida, Iowa, Kansas, 
Missouri and New Jersey, the average all-cause annual direct costs (2009 dollars) were $38,708 
(±$114,904) vs. $29,635 (±$105,644), respectively.13 Thus, the economic burden associated with 
refractory epilepsy is substantial (Table 2.8) and empirical study is needed to provide current 














Table 2.8: Direct Cost Estimates of Refractory Epilepsy 
Author 
(year) 
Study population Refractory 
Prevalence/Definition 





525 children and 
adults with epilepsy 
differing in disease 
severity in Italy 
20.4% of patients with 
relapsing seizures within 1-
2 years of diagnosis, 
reported by the treating 
physician, that could not be 
improved by further 
treatment changes or 
surgery 
Annual cost (2002 dollars) 
Total  
Hospital services 





€165 (U.S.$154)  






years) with a mean 
duration of epilepsy 
of 21 years in 
Belgium 
29% of patients with a 
mean duration of epilepsy 
of 21 years, assigned AED 
polytherapy using expert 
opinion of a multi-
disciplinary team involving 
noninvasive tests and 
neurophysiological 
examinations 






Laboratory tests  
(Mean) 
 
$2,421 (range = $387 - $7,409) 
$870 (range = 0$ - $6,310) 
$93 (range = $22 - $132) 
$1,218 (range = $110 - $2,285) 






from the outpatient 
clinic of a tertiary 
epilepsy center in 
Germany 
100% of patients with 
disease duration of 18.1 
(±15.3) years, who were not 
newly diagnosed and were 
not presenting with their 
first seizure 
Three month cost (2003 dollars) 
Total 
Inpatient visits 
Outpatient visits  





€1,010 (±1,600) ($1,232 (±1,952)) 
€280 (±1,150) ($342 (±1,403)) 
€10 (±50) ($12 (±61)) 
€20 (±50) ($24 (±61)) 
€90 (±890) ($110 (±1,086)) 
€10 (±40) ($12 (±49)) 








Table 2.8: Direct Cost Estimates of Refractory Epilepsy (Continued) 
Author 
(year) 
Study population Refractory 
Prevalence/Definition 




outpatients in Spain 
18.5% of patients in general 
clinics and 36.0% in 
specialized clinics with 
failure of at least three 
drugs, in monotherapy or 
combination therapy, to 
provide seizure control, 
with overall treatment 
duration of at least one 
year, and at least one 
seizure during the previous 
three months   







€4,977 (±6,490) ($7,217 (±9,411) 
€1,400 (±6,034) ($2,030 (±8,749) 
€317 (±325) ($460 (±471) 
€2,924 (±2,277) ($4,240 (±3,302) 




84,755 new adult 
epilepsy cases and 
the prevalence 
cohort consisting of 
1,155,746 cases of 
adult epilepsy 
45% of patients with partial 
seizures and 5% of the 
patients with generalized 
seizures based on model 
parameters estimated using 
literature and by a panel of 
three physicians with 
expertise in the field of 
epilepsy, chosen by a 
review of published 
literature involving authors 
of manuscripts discussing 
refractory epilepsy or 
quality of life issues 































Adults ≥18 years 






insurance in the 
U.S. 
3.2% in the Medicaid 
patients, and 1.7% in 
the employer 
population defined as 
at least two 
consecutive changes in 
AED therapy (switch 
to a different 
compound or addition 
of an adjunctive 
compound) occurring 
at least 30 days apart, 
followed by at least 
one epilepsy-related 
ED visit or 
hospitalization during 
the next 365 days 
Annual cost (2009 dollars) 


















Medicaid; employer population 
All-cause 
$38,708 ± $114,904; $24,853 ± $81,299 
$6,902 ± $31,181; $11,308 ± $62,399 
$400 ± $1,496; $586 ± $4,392 
$2,416 ± $11,759; $5,757 ± $24,888 
$86 ± $850; 556 ± $4,306 
$22,022 ± $106,033; $1,008 ± $5,428 
Epilepsy-related 
Not reported 
$4,102 ± $19,775; $6,700 ± $48,095 
$109 ± $610; $152 ± $972 
$467 ± $2,218; $703 ± $3,072 
$60 ± $712; $235 ± $1,797 
$1,502 ± $14,424; $103 ± $752 
$1,352 ± $4,580; $1,697 ± $3,979 
$5,615 ± $15,730; $4,497 ± $11,374 
Chen et al. 
(2013) 
79,149 eligible 
adults <65 years 
of age with partial 
epilepsy on 
commercial 
insurance in the 
U.S. 
11% of the patients 
based on having three 
lifetime AEDs 


























Table 2.8: Direct Cost Estimates of Refractory Epilepsy (Continued) 
Author 
(year) 
Study population Refractory 
Prevalence/Definition 
Direct cost categories Direct healthcare cost 
Cramer et 
al. (2014) 
10,107 adults ≥18 
years of age with 
partial epilepsy on 
commercial 
insurance in the 
U.S. 
15.2% of the patients who 
added AED(s) with at least 
three months of baseline 
therapy, followed by at 
least three months with both 
baseline and additional 
AED(s) 











$23,238 (±42,894)  
$15,842 (±$40,999)  
$7,247 (±$6,411)  
Epilepsy-related 
$12,399 ($25,773)  
$7,257 (±$25,202)  
$5,142 (±$4,110)  
AED = Antiepileptic drug 
SD = Standard deviation 








2.2.5 Pharmacotherapy in Refractory Epilepsy 
The treatment of refractory epilepsy varies with the type of epilepsy. Based on guidelines 
of the American Academy of Neurology (AAN) and the American Epilepsy Society (AES), there 
is sufficient evidence of efficacy and safety to use topiramate and oxcarbazepine as monotherapy 
in patients with refractory partial epilepsy. Gabapentin, lamotrigine, topiramate, tiagabine, 
oxcarbazepine, levetiracetam, and zonisamide are recommended for use as adjunctive treatment in 
patients with refractory partial epilepsy. In contrast, topiramate is the only drug that may be used 
for the treatment of generalized tonic-clonic seizures in adults (Table 2.9).90,91 
Table 2.9: Use of Antiepileptic drugs in the Management of Refractory Partial and 
Generalized Epilepsy 
AED As adjunctive therapy 
in partial epilepsy 




Gabapentin Appropriate to use 
(Level A) 






Appropriate to use 
(Level A) 
Can be used (Level B, 






Appropriate to use 
(Level A) 
Can be used (Level A) May be used (Level A) 
Tiagabine 
 
Appropriate to use 
(Level A) 
Insufficient evidence  
(Level U) 




Appropriate to use 
(Level A) 
Can be used (Level A) 
 




Appropriate to use 
(Level A) 
Insufficient evidence  
(Level U) 




Appropriate to use 
(Level A) 
Insufficient evidence  
(Level U) 
Insufficient evidence  
(Level U) 
AED = Antiepileptic drug 
Level of recommendation given by the American Academy of Neurology (AAN): 
Level A = Established as effective, ineffective or harmful or as useful/predictive or not useful/predictive;  
Level B = Probably effective, ineffective or harmful or useful/ predictive or not useful/predictive;  
Level U = Data inadequate or conflicting; treatment, test, or predictor unproven. 





2.2.5.1 Treatment Patterns in Refractory Epilepsy 
There is a dearth of well-controlled trials evaluating the utilization of AEDs in patients with 
refractory epilepsy. The only randomized prospective study by Alexandre et al. (2010), the study 
of outcome of pharmacoresistance in epilepsy (SOPHIE), evaluated the AED utilization patterns 
of 933 adults and 191 children with refractory epilepsy in 11 tertiary centers in Italy.92 The study 
reported that 79% of patients were taking polytherapy regimens, of which 54% received a 
combination of two AEDs, 35% received three AEDs, 9% received four AEDs, and 2% received 
five AEDs. Seventy-four percent of patients were prescribed at least one first-generation AED, 
while 81% were prescribed at least one second-generation AED. Levetiracetam was the most 
commonly prescribed AED (35%) followed by carbamazepine (34%), lamotrigine (30%), 
oxcarbazepine (23%), valproic acid (21%), topiramate (19%), phenobarbital (17%), clobazam 
(14%), and phenytoin (9%).93 
A study by Priscila de Freitas-Lima et al. (2013) evaluated the drug utilization patterns among 
112 adults with refractory epilepsy attending a tertiary referral center in Brazil. The authors 
reported that 7.1% of patients were on monotherapy, 60.7% were on polytherapy with two AEDs, 
and 32.1% were on polytherapy with three or more AEDs. Carbamazepine was the most common 
AED in monotherapy. Of the patients on polytherapy, all but one patient had at least one first-
generation AED, while at least one second-generation AED was prescribed to 70.5% of the 
patients.94  
Previous retrospective studies assessing the use of AED polytherapy in insurance claims 
datasets in the U.S. have reported about 80% of patients are on monotherapy as compared to 
polytherapy at baseline in patients with refractory epilepsy.10,11,13 Cunnington et al. (2011) 





regimen change, early in the course of illness. The study employed a retrospective cohort design 
using the U.S. Invision Data Mart Multiplan Database 2004 - 2008 to evaluate the treatment 
patterns consisting of a switch (change in the AED(s)), repeat (remaining on the same AED(s)), 
augmentation (increase in the number of AEDs prescribed), reduction (decrease in the number of 
AEDs with retention of at least one AED), termination (no additional AED within 180 days of 
previous AED use), and initiation (initiation of AED following termination). (Note: The study did 
not define overlapping periods in the treatment patterns). Patients with a gap of 31 to 180 days 
between AED refills were ignored and prescription claims on either side of the treatment gap were 
reviewed to classify as a switch, repeat, augmentation, or reduction (Figure 2.5). Eleven percent 
patients received polytherapy with an overlap of an adjunctive AED in the first 14 days epilepsy 
diagnosis, which was suggestive of severe epilepsy. Phenytoin was commonly used as 
monotherapy (33%), while the combination of phenytoin and levetiracetam was the most common 
polytherapy regimen (25.8%). The most common type of regimen change after the diagnosis was 
switch, followed by reduction, and then augmentation (Table 2.10). With the exception of 
initiating a new AED following termination, about 18% - 27% of patients’ changed AED regimen 
at least once in the first year post-diagnosis. The risk of a regimen change significantly reduced as 
time since epilepsy diagnosis increased and decreased with a previous regimen change. 
Specifically, 57.6% of patients showed changes in AED regimen (mean=1.3) in the first year, 
which was followed by 45.1% of patients who showed changes in AED regimen in the second year 
(mean=1.1) post diagnosis, possibly due to the use of rescue medications in the initial year 
followed by the prescription of a more stable long-term regimen. Use of polytherapy immediately 






Figure 2.5: Examples of Antiepileptic Drug Regimen Change 
 
PHB = phenobarbital 
LVT = levetiracetam 
CBZ = carbamazepine 
VPA = valproate  
Days of supply is 30 days 
Source: Cunnington et al. (2011)32 
 
Table 2.10: Frequency of Regimen Change in Patients with Newly Diagnosed Epilepsy 
Type of regimen change Summary statistic in one year after diagnosis* 
Switch 
(Change in the AED(s)) 
Mean number of changes per person = 0.41 
% Patients with ≥1 regimen change = 27.3 
Augmentation 
(Increase in the number of AEDs 
prescribed) 
Mean number of changes per person = 0.32 
% Patients with ≥1 regimen change = 20.3 
Reduction 
(Decrease in the number of AEDs with 
retention of at least one AED) 
Mean number of changes per person = 0.36 
% Patients with ≥1 regimen change = 24.8 
Termination 
(No additional AED within 180 days of 
previous AED use) 
Mean number of changes per person = 0.18 
% Patients with ≥1 regimen change = 17.8 
*No standard deviation reported 











 The study by Chen et al. was the only study to conduct an in depth evaluation of the 
treatment patterns of AED(s) among refractory patients with partial epilepsy in the U.S. using real 
world claims commercial claims data from 2004 - 2008. The study characterized the treatment 
pattern of patients before they reached refractory status, that is, following the use of the first AED 
by patients. Refractory epilepsy was subsequently defined based on having three lifetime AEDs. 
The most commonly prescribed AEDs in patients on monotherapy were phenytoin (15.2%) and 
levetiracetam (15.2%), followed by carbamazepine (12.2%), oxcarbazepine (11.3%), and 
lamotrigine (11.0%). Of the patients on polytherapy with two AEDs, levetiracetam was most 
frequently used along with phenytoin (6.4%), lamotrigine (6.0%), carbamazepine (5.3%), 
topiramate (4.7%), and oxcarbazepine (4.5%). The study further assessed the patterns of adding or 
switching to another AED among the patients. Addition was defined as the addition of another 
AED to the initial AED with at least a 30-day overlap in medication supply between the dispensing 
of these two AEDs, while a switch in therapy was defined as the discontinuation of the initial AED 
and start of another AED with less than a 30-day overlap in medication supply between the 
dispensing of the two AEDs. Among patients on monotherapy, 57.4% added another AED, while 
42.6% switched to another AED subsequently. Of the patients on combination therapy, 41.6% 
added a third AED, 42.6% discontinued one of the AEDs in combination therapy. Levetiracetam 
was the most common add-on or switch-to AED.10 
Monotherapy is usually the preferred treatment in patients with epilepsy as it is associated 
with; better compliance, fewer drug interactions, lower complexity in patients treated for other 
comorbid conditions, less adverse drug reactions, and lower health care costs. However, in the 
case of refractory epilepsy, seizure control usually needs drug trials consisting of switching or 





There is no evidence suggesting the clinical benefit of adding an adjunctive AED as 
compared to switching to an alternative monotherapy in patients with refractory epilepsy. A 
prospective randomized controlled study among patients with refractory partial epilepsy did not 
find differences in seizure remission and adverse events between patients switched to an alternative 
monotherapy and those patients who added an adjunctive AED to the pre-existing treatment. The 
patients had failed previous monotherapy once before being randomized to the two treatment 
strategies. Also, there was no difference in the probability of remaining on the allocated treatment 
between the two study groups.95  
In the case of cost savings, a 2005 study by Lee et al. compared the economic burden of 
switching and adding an adjunctive AED in patients with partial epilepsy, refractory to initial 
monotherapy. The study used the PharMetrics patient-centric database, to compare the healthcare 
utilization and costs of providing hospital admissions, ED visits, outpatient visits, office-based 
visits, and prescriptions in the six-month pre-period consisting of monotherapy and a 12-month 
post-period consisting of switching and adding an adjunctive AED. The six-month pre-index costs 
were doubled to annualize the costs. Monotherapy was defined as patients having a prescription 
for a single AED consisting of carbamazepine, phenytoin or valproic acid for at least six months. 
Adjunctive drugs in the add-on cohort consisted of carbamazepine, clorazepate dipotassium, 
divalproex sodium, felbamate, gabapentin, lamotrigine, levetiracetam, phenobarbital, phenytoin, 
primidone, tiagabine hydrochloride, topiramate, valproic acid, and zonisamide, while the switch-
to cohort consisted of patients whose non-oxcarbazepine (OXC) AED monotherapy was changed 
to OXC monotherapy. The switching group had an annual per-patient cost savings of $1,165 
(p<0.05) over the group that received an additional AED. Pharmacy cost differences were the 





more likely (Odds ratio (OR)=1.52, 95% CI=1.07-2.15, p<0.05) than the switch-to cohort to have 
an emergency department visit.96 
With the use of first-generation AEDs, adding an AED to an existing regimen was 
associated with side effects in patients. However, with the advent of newer drugs, adding a second- 
and a third-generation AED is reported to improve outcomes in comparison to switching to another 
AED. A study using the Truven Health MarketScan Commercial Claims and Encounter Database 
(2007 - 2009) found cost savings in potentially DRE patients with partial onset seizures who 
changed from monotherapy to adjunctive therapy. The study assessed the 12-month all-cause and 
epilepsy-related healthcare utilization and costs comprising of hospitalizations, ED visits, 
outpatient visits, and AED and non-AED prescriptions following the change to adjunctive therapy. 
Use of adjunctive therapy was defined as those who received monotherapy and were changed to 
adjunctive therapy with an overlap of greater than 60 days with the initial AED. The average per-
month all-cause hospitalizations (5.3% vs. 3.0%, p<0.0001) and ED visits (8.2% vs. 4.8%, 
p<0.0001) and epilepsy-related hospitalizations (4.0% vs. 1.7%, p<0.0001) and ED visits (4.5% 
vs. 2.2%, p<0.0001) significantly reduced after the patients changed to adjunctive therapy from 
initial monotherapy. Likewise, the adjusted all-cause total costs signicantly reduced from $4,205 
per-month to $2,994 per-month (p<0.0001). In case of the epilepsy-related costs, there was a slight 
non-significant increase in pharmacy costs from U.S.$189 to $194 per-month (p=0.2082), while 
the adjusted epilepsy-related total costs significantly reduced from $1,601 per-month to $909 per-
month (p<0.0001), after patients transitioned to adjunctive therapy.24 
The newer AEDs have different MOAs and better side effect profiles as compared to the 
first generation AEDs. Most of these drugs have been approved by the Food and Drug 





epilepsy.20 There is increasing evidence that combining drugs with different MOAs may be more 
effective and result in fewer adverse-effects due to their ability to act on multiple drug targets as 
opposed to combining drugs with the same MOA.20,25,97 However, there is a dearth of randomized 
controlled trials and real-world evidence analyzing this approach.  
Margolis et al. (2014) studied the clinical and economic outcomes of adding an AED with 
a same MOA as compared to adding an AED with a different MOA in patients with partial-onset 
seizures. The study described the addition of an AED as an overlap of the days of supply of the 
AEDs for at least 90 days following initiation of the second AED. Patients were selected from the 
Truven Health MarketScan Commercial Claims and Encounters Database. Persistence was defined 
as the number of days from the addition of the AED to the end of available data when there was 
no claim for one of the AEDs prior to the last days of supply allowing for a gap of 30 days or half 
the days of supply from the previous prescription claim. Healthcare use consisted of inpatient 
admissions, ED visits and physician office visits.  The AED classes based on their primary MOA 
consisted of sodium channel blockers (SC), gamma-aminobutyric acid analogs (G), synaptic 
vesicle protein 2A binding (SV2), and multiple mechanisms (M). The SC class included 
carbamazepine, ethotoin, fosphenytoin, lacosamide, lamotrigine, oxcarbazepine, and phenytoin, 
while the G class included clonazepam, diazepam, gabapentin, phenobarbital, pregabalin, 
primidone, tiagabine, and vigabatrin. SV2 class included levetiracetam, while the M class included 
divalproex sodium, felbamate, topiramate, valproate sodium, valproic acid, and zonisamide. 
Patients on same-MOA (G+G and SC+SC) combinations had shortest persistence (344 (±345 
days) and 513 (±530 days)) as compared to patients on different-MOA combinations. Also, the 
results showed that patients on different-MOA combinations had a lower hazard of discontinuation 
compared to patients on same-MOA combinations. Also, the health care utilization differed by the 





(OR=0.85, 95% CI=0.74-0.98, p<0.05) compared to patients with SC combinations of same 
MOAs. In addition, G combinations of different MOAs had a lower risk of inpatient admissions 
(OR=0.72, 95% CI=0.54-0.95, p<0.05) compared to patients with SC combinations with the same 
MOAs.27 This was the only study that compared the utilization of patients on different MOA 
combinations. However, the study assessed patients with partial onset seizures alone. There is still 
a need to study the patterns of AED use and associated outcomes in patients with refractory 


















2.2.6 Adherence to Antiepileptic Drug Therapy 
Medication non-adherence is an important concern in epilepsy.98 Early studies using self-
reported patient estimates of adherence have reported that about half of the patients were adherent 
to AED therapy.99,100 The Morisky Medication Adherence Scale (MMAS) has been widely used 
to measure adherence of patients during an office visit. This patient-reported scale consisted of 
four questions with a score of 4 representing high adherence, and a score of 1 representing low 
adherence.101 Studies using claims data have reported that the rate of AED non-adherence ranges 
between 26% and 50% using a threshold of less than 0.8 to describe non-adherence in patients 
with epilepsy.29,102-106 It has been reported that poor adherence with AEDs leads to seizure 
recurrence and an increase in health care utilization and costs. Specifically, studies have reported 
higher ED costs (+$143 to +$260), inpatient costs (+$872 to +$1,799), and total health care costs 
(+$1,466 to +$2,674) in patients’ non-adherent to their AED regimen in comparison to patients’ 
adherent to AED regimen.102-104 The majority of the studies have assessed medication adherence 
in patients on monotherapy regimens, while no known studies have assessed adherence to AEDs 
among refractory patients. Due to lower pill burden and less regimen complexity, monotherapy 
patients may have better adherence rates than patients requiring two or more daily doses.102  
In the U.S. Medicaid population, the RANSOM (Research on Antiepileptic Non-adherence 
and Serious Outcomes in Medicaid) study is the only study that used prescription claims to 
evaluate the adherence of adults with epilepsy to AED regimen. The study assessed healthcare 
utilization and costs among adults using state Medicaid claims data from Florida, Iowa, and New 
Jersey from 1997 through 2006. The study assessed adherence of patients on any of the 12 AEDs 
(carbamazepine, ethosuximide, felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, 





zonisamide) using an open-cohort design. As all patients may not have required continuous AED 
throughout the observation, the study allowed a gap in AED use of 180 days or more as untreated 
periods and assessed adherence for each 90-day quarter. Adherence for each treated quarter was 
calculated using the medication possession ratio (MPR) method with numerator consisting of the 
number of days in a quarter with supplies for at least one AED and denominator consisting of the 
number of days in a quarter. The study reported that 26% of the patients were non-adherent (MPR 
less than 80%) to AEDs, and AED non-adherence was associated with a higher incidence of 
hospitalizations, inpatients days, and ED visits.29  
Among privately insured adults in the U.S., four retrospective studies used prescription 
claims to evaluate adherence of patients with epilepsy to AED regimens using MPR. Briesacher 
et al. (2008) used the MarketScan research database from 2001 - 2004 to measure adherence using 
MPR in patients newly diagnosed with epilepsy. MPR included the days of supply of dispensed 
drug during the follow-up year as the numerator and the number of days in the year as the 
denominator. The study eliminated patients with overlaps in the dispensed days for different 
generic drugs and summed those overlaps for same generic drugs. Overlaps for different dispensed 
drugs were eliminated as leftover supplies from previous refills were assumed to be discarded to 
begin the new drug. In contrast, overlaps for same dispensed drugs were not eliminated as patients 
were assumed to continue taking the drug from previous refills as part of the same regimen. In 
addition, patients with MPRs higher than 100% were truncated for 27% of the patients. The study 
found 60.8% of the patients had an MPR of 80% or more.105 Davis et al. (2008) used the 
PharMetrics Integrated Outcomes Database from 2000 - 2005 to identify AED adherence among 
adult patients aged 21 years or older in the U.S. MPR used to measure adherence was defined as 
the days of supply for all AED prescriptions divided by the number of days between AED initiation 





MPR of 0.78 and 61% of the patients adherent (MPR of 80% or more) to AED prescriptions.103 
Manjunath et al. (2009) used the PharMetrics Patient Centric Database from 2000 - 2005 to 
measure adherence to AEDs in a large cohort of adult patients diagnosed with epilepsy. The study 
operationalized MPR as a time-dependent variable and calculated the cumulative adherence from 
the time a patient initiated an AED to the end of each month, which was computed until the end 
of the follow-up period (Figure 2.6). The numerator of the MPR consisted of days of supply of 
AED to total days within each cumulative interval following AED initiation. The study reported 
50% of the patients had an MPR of 80% or more.106 
 





Source: Manjunath et al. (2009)106 
 
 Cramer at al. (2015) conducted a cross-sectional study of claims from the OptumInsight™ 
database for the year 2011 and evaluated the adherence to AED in adults diagnosed with epilepsy 
on a monotherpy regimen only. MPR was defined as the total days of therapy available in the study 
period divided by 365 days. The study reported a mean MPR of 0.899 (±0.13) in long-acting AED 
users and an MPR of 0.903 (±0.13) in short-acting AED users. Long-acting AEDs included 
phenytoin extended release, carbamazepine extended release, topiramate, divalproex extended 





zonisamide, while short-acting AEDs included levetiracetam, lamotrigine, carbamazepine, and 
oxcarbazepine.102 
 The adherence estimates mainly depend on the patient population, the medication regimen, 
and the method used to measure adherence (Table 2.11). A reason cited in literature for inadequate 
seizure control in patients with epilepsy is suboptimal adherence to AEDs.107 In patients commonly 
on polytherapy, adherence may be affected by the tolerance to multiple AEDs and the development 
of side effects.108 A study measuring the serum drug concentrations in hospitalized patients with 
refractory focal epilepsy reported poor adherence to AEDs.109 In medically refractory patients, 
adherence to AEDs in clinical practice has not been specifically studied, however, its study is 
important as seizure relapses can be minimized with optimal treatment adherence. Thus, no known 












Table 2.11: Adherence to Antiepileptic drugs in the U.S. 
Author 
(year) 
Study population Adherence definition Adherence estimate 
Patients on Medicaid 
Faught et al. 
(2009) 
Adults (N=33,658) on 
Medicaid from 
Florida, Iowa, and 
New Jersey (1997-
2006) 
MPR included the number of 
days in a quarter (each 90 
days) with supplies for at least 
one AED number of days in a 
quarter as the denominator. 
74% of the patients 
had an MPR of 80% 
or more 









MPR included the days of 
supply of dispensed drug 
during the follow-up year as 
the numerator and the number 
of days in the year as the 
denominator. 
60.8% of the patients 
had an MPR of 80% 
or more 
Davis et al. 
(2008) 
Adults (N=10,892) 





MPR used to measure 
adherence was defined as the 
days of supply for all AED 
prescriptions divided by the 
number of days between AED 
initiation and the expiration of 
the days of supply of the last 
observed AED refill. 
61% of the patients 
had an MPR of 80% 
or more; Mean MPR 
of 0.78 
Manjunath 







MPR consisted of days of 
supply of AED to total days 
within each cumulative 
interval following AED 
initiation.  
50% of the patients 
had an MPR of 80% 
or more 
Cramer at al. 
(2015) 
Adults (N=8,180) 




MPR was defined as the total 
days of therapy available in 
the study period divided by 
365 days.  
Mean MPR of 0.899 
(±0.13) in long-acting 
AED users; Mean 
MPR of 0.903 (±0.13) 
in short-acting AED 
users 









2.2.7 Comorbidities in Refractory Epilepsy 
Seidenberg et al. (2009) summarized data from six large studies from different countries 
and reported that 26.8% to 84% of patients with epilepsy had at least one comorbid condition.110 
Psychiatric disorders such as major depression, anxiety disorder, and psychosis have been 
commonly cited in literature.111 Depression is one of the most common comorbidities with a 
prevalence of about 60% in patients with drug-resistant focal epilepsy.112 Comorbidities in patients 
with seizure disorders impose a significant burden on patients, and their families, and affect the 
quality of life of patients. Also, these comorbidities have an impact on the tolerance of AEDs.113 
AEDs such as zonisamaide may lead to psychiatric adverse events such as psychosis and mania.114 
Also, AEDs such as barbiturates, phenytoin, carbamazepine, and topiramate may have detrimental 
effects on cognition functioning, motor speed, and attention, further complicating the management 
of epilepsy.115 
Comorbid conditions raise the cost of medical care, through increased pharmacy, outpatient 
office visits, and inpatient hospitalization.111 A study by Lee at el. (2005) assessed the effect of 
comorbidities on medical care use and costs among patients with partial seizure disorder refractory 
to initial monotherapy regimen using administrative claims data from PharMetrics (2000 - 2002). 
The study found higher odds of hospitalizations (OR=3.7, 95% CI=1.7-7.9) and higher mean 
treatment costs (p<0.0001) in patients with at least one comorbidity ($26,579 (±$15,407)) as 
compared to patients without any comorbidity ($10,471 (±$30,089). Comorbid depression had the 
highest impact on the odds of hospitalization (OR=3.5, 95% CI=2.13–5.8) and 83.1% greater 
treatment costs as compared to patients without depression.116  
In addition, comorbid psychiatric conditions may lead to differences in epilepsy 





inpatient settings for diagnostic evaluations of psychogenic non-epileptic events, thereby 
increasing the healthcare costs.117 A 2014 study by Hamilton et al. retrospectively followed 83 
patients with drug-resistant focal epilepsy for two years and assessed anxiety and/or depressive 
symptoms using 3 self-reported surveys; the Beck Depression Inventory-II (BDI-II), the 
Neurologic Disorders Depression Inventory-Epilepsy (NDDI-E), and the Patient Health 
Questionnaire-Generalized Anxiety Disorder 7 (PHQ-GAD 7). The study illustrated that the 
patients with anxiety and depressive symptoms had higher missed outpatient visits (median 0.84 
vs. median 0.48, p=0.02) and were more likely to undergo an inpatient admissions (56% vs. 24%, 
p=0.02) as compared to patients without those symptoms.118 
In addition, non-psychiatric comorbidities such as Alzheimer’s disease, brain tumor, 
meningitis, migraine, multiple sclerosis, and stroke are common in patients with uncontrolled 
epilepsy.10,13 Cramer et al. reported higher all-cause costs in patients with uncontrolled epilepsy as 
compared to patients with well-controlled epilepsy, suggesting that comorbid conditions may 
contribute to additional healthcare utilization and costs in those patients. Patients with uncontrolled 
epilepsy had a higher mean Charlson comorbidity index (0.7 (±1.5) vs. 0.5 (±1.3), p <0.001), with 
a significantly higher percentage of patients with head injury (1.3% vs. 0.7%, p<0.05), brain tumor 
(6.2% vs. 3.5%, p<0.001), cerebrovascular disease or stroke (12.7% vs. 6.3%, p<0.001), 
depression and other mood disorders (10.9% vs. 6.3%, p<0.001) as compared to patients with 
stable epilepsy.11 Thus, managing medically refractory epilepsy involves improvement in overall 





2.3 Texas Medicaid  
Texas Medicaid was instituted by the state and approved by the U.S. Department of Health and 
Human Services Commission (HHSC) under Section 1902 of the Social Security Act. The Texas 
Medicaid program provides health insurance coverage for low-income families, individuals with 
chronic disabilities, blind persons, low-income pregnant women, elderly people or seniors, non-
disabled children, and caretakers of dependent children. Medicaid enrollment in the state of Texas 
for clients under 21 was 2,780,581 million and for clients 21 and older was 833,943 in December 
2013.119 
Currently, most Medicaid services in Texas are delivered through managed care, with a large 
shift from the traditional Medicaid program to managed care in 2012. HHSC contracts with 
managed care organizations licensed by the Texas Department of Insurance and pays them a 
monthly amount to coordinate health services for the Medicaid members enrolled in their plans. 
The health plans contract directly with doctors and other health care providers to create provider 
networks for their members. There are four Medicaid programs in Texas: traditional Medicaid, 
STAR, STAR+PLUS, and STAR Health. The traditional Medicaid program has a fee-for-service 
(FFS) payment structure. The STAR program is Medicaid for children, newborns, and pregnant 
women, while STAR+PLUS is a Medicaid program for people who have disabilities or are 65 
years or older. Finally, STAR Health is Medicaid for children covered through the Texas 








2.4 Summary of Literature Review 
Epilepsy is a chronic disorder characterized by repeated seizures that affects about 2.2 
million cases in the U.S. and 50 million cases worldwide.2 Seizures are broadly categorized as 
generalized and partial seizures. Pharmacotherapy with AEDs is the foremost treatment paradigm 
in epilepsy. Monotherapy with an AED is usually effective in 60% of the patients with epilepsy, 
while the remaining patients, considered refractory, are candidates for additional treatment options 
such as AED titrations, VNS, and surgery.8 The ILAE commission defines refractory epilepsy as 
“failure of adequate trials of two tolerated and appropriately chosen and used AED schedules 
(whether as monotherapies or in combination) to achieve sustained seizure freedom.34 
Pseudoresistance due to incorrect diagnosis, inappropriate AED choice, dosage or administration 
regimen, and poor medication adherence needs to be ruled out before considering a patient as 
refractory.44 Applying the variations of ILAE definition, retrospective studies conducted in the 
U.S. using population-based administrative claims data have reported the prevalence of refractory 
epilepsy to be 1.7% to 15.2%.10,11,13 This wide range in the prevalence estimates of refractory 
epilepsy may be due to differences in population selection, and characterization of epilepsy.  
Patients with refractory epilepsy account for most of the burden associated with epilepsy 
due to higher number of comorbidities, increased hospitalization, ED and outpatient visits, social 
stigmatization, reduced quality of life, and a decreased life expectancy. Most of the estimates of 
the economic burden of refractory epilepsy are based on patient self-reported data from literature 
and expert panels. Of the few retrospective studies assessing the economic burden of refractory 
epilepsy in the U.S., the average all-cause annual direct cost (2009 dollar) was estimated at $23,238 
(±42,894) to $24,853 (±81,299) for privately insured employees and commercially insured 





Missouri and New Jersey estimated the average all-cause annual direct cost (2009 dollar) at 
$38,708 (±$114,904).13 The state Medicaid programs differ substantially from private insurance 
plans in terms of the demographic characteristics of the populations served, services covered, and 
payment arrangements. The Medicaid program in the state of Texas has the highest proportion of 
Hispanics (63%) the among non-elderly enrollees as compared to any other state.121 In the state of 
Texas, the lifetime prevalence of epilepsy was estimated at 1.7%. About 16% of Texans are 
enrolled in the Medicaid program. In 2013, patient encounters for AEDs ranked second amongst 
the patient encounters for medications prescribed for neurological disorders, with 850,916 
encounters which accounted for $48,307,471 in reimbursed AED claims.122 Given the high 
utilization of AEDs, an empirical study is needed to provide current estimates of the healthcare 
utilization and costs associated with Texas Medicaid patients who have refractory epilepsy. 
In patients with newly diagnosed epilepsy, monotherapy is usually the preferred treatment 
approach. However, in the case of refractory epilepsy, seizure control usually needs drug trials 
consisting of switching or adding an alternative monotherapy to the existing AED regimen.8,20 
There is insufficient evidence suggesting the clinical and economic benefit of adding an adjunctive 
AED as compared to switching to an alternative monotherapy in patients with refractory epilepsy. 
Previous studies assessed the AED utilization in clinical practice before the approval of newer 
AEDs in the U.S.10,24,29,32 As a result, there is a need to study the recent patterns of AED use and 
associated outcomes in patients with refractory epilepsy. Also, previous studies characterizing the 
adherence to AEDs are restricted to patients with epilepsy.29,102,103,105,106 No known study assessed 
the persistence behavior in patients with refractory epilepsy. Given the higher pill burden and 
regimen complexity in patients with refractory epilepsy, the role of adherence and persistence in 
refractory epilepsy needs to be explored. In the case of comorbidities, about three-fourths of the 





clinical burden and complicates the management of epilepsy.110 Moreover, comorbid conditions 
raise the cost of medical care, through increased pharmacy, outpatient office visits, and inpatient 



















2.5 Objectives and Hypotheses 
This study has 3 objectives concerning the (1) demographic and clinical characteristics, (2) 
treatment patterns, and (3) healthcare utilization and costs of patients with and without 
refractory epilepsy.  The objectives are listed below along with their related hypotheses. 
2.5.1 Objective 1: Demographic and Clinical Characteristics 
1. To compare the demographic and clinical characteristics of patients with refractory and 
non-refractory epilepsy. 
H01A: There is no significant difference in the mean age of patients between the refractory and 
non-refractory groups. 
H01B: The proportion of gender categories does not differ between the refractory and non-
refractory groups. 
H01C: The proportion of race/ethnicity categories does not differ between the refractory and 
non-refractory groups. 
H01D: The proportion of epilepsy type categories does not differ between the refractory and 
non-refractory groups. 
H01E: There is no significant difference in the comorbidity burden of patients between the 
refractory and non-refractory groups. 
H01F: There is no significant difference in the proportion of different types of index AED used 





H01G: There is no significant difference in the pill burden of patients between the refractory 
and non-refractory groups. 
2.5.2 Objective 2: Treatment Patterns 
 To compare the treatment patterns of patients with refractory and non-refractory 
epilepsy while controlling for age, gender, race/ethnicity, type of epilepsy, type of index 
AED, baseline CCI, number of psychiatric and presence of non-psychiatric comorbidities 
at follow-up, baseline pill burden, baseline all-cause inpatient visits, baseline number of 
all-cause outpatient visits, baseline all-cause total cost.  
H2A: Patients with refractory epilepsy are less likely to be adherent to AEDs as compared to 
patients with non-refractory epilepsy, while controlling for covariates. 
H2B: Patients with refractory epilepsy are less likely to be persistent (i.e., duration of 
medication use) to AEDs as compared to patients with non-refractory epilepsy, while 
controlling for covariates. 
H2C: Patients with refractory epilepsy are more likely to add an alternative AED as compared 
to patients with non-refractory epilepsy. 
H2D: Patients with refractory epilepsy are more likely to switch to an alternative AED as 








2.5.3 Objective 3: Healthcare Utilization and Costs 
 To compare the all-cause and epilepsy-related healthcare utilization and costs between 
refractory and non-refractory patients while controlling for age, gender, race/ethnicity, type 
of epilepsy, type of index AED, baseline CCI, number of psychiatric and presence of non-
psychiatric comorbidities at follow-up, baseline pill burden, baseline all-cause inpatient 
visits, baseline number of all-cause outpatient visits, baseline all-cause total cost.  
Healthcare Utilization 
H3A-C: Patients with refractory epilepsy have a higher number of all-cause medical visits 
consisting of inpatient hospitalizations (H3A), ED visits (H3B), and outpatient visits (H3C) at 
follow-up as compared to patients with non-refractory epilepsy, while controlling for 
covariates. 
H3D-F: Patients with refractory epilepsy have a higher number of epilepsy-related medical visits 
consisting of inpatient hospitalizations (H3D), ED visits (H3E), and outpatient visits (H3F) at 
follow-up as compared to patients with non-refractory epilepsy, while controlling for 
covariates. 
H3G: Patients with refractory epilepsy have longer lengths of stay for all-cause hospitalization 
as compared to patients with non-refractory epilepsy, while controlling for covariates. 
H3H: Patients with refractory epilepsy have longer lengths of stay for epilepsy-related 






H3I-J: Patients with refractory epilepsy have a higher number of all-cause pharmacy claims 
(H3I) and epilepsy-related pharmacy claims (H3J) as compared to patients with non-refractory 
epilepsy, while controlling for covariates. 
Healthcare Cost 
H3K-M: Patients with refractory epilepsy have a higher all-cause medical costs consisting of 
inpatient hospitalizations (H3K), ED visits (H3L), and outpatient visits (H3M) at follow-up as 
compared to patients with non-refractory epilepsy, while controlling for covariates. 
H3N-P: Patients with refractory epilepsy have a higher epilepsy-related medical costs consisting 
of inpatient hospitalizations (H3N), ED visits (H3O), and outpatient visits (H3P) at follow-up as 
compared to patients with non-refractory epilepsy, while controlling for covariates. 
H3Q-R: Patients with refractory epilepsy have a higher cost of all-cause pharmacy claims (H3Q) 
and epilepsy-related pharmacy claims (H3R) as compared to patients with non-refractory 









Chapter 3 Methodology 
Chapter Overview 
This chapter provides a description of the methodology used to evaluate the treatment patterns 
and healthcare utilization and costs between patients with refractory and non-refractory epilepsy. 
The chapter includes a description of the data source, study population, sample selection criteria, 
study design, study variables, statistical analyses, sample size calculations, and potential 
limitations for the study.  
3.1 Institutional Review Board Approval 
The study proposal was reviewed by the Institutional Review Board (IRB) of The University 
of Texas at Austin and by Texas Medicaid. A waiver of informed consent was requested as the 
study used de-identified patient claims and, as a result, did not meet the definition of research 
involving human subjects. 
3.2 Data Source 
The proposed study used Texas Medicaid claims data from September 01, 2007 through 
December 31, 2013. The services provided by the Texas Medicaid program include office-based 
outpatient services, inpatient and outpatient hospital services, long-term care services, lab services, 








3.3 Study Population 
All patients enrolled in Texas Medicaid between September 01, 2007 and December 31, 
2013 (Figure 3.1) who met the sample selection criteria, as discussed in the next section, were 
included in the study. 
3.3.1 Study Inclusion Criteria  
Patients were included in the study if they: 1) had at least one AED prescription claim in 
the identification period (March 01, 2008 through December 31, 2011); 2) had at least one inpatient 
claim and/or at least two outpatient claims associated with an epilepsy diagnosis (ICD-9-CM code: 
345.xx) or other convulsions (ICD-9-CM code: 780.39) in any diagnosis field within 6 months of 
the first AED use; 3) had two epilepsy-related outpatient claims at least 30 days apart to ensure 
that the claims were not to rule out the condition; 4) were 18-62 years of age at the index date; 5) 
were continuously enrolled in Texas Medicaid from 6 months prior to the first AED use through 
24 months after the first AED use. 
3.3.2 Study Exclusion Criteria  
Patients were excluded from the study if they: 1) had an AED claim in the 6-month period 
prior to their first AED use during the identification period; 2) had less than three months of any 
AED use, excluding diazepam, without a gap of more than 60 days in the post-identification period 
to ensure that the AEDs were not dispensed for prophylactic use; 3) had evidence of pregnancy in 







3.4 Study Design 
The study employed a retrospective cohort design using individual patient claims from 
Texas Medicaid medical and prescription databases. The study outcomes were compared across 
two mutually exclusive cohorts: 1) patients on three or more AEDs, excluding diazepam, in the 
12-month identification period were defined as the refractory cohort; and 2) all other patients who 
met the study selection criteria were defined as the non-refractory cohort (i.e., they had less than 
3 AEDs in the 12-month identification period). Below is an explanation regarding the basis for 
which the above cohorts were defined. 
To better characterize these patients and to increase the validity of refractory AED use in 
this study, medication profiles from the study sample were reviewed and discussed with a clinician 
expert (Appendix IA). Based on these discussions, a determination regarding the classification of 
refractory and non-refractory patients was made. Since diazepam is not used chronically, it was 
not considered in the definition of refractory epilepsy (see point 1 above). The stepwise selection 
algorithm defining the refractory cohort considers the sequential nature of refractory epilepsy and 
is consistent with the ILAE definition.9 The ILAE commission defines refractory epilepsy as 
“failure of adequate trials of two tolerated and appropriately chosen and used AED schedules 
(whether as monotherapies or in combination) to achieve sustained seizure freedom.9 This 
definition has been previously used by Chen et al. to characterize refractory epilepsy.10 Manjunath 
et al., who used a Medicaid retrospective database, employed a criterion that each AED therapy 
had to have an interval of 30 days. This was a proxy for AED intolerance or inefficacy.13 However, 
this criterion was not employed in this study based on consultations with the clinical expert and 
review of patient profiles (Appendix IA). Technically, use of retrospective databases precludes 





made due to inefficacy and intolerance.  Thus, this study employed clinical expert opinion, which 
led to the definition of refractory patients as those with at least three AEDs in the 12-month follow-
up period.  
For objectives 1, 2, and 3, demographic and clinical characteristics, treatment patterns 
(adherence and persistence), and all-cause and epilepsy-related healthcare utilization and costs 
were compared between the two cohorts, that is, refractory vs. non-refractory epilepsy cohorts for 
the first and second year. In addition, treatment patterns consisting of addition and switch were 
compared between the two cohorts for the first year only. To minimize sample selection bias that 
may occur due to differences between the refractory and non-refractory groups, propensity score 
matching was used and will be discussed in the statistical analysis section.  
3.4.1 Refractory vs. Non-refractory Epilepsy Cohorts 
The identification period began the date of the first AED claim, while the baseline period 
(i.e., no AED use) was defined as the 6-month period prior to the beginning of the identification 
period (i.e., prior to the first AED claim). The index date was the date of the first AED claim. The 
identification period for both cohorts was the 12-month period used to characterize refractory and 
non-refractory cohorts. The follow-up period for both the cohorts was the 24-month period after 
the index date. Figure 3.1 illustrates the data collection period and Figure 3.2 illustrates the study 








 Figure 3.1: Data Collection Period 
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3.5 Study Variables 
The following section describes the dependent and independent variables, and the 
covariates for each objective. The cohorts have been explained in section 3.4.1. 
3.5.1 Demographic and Clinical Characteristics 
For objective 1, the demographic and clinical characteristics of the study population will 
be described and compared among the refractory and non-refractory cohorts (Table 3.1). The 
demographic characteristics consisted of age at index date, gender, race; and the clinical 
characteristics consisted of type of epilepsy, type of index AED use, Charlson Comorbidity Index 
(CCI), and pill burden. CCI and pill burden were measured during the baseline period.  
The main independent variable for objectives 1-3 was the cohort consisting of refractory 
and non-refractory epilepsy (Table 3.1). Regarding covariates (Table 3.1), the demographic 
characteristics included age, gender and race, and the clinical characteristics included type of 
epilepsy (Table 3.1), type of index AED (Table 3.2), comorbidity burden, and pill burden (Table 
3.3).  
The Deyo adaptation of the Charlson Comorbidity Index (CCI) was used to assess the 
baseline comorbidity burden (Table 3.3).123 Though the CCI was initially developed to predict in-
hospital mortality, it has been adapted and is widely used to measure comorbidity burden in 
administrative and claims databases.19 The number of psychiatric and non-psychiatric 
comorbidities was also evaluated to measure the comorbidity burden in the follow-up period. 
Psychiatric and non-psychiatric comorbidities identified in the first year were used as covariates 
for evaluating the effect on adherence, persistence, addition, switch, and healthcare utilization and 





psychiatric and non-psychiatric comorbidities identified in the first and second year follow-up 
periods and acute non-psychiatric comorbidities identified in the second year follow-up period 
were used as covariates for evaluating the effect on adherence, persistence, and healthcare 


















Table 3.1: Summary of Operational Definition of Independent Variables and Covariates 




Age Age of the respondent at the index date 







Type of epilepsy  1=Generalized (ICD-9-CM Code=345.00-345.31) 
2=Partial (ICD-9-CM Code=345.4x, 345.5x, 345.7x) 
3=Other convulsions (ICD-9-CM Code=780.39) 
4=Multiple types 
Type of  index AED 
(See Table 3.2) 
1=Sodium channel blockers  
2=GABA analogues 
3=Calcium channel actions 
4=Multiple actions 
5=Synaptic vesicle protein 2A binding 
6= Potassium channel activity 
7=Combination 
Charlson Comorbidity Index 
(See Table 3.3) 
Deyo adaptation of the Charlson Comorbidity index 
Non-psychiatric comorbidities (First 
and seconda follow-up years) (See 
Appendix IB) 
Number of non-psychiatric comorbidities: 
Alzheimer’s disease, Brain tumor, Head injury, 
Meningitis, Migraine, Stroke, Multiple Sclerosis,  
 
aFracture, Dislocation, Sprains and strains, Open 
wounds, Burns 
Psychiatric comorbidities (First and 
second follow-up years) 
(See Appendix IB) 
Number of psychiatric comorbidities: 
Anxiety disorders, Bipolar disorder, Depression, 
Psychosis, Personality disorder, Mental retardation 
Pill burden Number of AED and non-AED prescriptions 
 






Table 3.2: Categorization for Type of Antiepileptic Drugs 
Mechanism of Action Antiepileptic Drugs 
Sodium channel blocker Acetazolamide, carbamazepine, 
eslicarbazepine acetate, oxcarbazepine, 
phenytoin, fosphenytoin, ethotoin, 
lamotrigine, rufinamide, lacosamide 
GABA-related actions Diazepam, clonazepam, clobazam, 
phenobarbital, primidone, tiagabine, 
vigabatrin 
Calcium channel actions Gabapentin, pregabalin, ethosuximide 
Multiple actions Sodium valproate/valproic acid, felbamate, 
topiramate, perampanel, zonisamide 
SV2A actions Levetiracetam 
Potassium channel activity Retigabine/ezogabine 



















Table 3.3: Deyo Adaptation of the Charlson Comorbidity Index 
Comorbid Conditions Weights Deyo et al. codes 
 Myocardial infarction  1 410.xx, 412 
Congestive heart failure  1 428.x  
Peripheral vascular 
disease  
1 441.x, 443.9, 785.4, V43.4, 38.48 
Cerebrovascular disease  1 430-437.x, 438  
Dementia  1 290.x 
Chronic pulmonary 
disease  
1 490-496, 500-505, 506.4 
Connective tissue 
disease  
1 710.0-710.1, 710.4, 714.0-714.2, 714.81, 725 
Ulcer disease  1 
531.4x-531.7x, 532.4x-532.7x, 533.4x-533.7x, 534.4x-
534.7x, 531.0x-531.3x, 532.0x-532.3x, 533.0x-533.3x, 
534.0x-534.3x, 531.9, 532.9, 533.9, 534.9  
Mild liver disease  1 571.2, 571.4, 571.5, 571.6 
Diabetes  1 250.0x-250.3x, 250.7x  
Diabetes with end organ 
damage  
2 250.4x-250.6x  
Hemiplegia  2 342.x, 344.1 
Moderate or severe 
renal disease  
2 582.x, 583.0-583.7, 585, 586, 588.x 
Any tumor  2 140.x-172.x 
Leukemia 2 174.x-195.x  
Lymphoma 2 200.xx-208.xx 
Moderate or severe liver 
disease  
3 572.2-582.8, 456.0-456.2x 
Metastatic solid tumor  6 196.x-199.x 
AIDS  6 042.x-044.x  










3.5.2 Treatment Patterns 
For objective 2, AED treatment patterns consisting of adherence, persistence, addition, and 
switching were compared among the refractory and non-refractory cohorts (Table 3.5). For the 
treatment pattern variables of addition and switching, only those patients on two or more AEDs in 
the identification period were included. Treatment patterns included AED utilization measured 
from the Texas Medicaid pharmacy claims database. The pharmacy claims database includes: label 
name, GCN (Generic Code Number), NDC (National Drug Code), AHFS (American Hospital 
Formulary Service) code, dispense dates, quantity supplied, days of supply, and amount paid. The 




















Table 3.4: AHFS codes for Antiepileptic Drugs 
AHFS code Class Generic name 
281204 Anticonvulsant, 
Barbiturates 











Phenytoin, Phenytoin Sodium 



































Label names (generic and brand name) and GCNs were used to identify specific AEDs. 
Based on literature, the AEDs listed in Table 3.2 are identified for the treatment of epilepsy and 
were included in the study.10,11,27  
3.5.2.1 Medication Adherence and Persistence 
Medication adherence and persistence was assessed in both the first and second year 
follow-up periods after the index date. Adherence to AEDs was measured using the proportion of 
days covered (PDC) method, which is the number of days of possession of at least one AED 
divided by the total number of days in the follow-up period. 
For the purpose of this study, the following formula was used for calculating PDC29: 
PDC = 
Number of days with a prescription for at least one AED
Number of days in follow-up period (365 days)
 
A PDC of ≥ 0.80 was defined as adherent, while a PDC of < 0.80 was defined as non-
adherent. This threshold has been used in previous studies measuring AED adherence.29,103 A 
sensitivity analysis was conducted using 70% and 90% as cut-offs for adherence. Even if patients 
were on multiple therapies, PDC was measured based on a monotherapy assumption (i.e., did the 
patients have at least one AED in their possession during the follow-up period). 
Medication persistence was computed to determine the duration of medication use and was 
compared between the refractory and non-refractory cohorts. Medication persistence was defined 
as the number of days of continuous AED therapy without a gap of more than 60 days in the 
follow-up period of 365 days. This approach has been previously used in assessing AED treatment 
patterns.27 A pre-specified gap of 60 days allows for delays in the refill of a prescription. Since 





30 and 90 days was conducted. Table 3.5 provides a summary of operational definitions of 
treatment pattern variables. 
3.5.2.2 Addition and Switching of Antiepileptic Drugs 
Medication addition and switching was assessed in the first follow-up period after the index 
date. Since a proportion of patients in the non-refractory cohort were on one AED only in the one-
year identification period, their addition and switch patterns could not be assessed. As a result, 
only those patients on dual therapy or more (i.e., on two or more AEDs in the identification period) 
were included in the study for assessing the addition and switch patterns. These patients were 
matched 1:1 with the patients in the refractory group.  Section 3.6 explains the propensity score 
matching procedure used in the study.  
After discussion with a clinical expert, definitions for addition and switching were 
developed. Addition and switching was assessed based on generic drug names. Addition of an 
AED was defined as the addition of an alternative AED to the first or second AED with an overlap 
of at least 30 consecutive days. Switching was defined as the discontinuation of the first or second 
AED for at least 60 consecutive days and the start of an alternative AED within 30 days of 
discontinuing the initial AED.13,32 Addition and switch patterns based on AED mechanism of 









Table 3.5: Summary of Operational Definitions of Treatment Pattern Variables 
Variables Operational Definitions 
Treatment patterns 
Addition  Addition of at least one alternative AED 
0=No addition  
1=Addition 
Switch  Switch to an alternative AED 
0=No switch 
1=Switch 
Adherence Measured using the PDC method 
0=Non-adherent (PDC < 0.8) 
1=Adherent (PDC ≥ 0.80) 
Persistence  Number of days of continuous therapy without a gap of more than 60 days 
PDC = Proportion of Days Covered 
3.5.3 Healthcare Utilization and Costs 
Healthcare utilization and costs were assessed using the Texas Medicaid medical and 
prescription claims databases (Table 3.6). The medical claims database includes information on 
outpatient visits and inpatient visits, primary and secondary diagnoses, date of service, admission 
and discharge dates, type of provider, and amount paid. For objective 3, the annual epilepsy-related 
and all-cause healthcare utilization and costs in the first and second years in the follow-up period 
after the index date were computed and compared between the refractory and non-refractory 
cohorts. 
3.5.3.1 Epilepsy-related and All-cause Healthcare Utilization 
Epilepsy-related healthcare utilization was defined as the number of medical service claims 
associated with an epilepsy diagnosis (ICD-9-CM codes: 345.xx or 780.39) in the primary and/or 
secondary diagnosis fields.11,24 All-cause healthcare utilization included all medical service claims. 
Medical services included inpatient hospitalizations, ED visits, and outpatient visits. All-cause 





3.5.3.2 Epilepsy-related and All-cause Healthcare Costs 
The total epilepsy-related (i.e., diagnosis-related) healthcare costs included cost of 
epilepsy-related medical visits consisting of inpatient hospitalizations, ED visits, and outpatient 
visits and cost of AED prescriptions. The total all-cause healthcare costs included cost of all-
cause medical visits consisting of inpatient hospitalizations, ED visits, and outpatient visits and 






Table 3.6: Summary of Operational Definitions of Healthcare Utilization and Cost 
Variables 
Variables Operational Definitions 
Epilepsy-Related Healthcare Resource Utilization 
Number of epilepsy-related inpatient 
hospitalizations  
Number of inpatient visits with an epilepsy diagnosis 
Number of epilepsy-related ED visits Number of ED visits with an epilepsy diagnosis 
Number of epilepsy-related outpatient 
visits 
Number of outpatient visits with an epilepsy 
diagnosis 
Number of epilepsy-related pharmacy 
claims 
Number of AEDs  
All-Cause Healthcare Resource Utilization 
Number of all-cause inpatient 
hospitalizations  
Number of inpatient hospitalizations with and 
without an epilepsy diagnosis 
Number of all-cause ED visits Number of ED visits with and without an epilepsy 
diagnosis 
Number of all-cause outpatient visits Number of outpatient visits with and without an 
epilepsy diagnosis 
Number of all-cause pharmacy claims Number of AEDs and non-AEDs 
Epilepsy-Related Healthcare Costs 
Epilepsy-related inpatient 
hospitalization cost 
Cost of inpatient hospitalizations with an epilepsy 
diagnosis 
Epilepsy-related ED visit cost Cost of ED visits with an epilepsy diagnosis 
Epilepsy-related outpatient visit cost Cost of outpatient visits with an epilepsy diagnosis 
Epilepsy-related pharmacy costs  Sum of the costs of AED prescriptions 
Epilepsy-related total costs Sum of the epilepsy-related medical costs, and AED 
prescription costs 
All-Cause Healthcare Costs 
All-cause inpatient hospitalization cost  Cost of inpatient hospitalizations with and without an 
epilepsy diagnosis 
All-cause ED visit cost Cost of ED visits with and without an epilepsy 
diagnosis 
All-cause outpatient visit cost Cost of outpatient visits with and without an epilepsy 
diagnosis 
All-cause pharmacy costs  Sum of the costs of AED and non-AED prescriptions 
All-cause total costs Sum of the all-cause medical visit costs, and AED 
and non-AED prescription costs 
Baseline Healthcare Utilization and Costs 
Baseline All-cause inpatient visits Number of inpatient visits with and without an 
epilepsy diagnosis 
Baseline All-cause outpatient visits Number of outpatient visits with and without an 
epilepsy diagnosis 
Baseline All-cause total health care 
costs 
Sum of the all-cause medical visit costs and non-






3.6 Statistical Analyses 
All statistical analyses were two-tailed, performed using SAS for Windows, Version 9.3 
(SAS Institute, Cary, NC) with a priori significance of p<0.05. Frequencies, histograms, and 
normality tests were computed to check data distribution and abnormalities. Propensity scores 
were calculated using a logistic regression with a nearest neighbor match using a caliper set at 
0.05. A classification of refractory epilepsy (1=Yes, 0=No) was the binary dependent variable, and 
baseline covariates consisting of age, gender, race/ethnicity, type of epilepsy, baseline comorbidity 
burden measured using CCI, baseline pill burden, and baseline all-cause total costs were the 
predictors of selection in the refractory or non-refractory epilepsy group.  
Before matching, statistical comparison of baseline characteristics between the unmatched 
cohorts were conducted using Chi-square for categorical variables and Student’s t-test for 
continuous variables. After matching, to determine if a balance was achieved among the matched 
groups, statistical comparisons of baseline characteristics between the matched cohorts were 
conducted using McNemar’s tests for categorical variables and two-sided paired Student’s t-tests 
for continuous variables. In the case of baseline healthcare costs, due to the skewed nature of cost 










3.6.1 Objective 1: Demographic and Clinical Characteristics 
For objective 1, differences in baseline demographic and clinical characteristics comprising 
of gender, race, type of epilepsy, and type of index AED, were computed using the Pearson Chi-
square tests for categorical variables, while differences in age, comorbidity burden measured using 
the Deyo adaptation of CCI, and pill burden were computed using Student’s t-tests and Wilcoxon 
test for continuous variables across the unmatched refractory and non-refractory cohorts. After 
matching, comparisons of baseline characteristics between the matched cohorts were conducted 
using McNemar’s tests for categorical variables and two-sided paired Student’s t-tests and 
Wilcoxon signed-rank test for continuous variables. 
3.6.2 Objective 2: Treatment Patterns 
For objective 2, adjusted comparisons of medication adherence, and addition and switching 
with the refractory and non-refractory cohorts were computed using Conditional Logistic 
Regression, while the differences in medication persistence among the cohorts were evaluated 
using the Cox Proportional Hazards Regression model. The control variables included age, gender, 
race/ethnicity, type of epilepsy, type of initial AED, baseline CCI, number of psychiatric and non-
psychiatric comorbidities at follow-up, baseline pill burden, baseline number of all-cause inpatient 








3.6.2.1 Logistic Regression Analysis  
A multiple logistic regression analysis was used to account for a nominal variable and two 
or more independent variables. For objective 2, the nominal variable was treatment patterns (i.e., 
addition, switch, adherence), and the independent variables were the cohort covariates, to study 
the effect of the independent variables on the probability of having a specified treatment pattern. 
A conditional logistic regression analysis was employed to account for the matched nature of the 
sample.  
The assumptions for a logistic regression model are125: 
1) The observations are independent.  
2) The natural log of the odds ratio and the measurement variables have a linear relationship 
or a data transformation is needed. 
3) The dependent variable is a dichotomous variable. 
The structure of a logistic regression model is: 
𝐿𝑜𝑔𝑖𝑡[𝜃(𝓍)] = 𝑙𝑜𝑔[𝜃(𝓍) 1 − 𝜃(𝓍)⁄ ] =  𝛽0 + 𝛽1𝑥1 +  𝛽2𝑥2 + ⋯ +  𝛽𝑛𝑥𝑛 
Where, 
𝜃(𝓍): probability of success;  
1 −  𝜃(𝓍): probability of failure;  
𝛽0: constant of equation;  
𝛽1−𝑛: regression coefficients;  






3.6.2.2 Cox Proportional Hazards Regression 
Cox proportional hazards regression with a strata statement was used to account for the 
matched nature of the sample.  A Cox model provides an estimate of the treatment effect on 
survival or a time dependent measure (i.e., persistence), after adjusting for other covariates. The 
model from a Cox proportional hazards regression analysis yields an equation for the hazard as a 
function of several predictor variables.126 




} = 𝛽1𝑋𝑖1 +  𝛽2𝑋𝑖2 +  ⋯ +  𝛽𝑘𝑋𝑖𝑘 
Where, 
ℎ𝑖(𝑡): the hazard at time t; 
ℎ0(𝑡): the baseline hazard; 
𝑋: an independent variable in the model; 











3.6.3 Objective 3: Healthcare Utilization and Costs 
For objective 3, the number of visits for epilepsy-related and all-cause healthcare utilization 
and the annual epilepsy-related and all-cause healthcare costs were computed and compared 
among the refractory and non-refractory cohorts. Poisson regression models were used to compute 
healthcare utilization in objective 3. Regarding healthcare costs, a Generalized Linear Model 
(GLM) was used to account for the matched nature of the sample. The covariates in the models 
included age, gender, race/ethnicity, type of epilepsy, type of index AED, baseline CCI, baseline 
pill burden, baseline number of all-cause inpatient visits, baseline number of all-cause outpatient 
















3.6.3.1 Poisson Regression 
 Poisson regression is used to model count data. Zero-inflated Poisson (ZIP) regression 
models were used with data that was comprised of excess of zeros. A ZIP model has two parts, a 
Poisson count model and a logit model for predicting excess zeros. In ZIP, the excess zeros are 
generated by a separate process from the count values and can be modeled independently.128  
 The simplest Poisson regression equation can be written as: 
𝑙𝑜𝑔(𝜇) =  𝛽0 +  𝛽1𝐸 + 𝑙𝑜𝑔(𝑁) 
Where,  
𝜇 =  𝜆𝑁: number of events per person-time at risk;  
𝐸: independent variable; 
exp(𝛽1): rate ratio; 
𝛽0: constant of equation; 














3.6.3.2 Generalized Linear Models 
A multiple regression model typically takes the following form: 
𝑌 = 𝛽0 +  𝛽1𝑋2 +  𝛽2𝑋2 + ⋯ +  𝛽𝑘𝑋𝑘 + 𝑒 
Where, 
𝑌 variable: a vector of observations;  
𝑋 variables: linearly associated covariates;  
𝛽: regression coefficients; 















Generalized Linear Models 
Generalized linear models (GLM) relate the responses of the dependent variable and 
predictor variables by providing a framework comprising of traditional linear model theory to 
nonlinear data.129   
GLMs take on the following standard model form: 
𝑌 = 𝑔(𝛽0 +  𝛽1𝑋2 +  𝛽2𝑋2 + ⋯ +  𝛽𝑘𝑋𝑘 + 𝑒) 
Where,  
𝑌 variable: a vector of observations; 
𝑋 variables: linearly associated covariates;  
𝛽: regression coefficients;  
𝑒: error variability that cannot be accounted for by the predictors; 
𝑔 (…): a monotonic function which acts on E(y) relating the means of the responses to the linear 
predictors.  
Weighting the observations inversely according to the variance functions then completes 
the estimation of the nonlinear regression equation. This weighting procedure is equivalent to 
maximum likelihood estimation (MLE), of which the Newton-Raphson and Fisher-Scoring 
methods are among the most efficient and widely used, to determine the values of the β 
coefficients.  
The inverse function of g(…) , is called the link function. For the general linear model, the 
dependent variable values follow the normal distribution where the link function is a simple 
identity function (the linear combination of values for the non-transformed predictor variables). 






variable include logistic regression with a proportional response variable, binomial distribution 
and logit link function, Poisson regression in log linear model with a counting response variable, 
Poisson distribution and log link function, and gamma model with log link that include a positive 
and continuous response variable, gamma distribution and a log link function.130,131  
3.7 Sample Size Calculations 
This section describes the sample size calculations for all statistical analyses. For objective 
1, sample size calculations were not conducted as it involves descriptive statistics. 
3.7.1 Logistic Regression Analysis  
Sample size estimates for the model were based on the G-power software. By varying the 
sample parameters required for sample size calculations, the largest sample size of 1,283 was 
chosen for the logistic regression (Table 3.7).132 
Table 3.7: Estimates of Sample Size for Logistic Regression Analysis 
Odds Ratio  1.5  2.0  2.5  3.0  
Pr(Y=1|X=1)Hoa  0.03  0.03  0.03  0.03  
R-squaredb  0.1  0.1  0.1  0.1  
Total Sample Size  988  324  182  126 
Odds Ratio  1.5  2.0  2.5  3.0  
Pr(Y=1|X=1)Hoa  0.03  0.03  0.03  0.03  
R-squaredb  0.2  0.2  0.2  0.2  
Total Sample Size  1,123  364 204 141  
Odds Ratio  1.5  2.0  2.5  3.0  
Pr(Y=1|X=1)Hoa  0.03  0.03  0.03  0.03  
R-squaredb  0.3  0.3  0.3  0.3  
Total Sample Size  1,283  416  233  161 
Y = dependent variable; X = independent variables (IV); test family = Z tests number of tails = 2, α = 0.05 (two 
tailed), β = 0.20 (power = 80%), a binomial distribution was assumed for the IV of interest (X1)  
a Denotes the probability of an event under Ho (lowest possible value which translates to highest possible sample 
size after evaluating the values reported across studies in the literature). b The value achieved when X1 is regressed 






3.7.2 Cox Proportional Hazards Regression Analysis  
The estimates of sample size required for the Cox proportional hazards regression analysis 
were obtained using the PASS (Power Analysis & Sample Size) software. By varying the sample 
parameters required for sample size calculations, the largest sample size of 1,662 was chosen for 
the Cox proportional hazards regression (Table 3.8).133  
Table 3.8: Estimates of Sample Size for Cox Proportional Hazards Regression Analysis 
B (log Hazard ratio)a  1.5  1.5  1.5  
P(Overall Event Rate)b  0.3  0.5  0.7 
R-squaredc  0.1  0.1  0.1  
Total Sample Size  1,292  776  554  
B (log Hazard ratio)a  1.5  1.5  1.5  
P(Overall Event Rate)b  0.3  0.5  0.7  
R-squaredc  0.3  0.3 0.3  
Total Sample Size  1,662 997  712 
B (log Hazard ratio)a  3.0  3.0  3.0  
P (Overall Event Rate)b  0.3  0.5  0.7 
R-squaredc  0.1  0.1  0.1  
Total Sample Size  323 194 139  
B (log Hazard ratio)a  3.0  3.0  3.0  
P(Overall Event Rate)b  0.3  0.5  0.7 
R-squaredc  0.3  0.3  0.3  
Total Sample Size  416  250 178  
B (log Hazard ratio)a  4.5  4.5 4.5 
P(Overall Event Rate)b  0.3  0.5  0.7 
R-squaredc  0.1  0.1  0.1  
Total Sample Size  144  87  62  
B (log Hazard ratio)a  4.5 4.5 4.5 
P (Overall Event Rate)b  0.3  0.5  0.7 
R-squaredc  0.3  0.3  0.3  
Total Sample Size  185  111  80 
Y = dependent variable; X = independent variables (IV); α = 0.05 (two tailed), β = 0.20 (power = 80%), standard 
deviation = 0.1  
a Known as the regression coefficient defined as the predicted change in log(base e) hazards at one unit change in X1 
when the other covariates are held constant  
b Denotes the proportion of subjects in which the event of interest occurs during the duration of the study (Based on 
values reported in the literature, the modeled event was medication discontinuation over a 12-month follow-up 
period) 






3.7.3 Multiple Regression Analysis 
The sample size for the GLM model was estimated using the multiple regression test in the 
G-power software.132 The sample size estimate was calculated using a fixed effect linear multiple 
regression model with R2 deviation from zero, 𝛼 of 0.05, and a power of 0.80. Based on the number 
of predictor variables (n = 12) and an effect size of 0.02, a sample size of 1,304 patients was 
required to test objectives 3 and 4. Thus, for all statistical analyses, a minimum sample size of 




Table 3.9: Summary of Objectives, Hypotheses, Study Variables, and Statistical Tests 











Objective 1: To compare the demographic and clinical characteristics of patients with refractory and non-refractory epilepsy 
H01A: There is no significant difference in 
the mean age of patients between the 







H01B: The proportion of gender categories 





Categorical McNemar’s testsa 
H01C: The proportion of race/ethnicity 
categories does not differ between the 




Categorical McNemar’s testsa 
H01D: The proportion of epilepsy type 
categories does not differ between the 






Categorical McNemar’s testsa 
H01E: There is no significant difference in 
the comorbidity burden of patients 










H01F: There is no significant difference in 
the proportion of different types of index 
AED used between the refractory and 
non-refractory groups. 





Categorical McNemar’s testsa 
H01G: There is no significant difference in 
the pill burden of patients between the 
refractory and non-refractory groups. 














Table 3.9: Summary of Objectives, Hypotheses, Study Variables, and Statistical Tests (Continued) 











Objective 2: To compare the treatment patterns of patients with refractory and non-refractory epilepsy 
H2A: Patients with refractory epilepsy are 
less likely to be adherent to AEDs as 
compared to patients with non-refractory 










H2B: Patients with refractory epilepsy 
have lesser duration of medication use 
prior to discontinuation as compared to 
patients with non-refractory epilepsy, 












H2C: Patients with refractory epilepsy are 
more likely to add an adjunctive AED as 











H2D: Patients with refractory epilepsy are 
more likely to switch to an alternative 
AED as compared to patients with non-
refractory epilepsy. 


















Table 3.9: Summary of Objectives, Hypotheses, Study Variables, and Statistical Tests (Continued) 











Objective 3: To compare the all-cause and epilepsy-related healthcare utilization and costs between refractory and non-refractory 
patients 
H3A-C: Patients with refractory epilepsy 
have a higher number of all-cause 
medical visits consisting of inpatient 
hospitalizations (H3A), ED visits (H3B), 
and outpatient visits (H3C) at follow-up 
as compared to patients with non-













H3D-F: Patients with refractory epilepsy 
have a higher number of epilepsy-related 
medical visits consisting of inpatient 
hospitalizations (H3D), ED visits (H3E), 
and outpatient visits (H3F) at follow-up as 
compared to patients with non-refractory 













H3G: Patients with refractory epilepsy 
have longer length of stays for all-cause 
hospitalization as compared to patients 
with non-refractory epilepsy, while 













H3H: Patients with refractory epilepsy 
have longer length of stays for epilepsy-
related hospitalization as compared to 
patients with non-refractory epilepsy, 



















Table 3.9: Summary of Objectives, Hypotheses, Study Variables, and Statistical Tests (Continued) 











H3I-J: Patients with refractory epilepsy 
have a higher number of all-cause 
pharmacy claims (H3I) and epilepsy-
related pharmacy claims (H3J) as 
compared to patients with non-refractory 
epilepsy, while controlling for covariates. 








H3K-M: Patients with refractory epilepsy 
have a higher all-cause medical costs 
consisting of inpatient hospitalizations 
(H3K), ED visits (H3L), and outpatient 
visits (H3M) at follow-up as compared to 
patients with non-refractory epilepsy, 











H3N-P: Patients with refractory epilepsy 
have a higher epilepsy-related medical 
costs consisting of inpatient 
hospitalizations (H3N), ED visits (H3O), 
and outpatient visits (H3P) at follow-up as 
compared to patients with non-refractory 












H3Q-R: Patients with refractory epilepsy 
have a higher cost of all-cause pharmacy 
claims (H3Q) and epilepsy-related 
pharmacy claims (H3R) as compared to 
patients with non-refractory epilepsy, 











*Cohort covariates include: age, gender, race/ethnicity, type of epilepsy, type of AED, baseline CCI, number of psychiatric and presence of non-psychiatric 






Chapter 4 Results 
Chapter Overview 
This chapter provides a detailed description of the study results. First, the sample attrition 
table is presented, followed by the characteristics of the study sample. Next, the results of the study 
are presented in the order of the study objectives and hypotheses. 
4.1 Sample Selection 
For the present study, each patient in Texas Medicaid was followed for 2.5 years. The 
identification period began on the date of first AED claim, while the baseline period (i.e., no AED 
use) was defined as the 6-month period prior to the beginning of the identification period (i.e., 
prior to the AED claim). The index date was the date of the first AED claim. The 12-month 
identification period was used to characterize refractory and non-refractory cohorts. Patients were 
followed for a 24-month period after the index date. 
All patients in Texas Medicaid between September 01, 2007 and December 31, 2013 who met 
the sample selection criteria were included in the study (Figure 4.1). The Texas Medicaid 
population was comprised of 349,916 patients who had at least one AED prescription in the index 
period (i.e., between March 01, 2008 and December 31, 2011). After applying the remaining study 
inclusion and exclusion criteria, a sample size of 10,599 patients was obtained. Of these, 2,809 













































At least one AED in index perioda with no baseline use 
N=349,916 
 
18-62 years of age at index date 
N=209,600 
 
1 inpatient or 2 outpatient claims 30 days apart with epilepsy diagnosis 
N=26,823 
 
Continuously enrolled 6 months pre- and 24 months post-index date 
N=16,724 
3 months of chronic AED use without a gap of 60 days in follow-up periodb 
N=13,791 
 
Not pregnant in study periodc 
N=13,151d 
 
Not dual eligible for Medicare and Medicaid in study periodc 
N=10,599 
Final Total Sample Size 
 
Final Cohorts 
Refractory N=2,809; Non-refractory N=7,790 
 
aMarch 01, 2008 – December 31, 2011 
b2 years from index date 
c6-month pre- and 2-years post-index date 









4.2 Descriptive Statistics of the Entire Study Sample 
Patient characteristics consisting of demographics, clinical characteristics, and healthcare 
utilization and costs for the entire study sample are presented in Table 4.1. 
4.2.1 Demographic Characteristics 
The patients (n=10,599) had a mean (± SD) age of 38.7 (± 13.2) years. A slightly higher 
proportion of patients were females (51.6%) as compared to males (48.4%). Also, the highest 
proportion of patients were Caucasians (40.2%), followed by Hispanics (31.7%), African 
American (20.3%), and others or unknown race (7.8%).  
4.2.2 Clinical Characteristics 
The mean (± SD) number of AEDs in the identification period (i.e., within 12 months of 
index date) was (2.0 (± 1.0). The highest proportion of patients was on one AED (38.5%), followed 
by patients on two AEDs (35.0%), and patients on three or more AEDs (26.5%). Also, a majority 
of the patients was on monotherapy (82.7%) on the index date (i.e., date of the first AED use). A 
majority of the patients had an epilepsy diagnosis classified as other convulsions (79.8%). The 
highest proportion of patients had claims for sodium channel blockers (40.5%) on the index date, 
followed by those with claims for AEDs with multiple actions (20.0%), AED combinations 
(14.5%), and GABA analogues (10.9%). Patients had a mean of 1.0 (± 1.1) psychiatric comorbidity 
at baseline (i.e., within 6 months pre-index), 1.4 (± 1.3) in the first year of follow-up, and 1.8 (± 
1.4) in the second year of follow-up. Of the psychiatric comorbidities, the highest proportion of 
patients had personality disorder in both the first (36.1%) and second (46.1%) year of follow-up, 






Regarding non-psychiatric comorbidities, the mean (± SD) number at baseline was 0.4 (± 0.7), 0.6 
(± 0.8) in the first year of follow-up, and 0.6 (± 0.9) in the second year of follow-up. Of the non-
psychiatric comorbidities, the highest proportion of patients had stroke in the first (11.0%) and 
second (14.8%) year of follow-up, followed by sprain in the first year (10.1%) of follow-up and 
migraine in the second year (10.2%) of follow-up. The mean (± SD) CCI score in the baseline 
period was 0.8 (± 1.4). 64.0% of patients had a CCI score of 0. In the baseline period, the mean (± 
SD) pill burden of patients was 7.8 (± 6.5). 23.9% of patients had a pill burden of greater than or 
equal to 11 pills. 
4.2.3 Healthcare Utilization and Costs 
In the baseline period, the mean (± SD) prescription cost per patient was $3,286 (± 
$4,503).  Although, the majority of patients did not have an all-cause inpatient visit (80.9%), the 
patients had a mean (± SD) all-cause inpatient visit cost of $2,006 (± $9,020). 25.8% of patients 
had 18 or more all-cause outpatient visits and had a mean (± SD) all-cause outpatient visit cost of 























  N % 
Demographic Characteristics 
Age at index date¶ 
  Mean ± SD, year 38.7 ± 13.2 
Gender 
  Male  5,131 48.4 
  Female 5,468 51.6 
Race/Ethnicity 
  Caucasian 4,262 40.2 
  African American 2,152 20.3 
  Hispanic 3,357 31.7 
  Other/Unknowna 828 7.8 
Clinical Characteristics 
Number of antiepileptic drugs in the identification period§ 
  Mean ± SD 2.0 ± 1.0 
  One Antiepileptic drug 4,081 38.5 
  Two Antiepileptic drugs 3,709 35.0 
  Three or more Antiepileptic drugs 2,809 26.5 
Type of therapy at index dateb 
  Monotherapy 8,769 82.7 
  Dual therapy 1,429 13.5 
  Triple therapy or more 236 2.2 
Type of epilepsy at first visit 
  Generalized 1,003 9.4 
  Partial 750 7.1 
  Other convulsions 8,453 79.8 
  Multiple typesc 393 3.7 
Type of index Antiepileptic drug 
  Sodium channel blockers  4,297 40.5 
  Gamma-aminobutyric acid (GABA) analogues 1,157 10.9 
  Calcium channel blockers 492 4.6 
  Multiple actions 2,115 20.0 
  Synaptic vesicle protein 2A binding 1,004 9.5 
  Potassium channel agonist 0 0.0 



















  N % 
Clinical Characteristics 
Baseline psychiatric comorbidities 
  Mean ± SD 1.0 ± 1.1 
  0 4,464 42.1 
  1 3,210 30.3 
  >1 2,925 27.6 
Follow-up psychiatric comorbidities (First year) 
  Mean ± SD 1.4  ± 1.3 
  0 3,263 30.8 
  1 3,212 30.3 
  >1 4,124 38.9 
Type of psychiatric comorbidities (First year)e 
  Depression 2,775 26.2 
  Anxiety 2,034 19.2 
  Bipolar disorder 911 8.6 
  Psychosis 2,253 21.3 
  Personality disorder 3,827 36.1 
  Mental retardation 2,592 24.5 
Follow-up psychiatric comorbidities (Second year) 
  Mean ± SD 1.8  ± 1.4 
  0 2,260 21.3 
  1 2,931 27.7 
  >1 2,649 25.0 
Type of psychiatric comorbidities (Second year)e 
  Depression 3,638 34.3 
  Anxiety 2,805 26.5 
  Bipolar disorder 1,265 11.9 
  Psychosis 2,817 26.6 
  Personality disorder 4,884 46.1 
  Mental retardation 3,201 30.2 
Baseline non-psychiatric comorbiditiesf 
  Mean ± SD 0.4 ± 0.7 
  0 7,683 72.5 



















  N % 
Clinical Characteristics 
Baseline non-psychiatric comorbiditiesf 
  >1 634 6.0 
Follow-up non-psychiatric comorbidities (First year) 
  Mean ± SD 0.6  ± 0.8 
  0 6,437 60.7 
  1 2,836 26.8 
  >1 1,326 12.5 
Type of non-psychiatric comorbidities (First year)e 
  Fracture 809 7.6 
  Dislocation 193 1.8 
  Sprain 1,067 10.1 
  Open wounds 1,007 9.5 
  Burns 39 0.4 
  Alzheimer’s disease 364 3.4 
  Brain tumor 156 1.5 
  Head injury  205 1.9 
  Meningitis 51 0.5 
  Migraine 763 7.2 
  Stroke 1,163 11.0 
  Multiple sclerosis 83 0.8 
Follow-up non-psychiatric comorbidities (Second year) 
  Mean ± SD 0.6  ± 0.9 
  0 5,988 56.5 
  1 3,000 28.3 
  >1 1,611 15.2 
Type of non-psychiatric comorbidities (Second year)e 
  Fracture 725 6.8 
  Dislocation 169 1.6 
  Sprain 981 9.3 
  Open wounds 966 9.1 
  Burns 57 0.5 
  Alzheimer’s disease 523 4.9 



















  N % 
Type of non-psychiatric comorbidities (Second year)e 
  Head injury  325 3.1 
  Meningitis 97 0.9 
  Migraine 1,077 10.2 
  Stroke 1,573 14.8 
  Multiple sclerosis 122 1.2 
Baseline Charlson Comorbidity Index 
  Mean ± SD 0.8 ± 1.4 
  0 6,784 64.0 
  1 1,979 18.7 
 >1 1,836 17.3 
Baseline pill burden 
  Mean ± SD 7.8 ± 6.5 
  0 628 5.9 
  1 497 4.7 
  2-4 2,555 24.1 
  5-7 2,594 24.5 
  8-10 1,792 16.9 
  ≥11 2,533 23.9 
Healthcare Utilization and Costs 
Baseline prescription cost 
Mean ± SD, $ 3,286 ± 4,503 
Baseline all-cause inpatient visit 
  Mean ± SD 0.3 ± 0.7 
0 8,574 80.9 
1 1,443 13.6 
>1 582 5.5 
Baseline all-cause inpatient cost 
  Mean ± SD, $ 2,006 ± 9,020 
Baseline all-cause outpatient visit 
Mean ± SD 14.2 ± 14.9 
0 132 1.2 
1 432 4.1 



















  N % 
Healthcare Utilization and Costs 
Baseline all-cause outpatient visit 
6-9 2,176 20.5 
10-13 1,658 15.6 
14-17 1,140 10.8 
≥18 2,735 25.8 
Baseline all-cause outpatient cost 
Mean ± SD, $ 3,984 ± 8,445 
Baseline all-cause total healthcare cost 
Mean ± SD, $ 9,276 ± 15,000 
¶Date of first AED use; §12 months of index date 
aOther race was comprised of patients belonging to American Indian and Asian race 
bTotals may not add up to 100.0% as patients on diazepam (1.6%) only in identification period are not included 
cPatients with more than one type of epilepsy seizures at first visit  
dPatients with more than one AED of a different type on index date 
eTotals may not add up to 100.0% as patients may have had more than one comorbidity 




































4.3 Descriptive Statistics of Patient cohorts (Unmatched) 
Of the entire study sample comprising of 10,599 patients, 26.5% of the patients had three 
or more AEDs in the identification period and were identified as refractory, while the remaining 
73.5% of the patients, with one or two AEDs in the identification period, were identified as non-
refractory. Patient characteristics consisting of demographics, clinical characteristics, and baseline 
healthcare utilization and costs stratified by refractory and non-refractory status, before matching, 
are presented in Table 4.2. Overall, there were statistically significant differences (p<0.05) in all 
the characteristics, except for baseline CCI and multiple types of epilepsy, among the refractory 
and non-refractory cohorts. 
4.3.1 Demographic Characteristics 
Table 4.2 shows that the mean (± SD) age of the patients in the refractory group (38.0 [± 
12.7]) was significantly lower (p=0.0015) than the mean (± SD) age of the patients in the non-
refractory group (38.9 [± 13.4]). A significantly lower (p<0.0001) proportion of patients in the 
refractory group (44.6%) compared to patients in the non-refractory group (49.8%) were male. 
Regarding race/ethnicity, a significantly higher proportion of patients in the refractory group were 
Caucasian (42.8% vs. 39.3%; p=0.011) and Hispanic (34.4% vs. 30.7%; p=0.0003) compared to 
patients in the non-refractory group. In contrast, a significantly lower proportion of patients in the 
refractory group were African American (15.9% vs. 21.9%; p<0.0001) and other/unknown 








4.3.2 Clinical Characteristics 
A significantly higher proportion of patients in the refractory group had epilepsy of the 
generalized (10.7% vs. 9.0%; p=0.0082) and partial type (8.6% vs. 6.5%; p=0.0003) compared to 
patients in the non-refractory group. In contrast, a significantly lower proportion of patients in the 
refractory group had other convulsions (77.0% vs. 80.7%; p=0.0003) compared to patients in the 
non-refractory group. Regarding index AED type, a significantly higher proportion of the patients 
were on GABA analogues (12.1% vs. 10.5%; p=0.0153), calcium channel actions (7.7% vs. 3.5%; 
p<0.0001), and on combination AEDs (26.5% vs. 10.1%; p<0.0001) compared to patients in the 
non-refractory group. In contrast, a significantly lower proportion of patients in the refractory 
group were on sodium channel blockers (27.6% vs. 45.2%; p<0.0001), AEDs with multiple actions 
(18.3% vs. 20.6%; p=0.0104), and on synaptic vesicle protein 2A binding agents (7.8% vs. 10.1%; 
p=0.0004) compared to patients in the non-refractory group. In the case of comorbidity burden, 
there was no significant difference in the CCI measured in the baseline period between patients in 
the refractory and non-refractory groups. Patients in the refractory group (1.6 [± 1.4]) had 
significantly (p<0.0001) higher mean (± SD) number of psychiatric comorbidities in the first year 
follow-up period compared to patients in the non-refractory group (1.4 [± 1.3]). Also, a 
significantly higher (p<0.0001) proportion of patients in the refractory group (47.1%) had at least 
one non-psychiatric comorbidity compared to patients in the non-refractory group (36.4%). 
Similarly, patients in the refractory group (2.1 [± 1.5]) had significantly (p<0.0001) higher mean 
(± SD) number of psychiatric comorbidities in the second year follow-up period compared to 
patients in the non-refractory group (1.6 [± 1.4]). Also, a significantly higher (p<0.0001) 
proportion of patients in the refractory group (51.2%) had at least one non-psychiatric comorbidity 






in the refractory group (8 pills) was significantly higher (p<0.0001) than the median pill burden of 
the patients in the non-refractory group (6 pills).  
4.3.3 Healthcare Utilization and Costs 
In the baseline period, a significantly higher (p<0.0001) proportion of patients in the 
refractory group (21.6%) had at least one all-cause inpatient visit compared to patients in the non-
refractory group (18.2%). Patients in the refractory group (12 visits) had significantly higher 
(p=0.0330) median all-cause outpatient visits compared to patients in the non-refractory group (10 
visits). Also, patients in the refractory group ($7,808) had significantly higher (p<0.0001) median 




























Table 4.2: Comparison of Patient Characteristics by Refractory/Non-Refractory Status 
(Unmatched) (N=10,599) 
Characteristics 
All Refractory Non-refractory 
p-value 
n=10,599 n=2,809 n=7,790 
N % N % N % 
Demographics 
Age at index datea 
  Mean ± SD, year 38.7 ± 13.2 38.0 ± 12.7 38.9 ± 13.4 0.0015  
Genderb 
Male 5,131 48.4 1,252 44.6 3,879 49.8 <0.0001 
Female 5,468 51.6 1,557 55.4 3,911 50.2 
Race/Ethnicityb  
Caucasian 4,262 40.2 1,202 42.8 3,060 39.3 0.0011 
African 
American 
2,152 20.3 446 15.9 1,706 21.9 <0.0001 
Hispanic 3,357 31.7 966 34.4 2,391 30.7 0.0003 
Other/Unknown 828 7.8 195 6.9 633 8.1 <0.0001 
Clinical Characteristics 
Type of epilepsy at first visitb  
Generalized 1,003 9.5 301 10.7 702 9.0 0.0082 
Partial 750 7.1 241 8.6 509 6.5 0.0003 
Other 
convulsions 
8,453 79.8 2,164 77.0 6,289 80.7 <0.0001 
Multiple types 393 3.7 103 3.7 290 3.7  0.8930 
Type of index Antiepileptic drugb 
Sodium channel 
blockers  
4,297 40.5 774 27.6 3,523 45.2 <0.0001 
GABA analogues 1,157 10.9 341 12.1 816 10.5 0.0153 
Calcium channel 
actions 
492 4.6 217 7.7 275 3.5 <0.0001 




1,004 9.5 219 7.8 785 10.1 0.0004 
Combination 1534 14.5 744 26.5 790 10.1 <0.0001 
Baseline Charlson Comorbidity Indexa,b  
Mean ± SD 0.8 ± 1.4 0.8 ± 1.4 0.7 ± 1.4 0.5050 
0 6,784 64.0 1,775 63.2 5,009 64.3 0.2931 
1 1,979 18.7 534 19.0 1,445 18.5 0.5910 
>1 1,836 17.3 500 17.8 1,336 17.2 0.4353 
Number of psychiatric comorbidities (First year)a,d 








Table 4.2: Comparison of Patient Characteristics by Refractory/Non-Refractory Status 
(Unmatched) (N=10,599) (Continued) 
Characteristics 
 
All Refractory Non-refractory  
n=10,599 n=2,809 n=7,790  
N % N % N % p-value 
Clinical Characteristics 
Non-psychiatric comorbidities (First year)b,d 
Yes 4,162 39.3 1,324 47.1 2,838 36.4 <0.0001
  
  
No 6,437 60.7 1,485 52.9 4,952 63.6 
Number of psychiatric comorbidities (Second year)a,d 
Mean ± SD 1.8  ± 1.4 2.1  ± 1.5 1.6  ± 1.4 <0.0001
  
Non-psychiatric comorbidities (Second year)b,d 
Yes 4,611 43.5 1,437 51.2 3,174 40.7 <0.0001 
No 5,988 56.5 1,372 48.8 4,616 59.3 
Baseline pill burdenc 
Median  
(Mean ± SD) 
6 




(7.2 ± 6.0) 
<0.0001 
Baseline Healthcare Utilization and Cost 
Baseline all-cause inpatient visitb  
Yes 2,025 19.1 607 21.6 1418 18.2 <0.0001 
No 8,574 80.9 2202 78.4 6372 81.8 
Baseline all-cause outpatient visitc 
Median  
(Mean ± SD) 
10 
(14.2 ± 14.9) 
12 
(15.8 ± 15.3) 
10 
(13.7 ± 14.7) 
0.0330 
Baseline all-cause total healthcare costc 
Median, $  
(Mean ± SD), $ 
5,485 
(9,276 ± 15,000) 
7,808 
(11,778 ± 17,101) 
4,651 





dMeasured in the follow-up period 




















4.4 Characteristics of Patient cohorts (Matched) 
4.4.1 Use of Propensity Score Matching 
For the present study, as refractory and non-refractory groups differed on the baseline 
characteristics (Table 4.2), 1:1 propensity score matching was performed to minimize the sample 
selection bias that may occur due to residual differences between the groups. Propensity scores 
were estimated using a logistic regression with a nearest neighbor matching approach using a 
caliper set at 0.05. A classification of refractory epilepsy (1=Yes, 0=No) was specified as the 
binary dependent variable in the model. Groups were matched on baseline covariates consisting of 
age, gender, race/ethnicity, type of epilepsy, comorbidity burden measured using CCI, pill burden, 
and all-cause total cost.  
To check if group balance was achieved among the matched groups, statistical comparisons 
of baseline characteristics between the matched pairs were conducted using McNemar’s tests for 
categorical variables and two-sided paired Student’s t-tests for continuous variables. In the case of 
baseline healthcare utilization and cost, due to the skewed nature of the data, unadjusted 
comparisons between the matched cohorts were conducted using the Wilcoxon signed-rank test.  
Table 4.3 presents the patient characteristics consisting of demographics, clinical 
characteristics, healthcare utilization and costs stratified by refractory and non-refractory status, 
after matching. Overall, the propensity score matching balanced the covariates of age, gender, 
Caucasian and other/unknown race/ethnicity, partial, other and multiple types of epilepsy, baseline 
CCI, and baseline pill burden across the two groups. However, there were significant differences 
in African American and Hispanic race/ethnicity, generalized type of epilepsy, and baseline all-






matching process. For the other covariates included in the study, there were significant differences 
in type of index antiepileptic drug, and number of psychiatric comorbidities and presence of one 
or more non-psychiatric comorbidities at first and second year of follow-up. Nearly 47.2% of the 
study sample was lost during the propensity score matching process. The matched study sample 
was comprised of 5,596 patients: 2,798 patients in the refractory group and 2,798 patients in the 

















4.4.2 Objective 1: Demographic and Clinical Characteristics 
1. To compare the demographic and clinical characteristics of patients with refractory and 
non-refractory epilepsy. 
Age 
H01A: There is no significant difference in the mean age of patients between the refractory and 
non-refractory groups. 
The mean (± SD) age of patients in the refractory group was 38.0 (± 12.7) years and in the 
non-refractory group was 37.9 (± 13.6) years. Paired T-test test showed that the mean age of 
patients did not differ significantly among the groups.  
H01A: Failed to reject 
Gender 
H01B: The proportion of gender categories does not differ between the refractory and non-
refractory groups.  
For patients in the refractory group, the proportion of males was 44.7% and females was 
55.3%, while for patients in the non-refractory group; the proportion of males was 43.4% and 
56.6%. McNemar’s test revealed that the gender categories did not differ significantly among the 
groups. 








H01C: The proportion of race/ethnicity categories does not differ between the refractory and non-
refractory groups. 
For patients in the refractory group, the proportion of Caucasians was 42.9%, African 
Americans was 15.9%, Hispanics was 34.3%, and other/unknown race was 6.9%, while for 
patients in the non-refractory group; the proportion of Caucasians was 40.9%, African Americans 
was 20.9%, Hispanics was 30.5%, and other/unknown race was 7.8%. McNemar’s test revealed 
that the proportion of African Americans (p<0.0001) and Hispanics (p=0.0020) differed 
significantly (p<0.0001) among the groups. However, the proportion of Caucasians and 
other/unknown race did not differ significantly among the groups. 
H01C: Rejected 
Type of epilepsy 
H01D: The proportion of epilepsy type categories does not differ between the refractory and non-
refractory groups. 
For patients in the refractory group, the proportion of patients with generalized epilepsy 
was 10.7%, partial epilepsy was 8.6%, other convulsions was 77.1%, and multiple epilepsy types 
was 3.6%, while for patients in the non-refractory group; the proportion of patients generalized 
epilepsy was 12.5%, partial epilepsy was 7.2%, other convulsions was 77.3%, and multiple 






epilepsy differed significantly (p=0.0288) among the groups. However, the proportion of patients 
with partial, other and multiple types of epilepsy did not differ significantly among the groups.  
H01D: Rejected 
Comorbidity burden 
H01E: There is no significant difference in the comorbidity burden of patients between the 
refractory and non-refractory groups. 
The mean (± SD) comorbidity burden of patients in the refractory group and non-refractory 
group was 0.8 (± 1.4). Paired T-test test showed that the mean comorbidity burden of patients did 
not differ significantly among the groups.  
H01E: Failed to reject 
Type of index AED 
H01F: The proportion of the AED type categories does not differ between the refractory and non-
refractory groups. 
For patients in the refractory group, the proportion of patients on sodium channel blockers 
was 27.6%, on GABA analogues was 12.0%, on calcium channel action agents was 7.7%, on 
multiple action agents was 18.3%, on synaptic vesicle protein 2A binding agents was 7.8%, and 
on AED combinations was 26.5%, while for patients in the non-refractory group; the proportion 
of patients on sodium channel blockers was 43.2%, on GABA analogues was 10.2%, on calcium 






2A binding agents was 9.8%, and on AED combinations was 26.5%. McNemar’s test revealed that 
the proportion of patients on sodium channel blockers (p<0.0001), GABA analogues (p=0.0325), 
calcium channel action agents (p<0.0001), multiple action agents (p<0.0001), synaptic vesicle 
protein 2A binding agents (p=0.0082), and AED combinations (p<0.0001) differed significantly 
among the groups.  
H01F: Rejected 
Pill burden 
H01G: There is no significant difference in the pill burden of patients between the refractory and 
non-refractory groups. 
The median pill burden of patients in the refractory group and non-refractory group was 8 
pills. Wilcoxon signed-rank test showed that the median pill burden of patients did not differ 
significantly among the groups.  
H01G: Failed to reject 
Although not part of the study objectives, there were significant differences in the number 
of psychiatric comorbidities and the presence of one or more non-psychiatric comorbidities at first 
and second year of follow-up, and baseline all-cause total healthcare cost across the two groups. 
Paired t-test showed that patients in the refractory group (1.6 [± 1.4]; 1.3 [± 1.3]) had significantly 
higher mean (± SD) number of psychiatric comorbidities compared to patients in the non-
refractory group (2.1 [± 1.5]; 1.8 [± 1.4]) at first (p<0.0001) and second (p<0.0001) year of follow-






in the refractory group (47.2%; 51.2%) had one or more non-psychiatric comorbidities compared 
to patients in the non-refractory group (38.0%; 41.4%) at first (p<0.0001) and second (p<0.0001) 
year of follow-up, respectively. Regarding baseline all-cause total healthcare cost, Wilcoxon 
signed-rank test showed that patients in the refractory group ($7,778) had significantly higher 
(p<0.0001) median all-cause total healthcare cost compared to patients in the non-refractory group 
($6,216). In addition, McNemar’s test revealed that the proportion of patients with at least one 
baseline all-cause inpatient visit did not differ significantly among the groups. Also, Wilcoxon 
signed-rank test showed that the median baseline all-cause outpatient visits of patients did not 















Table 4.3: Comparison of Patient Characteristics by Refractory/Non-Refractory Status 
(Matched) (N=10,599) 
Characteristics 
All Refractory Non-refractory 
p-value 
n=5,596 n=2,798 n=2,798 
N % N % N % 
Demographics 
Age at index datea,e 
  Mean ± SD, year 38.0 ± 13.1 38.0 ± 12.7 37.9 ± 13.6 0.7184 
Genderb,e 
Male 2,464 44.0 1,251 44.7 1,213 43.4 0.3055 
  Female 3,132 56.0 1,547 55.3 1,585 56.6 
Race/Ethnicityb,e  
Caucasian 2,343 41.9 1,199 42.9 1,144 40.9 0.1391 
African 
American 1,030 18.4 446 15.9 584 20.9 <0.0001 
Hispanic 1,813 32.4 960 34.3 853 30.5 0.0020 
Other/Unknown 410 7.3 193 6.9 217 7.8 0.2183 
Clinical Characteristics 
Type of epilepsy at first visitb,e  
Generalized 650 11.6 299 10.7 351 12.5 0.0288 
Partial 442 7.9 241 8.6 201 7.2 0.0504 
Other 
convulsions 4,319 77.2 2,156 77.1 2,163 77.3 0.8237 
Multiple types 185 3.3 102 3.6 83 3.0 0.1486 
Type of index Antiepileptic drugb 
Sodium channel 
blockers  1,983 35.4 773 27.6 1,210 43.2 <0.0001 
GABA analogues 623 11.1 337 12.0 286 10.2 0.0325 
Calcium channel 
actions 310 5.5 216 7.7 94 3.4 <0.0001 
Multiple actions 1,149 20.5 513 18.3 636 22.7 <0.0001 
Synaptic vesicle 
protein 2A 
binding 490 8.8 217 7.8 273 9.8 0.0082 
Combination 1,041 18.6 742 26.5 299 10.7 <0.0001 
Baseline Charlson Comorbidity Indexa,b  
Mean ± SDe 0.8 ± 1.4  0.8 ± 1.4 0.8 ± 1.4 0.8124  
0 3,515 62.8 1,773 63.4 1,742 62.3 0.3698 
1 1,085 19.4 531 19.0 554 19.8 0.4288 
>1 996 17.8 494 17.7 502 17.9 0.7220 
Number of psychiatric comorbidities (First year)a,d  








Table 4.3: Comparison of Patient Characteristics by Refractory/Non-refractory Status 
(Matched) (Continued) (N=10,599) 
Characteristics 
 
All Refractory Non-refractory 
p-value n=5,596 n=2,798 n=2,798 
N % N % N %  
Clinical Characteristics 
Non-psychiatric comorbidities (First year)b,d 
  Yes 2,382 42.6 1,320 47.2 1,062 38.0 <0.0001 
    No 3,214 57.4 1,478 52.8 1,736 62.0 
Number of psychiatric comorbidities (Second year)a,d 
  Mean ± SD 1.9  ± 1.4 2.1  ± 1.5 1.8  ± 1.4 <0.0001 
Non-psychiatric comorbidities (Second year)b,d  
Yes 2,592 46.3 1,434 51.3 1,158 41.4 <0.0001 
No 3,004 53.7 1,364 48.7 1,640 58.6 
Baseline pill burdenc,e 
Median  
(Mean ± SD) 
8 
(9.5 ± 7.3) 
8 
(9.5 ± 7.3) 
8 
(9.4 ± 7.3) 
0.8133  
Baseline Healthcare Utilization and Cost 
Baseline all-cause inpatient visitb  
Yes 1,202 21.5 600 21.4 602 21.5 0.9469 
No 4,394 78.5 2,198 78.6 2,196 78.5   
Baseline all-cause outpatient visitc 
Median  
(Mean ± SD) 
12 
(16.1 ± 15.9) 
11.5 
(15.7 ± 15.1) 
12 
(16.5 ± 16.7) 
0.2534 
Baseline all-cause total healthcare costc,e,f  
Median  
(Mean ± SD) 
7,064 
(11,308 ± 17,509) 
7,778 
(11,308 ± 17,509) 
6,216 




cWilcoxon signed-rank test 
dMeasured in the follow-up period 
eUsed as predictors of selection in refractory or non-refractory group with caliper set at 0.05(matching) 
fAdjusted to 2013 US dollars 

















4.4.3 Objective 2: Treatment Patterns 
 To compare the treatment patterns of patients with refractory and non-refractory epilepsy 
while controlling for age, gender, race/ethnicity, type of epilepsy, type of index AED, baseline 
CCI, number of psychiatric and presence of non-psychiatric comorbidities at follow-up, 
baseline pill burden, presence of baseline all-cause inpatient visits, baseline number of all-
cause outpatient visits, and baseline all-cause total cost.  
4.4.3.1 Medication Adherence 
H2A: Patients with refractory epilepsy are less likely to be adherent to AEDs as compared to 
patients with non-refractory epilepsy, while controlling for covariates. 
Medication adherence was assessed in the first and second year follow-up period after the 
index date. Adherence to AEDs was measured using the proportion of days covered (PDC) 
method. 
For the purpose of this study, the following formula was used for calculating PDC: 
PDC = 
Number of days with a prescription for at least one AED
Number of days in follow−up period (365 days)
 
Medication adherence was measured using both descriptive statistics and regression 
models. Patients with a PDC value of greater than or equal to 80% were considered adherent and 
a PDC value of less than 80% were considered non-adherent. A sensitivity analysis on 70% and 
90% cut-off was conducted. Paired T-test was used to assess differences in adherence as a 






who were adherent (categorical). Conditional logistic regression was used to compare and 
determine differences in medication adherence patterns of patients with refractory and non-
refractory epilepsy while controlling for age, gender, race/ethnicity, type of epilepsy, type of index 
AED, baseline CCI, number of psychiatric and presence of non-psychiatric comorbidities at 
follow-up, baseline pill burden, presence of baseline all-cause inpatient visits, baseline number of 

















4.4.3.1.1 Medication Adherence (Unadjusted Analyses using Paired T-Test and McNemar’s 
test) 
 Table 4.4 presents medication adherence patterns stratified by refractory and non-refractory 
status. Mean (± SD) adherence of patients in the second year of follow-up was 82.8% (± 23.4%). 
The mean (± SD) adherence of the patients in the refractory group (88.6 [± 19.1]) was significantly 
higher (p<0.0001) than the mean (± SD) adherence of the patients in the non-refractory group 
(77.0% [± 25.8%]). A significantly higher (p<0.0001) proportion of patients in the refractory group 
(85.7%) compared to patients in the non-refractory group (62.8%) were adherent (PDC≥80%) in 
the second year of follow-up. Although overall medication adherence was higher, a similar trend 
was observed in the first year of follow-up (Appendix II).  
Table 4.4: Comparison of Medication Adherence in the Second Year of Follow-Up by 
Refractory/Non-Refractory Status (N=5,596) 
Medication Adherence 
All Refractory Non-refractory 
p-value 
n=5,596 n=2,798 n=2,798 
N % N % N % 
PDC 
  Mean ± SD, % 82.8 ± 23.4 88.6 ± 19.1 77.0 ± 25.8 <0.0001a 
  Adherent (PDC≥80%) 4,156 74.3 2,399 85.7 1,757 62.8 
<0.0001b 
  Non-Adherent (PDC<80%) 1,440 25.7 399 14.3 1,041 37.2 
PDC=Proportion of days covered 
aPaired T-test 
bMcNemar’s test 
















4.4.3.1.2 Medication Adherence (Adjusted Analysis using Conditional Logistic Regression) 
Table 4.5 presents the results of the conditional logistic regression model comparing the 
likelihood of being adherent in the second-year of follow-up by refractory and non-refractory 
groups while controlling for covariates. The results of the overall model fit testing the null 
hypothesis that all parameter estimates are equal to zero indicated that the null hypothesis was 
rejected (p<0.05). Results showed that compared to patients in the non-refractory group, patients 
in the refractory group were 3.6 times (OR=3.553; 95% CI=3.060-4.125; p<0.0001) more likely 
to adhere to AEDs, after controlling for covariates. Regarding covariates, African Americans had 
28.5% (OR=0.715; 95% CI=0.547-0.935; p=0.0142) lower likelihood than Caucasians to adhere 
to AEDs, after controlling for covariates. Patients with a CCI score of 1 had 28.2% (OR=0.718; 
95% CI=0.528-0.977; p=0.0348) lower likelihood than patients with a CCI score of 0 to adhere to 
AEDs, after controlling for covariates. Patients with one or more inpatient visits in the baseline 
period had 24.2% (OR=0.758; 95% CI=0.575-0.998; p=0.0486) lower likelihood than patients 
with no inpatient visits in the baseline period to adhere to AEDs, after controlling for covariates. 
Results were robust in the sensitivity analyses conducted using 70% and 90% cut-off for adherence 
(Appendix II). Similarly, results of the conditional logistic regression model comparing the 
likelihood of being adherent in the first year of follow-up by refractory and non-refractory groups 
showed that compared to patients in the non-refractory group, patients in the refractory group had 







Table 4.5: Conditional Logistic Regression Analysis Comparing the Likelihood of being 





95% CI Wald X2 p-value 
Refractorya 3.553 3.06-4.125 277.01 <0.0001 
Age at index 0.998 0.982-1.015 0.05 0.8277 
Malea 1.347 0.965-1.88 3.06 0.0804 
African American racea 0.715 0.547-0.935 6.02 0.0142 
Other racea 0.865 0.684-1.095 1.46 0.2282 
Partial type of epilepsy at first visita 1.382 0.805-2.373 1.38 0.2404 
Other type of epilepsy at first visita 0.973 0.554-1.71 0.01 0.9244 
Multiple actions of index AEDa 1.235 0.996-1.532 3.69 0.0548 
Baseline CCI of 1a 0.718 0.528-0.977 4.46 0.0348 
Baseline CCI greater than 1a 0.699 0.424-1.15 1.99 0.1584 
Number of psychiatric comorbidities at follow-up 0.940 0.872-1.014 2.57 0.1095 
Non-psychiatric comorbidities at follow-upa 0.940 0.756-1.169 0.31 0.5792 
Baseline pill burden 1.024 0.929-1.128 0.23 0.6321 
Baseline all-cause inpatient visitsa 0.758 0.575-0.998 3.89 0.0486 
Number of baseline all-cause outpatient visits 1.000 0.992-1.009 0.01 0.9562 
Baseline total all-cause healthcare cost 1.000 1.000-1.000 0.21 0.6511 
CI=Confidence Interval; AED=Antiepileptic drug; CCI=Charlson Comorbidity Index 
aReference categories: Non-refractory; Female; Caucasian; Generalized type of epilepsy; Single action of   index 
AED; CCI=0; No non-psychiatric comorbidity; No baseline inpatient visit 
Note: Some variable categories were collapsed due to small cell sizes. 
Race/Ethnicity into three groups (Caucasian, African American and Other);  
Type of epilepsy into three groups (Generalized, Partial and Other);  
Type of index Antiepileptic drug into two groups (Single and Multiple actions). 
Model Fit: likelihood ratio=424.1450; df=16; p<0.0001 
Significant at p<0.05 (in bold) 
H2A: Patients with refractory epilepsy are less likely to be adherent to AEDs as compared to 












H2B: Patients with refractory epilepsy are less likely to be persistent (i.e., duration of medication 
use) to AEDs as compared to patients with non-refractory epilepsy, while controlling for 
covariates. 
Medication persistence (duration of medication use prior to discontinuation) was assessed 
in the first and second year follow-up period after the index date. Medication persistence was 
defined as the number of days of continuous AED therapy without a gap of more than 60 days in 
the follow-up period of 365 days. A pre-specified gap of 60 days allowed for delays in the refill of 
a prescription. Since there was no standard gap for the calculation of persistence in epilepsy, a 
sensitivity analysis on 30 and 90 days was conducted. 
Medication persistence was measured using both descriptive statistics and regression 
models. A paired T-test was used to assess differences in persistence as a continuous measure. Cox 
proportional hazards regression was used to compare and determine differences in the duration of 
medication use prior to discontinuation (persistence) of patients with refractory and non-refractory 
epilepsy while controlling for age, gender, race/ethnicity, type of epilepsy, type of index AED, 
baseline CCI, number of psychiatric and presence of non-psychiatric comorbidities at follow-up, 
baseline pill burden, presence of baseline all-cause inpatient visits, baseline number of all-cause 









4.4.3.2.1 Medication Persistence (Unadjusted Analysis using Paired T-Test) 
 Table 4.6 presents medication persistence patterns stratified by refractory and non-refractory 
status. Mean (± SD) persistence of patients in the second year of follow-up was 311.5 (± 102.5). 
The mean (± SD) persistence of the patients in the refractory group (328.0 [± 87.3]) was 
significantly higher (p<0.0001) than the mean (± SD) persistence of the patients in the non-
refractory group (294.9 [± 113.4]). Although overall medication persistence was higher, a similar 
trend was observed in the first year of follow-up (Appendix III).  
Table 4.6: Comparison of Medication Persistence in the Second Year of Follow-Up by 
Refractory/Non-Refractory Status (N=5,596) 
Medication Persistence 
All Refractory Non-refractory 
p-value n=5,596 n=2,798 n=2,798 
Persistence (60 day gap) 
  Mean ± SD 311.5 ± 102.5 328.0 ± 87.3 294.9 ± 113.4 <0.0001a 
aPaired T-test 

















4.4.3.2.2 Medication Persistence (Adjusted Analysis using Cox Proportional Hazard 
Regression) 
Table 4.7 presents the results of the Cox proportional hazard regression model comparing 
the discontinuation (persistence) in the second-year of follow-up by refractory and non-refractory 
groups while controlling for covariates. The results of the overall model fit testing the null 
hypothesis that all parameter estimates are equal to zero indicated that the null hypothesis was 
rejected (p<0.05). Results showed that compared to patients in the non-refractory group, patients 
in the refractory group had 34.7% (HR=0.653; 95% CI=0.608-0.702; p<0.0001) lower hazard rate, 
after controlling for covariates. Regarding covariates, males had 31.7% (HR=0.805; 95% 
CI=0.687-0.944; p=0.0076) lower hazard rate than females, after controlling for covariates. 
Patients with a CCI of 1 in the baseline period had 16.9% (HR=1.169; 95% CI=1.008-1.356; 
p=0.0394) higher hazard rate than patients with CCI of 0 in the baseline period, after controlling 
for covariates. Patients with one or more inpatient visits in the baseline period had 17.0% 
(HR=1.170; 95% CI=1.022-1.338; p=0.0227) higher hazard rate than patients with no inpatient 
visit in the baseline period, after controlling for covariates. Results were robust in the sensitivity 
analyses conducted using 30 and 90-day gap period (Appendix III). Similarly, results of the cox 
proportional hazard regression model comparing the discontinuation (persistence) in the first year 
of follow-up by refractory and non-refractory groups showed that compared to patients in the non-
refractory group, patients in the refractory group had significantly lower (p<0.05) hazard rate, after 






Table 4.7: Cox Proportional Hazard Regression Analysis Comparing the Likelihood of 
Discontinuation (Persistence 60 Day Gap) in the Second Year of Follow-Up among 








Refractorya 0.653 0.608 - 0.702 135.04 <0.0001 
Age at index 0.994 0.986 - 1.002 2.07 0.1500 
Malea 0.805 0.687 - 0.944 7.13 0.0076 
African American racea 1.077 0.938 - 1.237 1.12 0.2910 
Other racea 0.985 0.881 - 1.101 0.07 0.7894 
Partial type of epilepsy at first visita 0.88 0.689 - 1.125 1.04 0.3080 
Other type of epilepsy at first visita 0.822 0.625 - 1.082 1.96 0.1618 
Multiple actions of index AEDa 0.941 0.849 - 1.042 1.36 0.2439 
Baseline CCI of 1a 1.169 1.008 - 1.356 4.24 0.0394 
Baseline CCI greater than 1a 1.021 0.799 - 1.305 0.03 0.8677 
Number of psychiatric comorbidities at follow-up 1.027 0.991 - 1.065 2.14 0.1435 
Non-psychiatric comorbidities at follow-upa 0.973 0.874 - 1.083 0.25 0.6188 
Baseline pill burden 1.028 0.982 - 1.077 1.38 0.2399 
Baseline all-cause inpatient visitsa 1.170 1.022 - 1.338 5.19 0.0227 
Number of baseline all-cause outpatient visits 0.999 0.995 - 1.003 0.18 0.6698 
Baseline total all-cause healthcare cost 1.000 1.000 – 1.000 0.97 0.3243 
CI=Confidence Interval; AED=Antiepileptic drug; CCI=Charlson Comorbidity Index 
aReference categories: Non-refractory; Female; Caucasian; Generalized type of epilepsy; Single action of   index 
AED; CCI=0; No non-psychiatric comorbidity; No baseline inpatient visit 
Note: Some variable categories were collapsed due to small cell sizes. 
Race/Ethnicity into three groups (Caucasian, African American and Other);  
Type of epilepsy into three groups (Generalized, Partial and Other);  
Type of index Antiepileptic drug into two groups (Single and Multiple actions). 
Model Fit: likelihood ratio=187.7891; df=16; p<0.0001 
Significant at p<0.05 (in bold) 
H2B: Patients with refractory epilepsy are less likely to be persistent to AEDs as compared to 










4.4.3.3 Medication Addition and Switching (Sample Selection) 
Medication addition and switch patterns were assessed in the first year follow-up period 
after the index date. For the purpose of this analysis, only those patients on dual therapy (i.e., on 
two AEDs only in the identification period) of the 7,790 patients in the non-refractory group were 
included. This left a sample of 3,709 patients in the non-refractory group. This was necessary 
because it was not possible for patients on monotherapy (i.e., on one AED only in the identification 
period) to addition or switch to an alternative AED. These 3,709 patients were matched 1:1 with 
the 2,809 patients in the refractory group.  Propensity scores were estimated using a logistic 
regression with a nearest neighbor matching approach using a caliper set at 0.05. A classification 
of refractory epilepsy (1=Yes, 0=No) was specified as the binary dependent variable in the model. 
Groups were matched on baseline covariates consisting of age, gender, race/ethnicity, type of 
epilepsy, comorbidity burden measured using CCI, pill burden, and all-cause total cost.  
Overall, the propensity score matching balanced the covariates of age, gender, Caucasian, 
Hispanic and other race/ethnicity, type of epilepsy, GABA analogues, AEDs with multiple actions 
and synaptic vesicle 2A protein binding agents, baseline CCI, and baseline pill burden across the 
two groups (Appendix IV). 16.9% of the study sample was lost during the propensity score 
matching process. The matched study sample was comprised of 5,414 patients consisting of 2,707 









4.4.3.3.1 Medication Addition 
H2C: Patients with refractory epilepsy are more likely to add an alternative AED as compared 
to patients with non-refractory epilepsy. 
Addition of an AED was defined as the addition of an alternative AED to the first or second 
AED with an overlap of at least 30 consecutive days. Medication addition was measured using 
both descriptive statistics and regression models. McNemar’s test was used to assess differences 
in the proportions of patients who added an AED (categorical) by refractory/non-refractory status. 
Conditional logistic regression was used to compare and determine differences in the medication 
addition patterns of patients with refractory and non-refractory epilepsy while controlling for age, 
gender, race/ethnicity, type of epilepsy, type of index AED, baseline CCI, number of psychiatric 
and presence of non-psychiatric comorbidities at follow-up, baseline pill burden, presence of all-













4.4.3.3.1.1 Medication Addition (Unadjusted Analysis using McNemar’s test) 
 Table 4.8 presents medication addition patterns stratified by refractory and non-refractory 
status. A significantly higher (p<0.0001) proportion of patients in the refractory group (95.1%) 
compared to patients in the non-refractory group (85.2%) added an alternative AED in the first 
year of follow-up.  
 Table 4.9 presents the descriptive statistics of medication addition patterns of refractory and 
non-refractory patients stratified by the MOA of alternative AED. Of all the patients adding an 
AED, a higher proportion of patients added an alternative AED of a different MOA (76.4%) as 
compared to patients adding an alternative AED of a same MOA (23.6%). A significantly lower 
(p<0.0001) proportion of patients in the refractory group (67.1%) compared to patients in the non-
refractory group (86.8%) added an alternative AED of a different MOA in the first year of follow-
up.  
Table 4.8: Comparison of Medication Addition in the First Year of Follow-Up by 
Refractory/Non-Refractory Status (N=5,414) 
Medication Addition 
All Refractory Non-refractory 
p-value 
n=5,414 n=2,707 n=2,707 
N % N % N % 
  Yes 4,880 90.1 2,573 95.1 2,307 85.2 
<0.0001a 
  No 534 9.9 134 4.9 400 14.8 
aMcNemar’s test 









Table 4.9: Comparison of Medication Addition in the First Year of Follow-Up Stratified by 
Mechanism of Action of Alternative AED and Refractory/Non-Refractory Status (N=5,414) 
Medication Addition 
All Refractory Non-refractory 
p-value 
n=5,414 n=2,707 n=2,707 
N % N % N % 
Same MOAa 1,151 23.6 846 32.9 305 13.2 
<0.0001c 
Different MOAb 3,729 76.4 1,727 67.1 2,002 86.8 
Total 4,880 100.0 2,573 100.0 2,307 100.0  
MOA=Mechanism of Action 
aAdding an alternative AED of same MOA 
bAdding an alternative AED of different MOA 
cMcNemar’s test 























4.4.3.3.1.2 Medication Addition (Adjusted Analysis using Conditional Logistic 
Regression) 
Table 4.10 presents the results of the conditional logistic regression model comparing the 
likelihood of addition in the first-year of follow-up by refractory and non-refractory groups while 
controlling for covariates. The results of the overall model fit testing the null hypothesis that all 
parameter estimates are equal to zero indicated that the null hypothesis was rejected (p<0.05). 
Results showed that compared to patients in the non-refractory group, patients in the refractory 
group were 3.7 times (OR=3.723; 95% CI=2.902-4.776; p<0.0001) more likely to add an 
alternative AED, after controlling for covariates. Regarding covariates, patients on AEDs with 
multiple actions were 2.2 times (OR=2.150; 95% CI=1.510-3.063; p<0.0001) more likely than 
patients on AEDs with single actions to add an alternative AED, after controlling for covariates. 
Patients with a CCI score greater than 1 had 45.4% (OR=0.546; 95% CI=0.303-0.981; p=0.0431) 
lower likelihood than patients with a CCI score of 0 to add an alternative AED, after controlling 
for covariates. With every unit increase in the number of psychiatric comorbidities, the likelihood 
of adding an alternative AED decreased by 20.2% (OR=0.798; 95% CI=0.698-0.912; p=0.0010), 
after controlling for covariates. Patients with one or more non-psychiatric comorbidities in the 
first-year follow-up period had 32.2% (OR=0.678; 95% CI=0.481-0.956; p=0.0268) lower 
likelihood than patients with no non-psychiatric comorbidity in the first-year follow-up period to 







Table 4.10: Conditional Logistic Regression Analysis Comparing the Likelihood of Addition 




95% CI Wald X2 p-value 
Refractorya 3.723 2.902-4.776 106.96 <0.0001 
Age at index 1.027 0.976-1.081 1.06 0.3028 
Malea 1.541 0.956-2.483 3.15 0.0759 
African American racea 0.957 0.61-1.502 0.04 0.8482 
Other racea 0.944 0.651-1.368 0.09 0.7606 
Partial type of epilepsy at first visita 2.541 0.875-7.376 2.94 0.0865 
Other type of epilepsy at first visita 1.316 0.394-4.397 0.20 0.6553 
Multiple actions of index AEDa 2.150 1.510-3.063 18.00 <0.0001 
Baseline CCI of 1a 0.643 0.412-1.003 3.78 0.0517 
Baseline CCI greater than 1a 0.546 0.303-0.981 4.09 0.0431 
Number of psychiatric comorbidities at follow-up 0.798 0.698-0.912 10.89 0.0010 
Non-psychiatric comorbidities at follow-upa 0.678 0.481-0.956 4.909 0.0268 
Baseline pill burden 0.961 0.755-1.225 0.109 0.7490 
Baseline all-cause inpatient visitsa 0.891 0.568-1.398 0.259 0.6157 
Number of baseline all-cause outpatient visits 1.005 0.991-1.019 0.549 0.4624 
Baseline total all-cause healthcare cost 1.000 1.000-1.000 0.47 0.4943 
CI=Confidence Interval; AED=Antiepileptic drug; CCI=Charlson Comorbidity Index 
aReference categories: Non-refractory; Female; Caucasian; Generalized type of epilepsy; Single action of   index 
AED; CCI=0; No non-psychiatric comorbidity; No baseline inpatient visit 
Note: Some variable categories were collapsed due to small cell sizes. 
Race/Ethnicity into three groups (Caucasian, African American and Other);  
Type of epilepsy into three groups (Generalized, Partial and Other);  
Type of index Antiepileptic drug into two groups (Single and Multiple actions). 
Model Fit: likelihood ratio=225.4370; df=16; p<0.0001 
Significant at p<0.05 (in bold) 
H2C: Patients with refractory epilepsy are more likely to add an alternative AED as compared to 
patients with non-refractory epilepsy. 













4.4.3.3.2 Medication Switch 
H2D: Patients with refractory epilepsy are more likely to switch to an alternative AED as 
compared to patients with non-refractory epilepsy. 
Switching was defined as the discontinuation of the first or second AED for at least 60 
consecutive days and the start of an alternative AED within (before/after) 30 days of discontinuing 
the initial AED. Medication switch was measured using both descriptive statistics and regression 
models. McNemar’s test was used to assess differences in the proportions of patients who switched 
to an alternative AED (categorical) by the refractory/non-refractory status. Conditional logistic 
regression was used to compare and determine differences in the medication switch of patients 
with refractory and non-refractory epilepsy while controlling for age, gender, race/ethnicity, type 
of epilepsy, type of index AED, baseline CCI, and number of psychiatric and presence of non-
psychiatric comorbidities at follow-up, baseline pill burden, presence of baseline all-cause 












4.4.3.3.2.1 Medication Switch (Unadjusted Analysis using McNemar’s test) 
 Table 4.11 presents medication switch patterns stratified by refractory and non-refractory status. 
A significantly higher (p<0.0001) proportion of patients in the refractory group (28.7%) compared 
to patients in the non-refractory group (10.6%) switched to an alternative AED in the first year of 
follow-up.  
 Table 4.12 presents the descriptive statistics of switch patterns of refractory and non-refractory 
patients stratified by the MOA of alternative AED. Of all the patients switching to an alternative 
AED, a higher proportion of patients switched to an alternative AED of a different MOA (79.1%) 
as compared to patients switching to an alternative AED of a same MOA (20.9%). A significantly 
lower (p<0.0001) proportion of patients in the refractory group (77.9%) compared to patients in 
the non-refractory group (82.5%) switched to an alternative AED of a different MOA in the first 
year of follow-up.  
Table 4.11: Comparison of Medication Switch in the First Year of Follow-Up by 
Refractory/Non-Refractory Status (N=5,414) 
Medication Switch 
All Refractory Non-refractory 
p-value 
n=5,414 n=2,707 n=2,707 
N % N % N % 
  Yes 1,063 19.6 777 28.7 286 10.6 
<0.0001a 
  No 4,351 80.4 1,940 71.3 2,421 89.4 
aMcNemar’s test 










Table 4.12: Comparison of Medication Switch in the First Year of Follow-Up Stratified by 
Mechanism of Action of Alternative AED and Refractory/Non-Refractory Status (N=5,414) 
Medication Switch 
All Refractory Non-refractory 
p-value 
n=5,414 n=2,707 n=2,707 
N % N % N % 
  Same MOAa 222 20.9 172 22.1 50 17.5 
<0.0001c 
  Different MOAb 841 79.1 605 77.9 236 82.5 
  Total 1,063 100.0 777 100.0 286 100.0  
MOA=Mechanism of Action 
aSwitch to an alternative AED of same MOA 
bSwitch to an alternative AED of different MOA 
cMcNemar’s test 





































4.4.3.3.2.2 Medication Switch (Adjusted Analysis using Conditional Logistic Regression) 
Table 4.13 presents the results of the conditional logistic regression model comparing the 
likelihood of switch in the first-year of follow-up by refractory and non-refractory groups while 
controlling for covariates. The results of the overall model fit testing the null hypothesis that all 
parameter estimates are equal to zero indicated that the null hypothesis was rejected (p<0.05). 
Results showed that compared to patients in the non-refractory group, patients in the refractory 
group were 3.6 times (OR=3.591; 95% CI=3.010-4.284; p<0.0001) more likely to switch to an 
alternative AED, after controlling for covariates. Regarding covariates, with every year increase 
in age, the likelihood of switching to an alternative AED was 5.8% lower (OR=0.942; 95% 
CI=0.902-0.984; p=0.0073), after controlling for covariates. Males had 48.0% (OR=0.520; 95% 
CI=0.352-0.770; p=0.0011) lower likelihood than females to switch to an alternative AED, after 
controlling for covariates. Patients with partial epilepsy had 66.5% (OR=0.335; 95% CI=0.168-
0.670; p=0.0020) lower likelihood than patients with generalized epilepsy to switch to an 
alternative AED, after controlling for covariates. Patients with other types of epilepsy had 73.1% 
(OR=0.269; 95% CI=0.105-0.692; p=0.0065) lower likelihood than patients with generalized 
epilepsy to switch to an alternative AED, after controlling for covariates. Patients on AEDs with 
multiple actions had 41.9% (OR=0.581; 95% CI=0.453-0.745; p<0.0001) lower likelihood than 
patients on AEDs with single actions to switch to an alternative AED, after controlling for 
covariates. Patients with a CCI score of 1 were 1.5 times (OR=1.458; 95% CI=1.032-2.058; 
p=0.0323) more likely than patients with a CCI score of 0 to switch to an alternative AED, after 
controlling for covariates. With every unit increase in the number of psychiatric comorbidities, the 
likelihood of switching to an alternative AED increased by 1.2 times (OR=1.219; 95% CI=1.108-






the baseline period, the likelihood of switching to an alternative AED increased by 1.3 times 



















Table 4.13: Comparison of Medication Switch in the First Year of Follow-Up Stratified by 




95% CI Wald X2 p-value 
Refractorya 3.591 3.010-4.284 201.71 <0.0001 
Age at index 0.942 0.902-0.984 7.20 0.0073 
Malea 0.520 0.352-0.770 10.67 0.0011 
African American racea 1.036 0.738-1.455 0.04 0.8372 
Other racea 1.054 0.816-1.362 0.16 0.6872 
Partial type of epilepsy at first visita 0.335 0.168-0.670 9.56 0.0020 
Other type of epilepsy at first visita 0.269 0.105-0.692 7.42 0.0065 
Multiple actions of index AEDa 0.581 0.453-0.745 18.24 <0.0001 
Baseline CCI of 1a 1.458 1.032-2.058 4.58 0.0323 
Baseline CCI greater than 1a 1.215 0.769-1.921 0.70 0.4038 
Number of psychiatric comorbidities at follow-up 1.219 1.108-1.341 16.56 <0.0001 
Non-psychiatric comorbidities at follow-upa 0.927 0.719-1.195 0.34 0.5584 
Baseline pill burden 1.270 1.033-1.562 5.15 0.0232 
Baseline all-cause inpatient visitsa 1.272 0.882-1.836 1.66 0.1976 
Number of baseline all-cause outpatient visits 1.007 0.996-1.017 1.58 0.2083 
Baseline total all-cause healthcare cost 1.000 1.000-1.000 4.92 0.0266 
CI=Confidence Interval; AED=Antiepileptic drug; CCI=Charlson Comorbidity Index 
aReference categories: Non-refractory; Female; Caucasian; Generalized type of epilepsy; Single action of   index 
AED; CCI=0; No non-psychiatric comorbidity; No baseline inpatient visit 
Note: Some variable categories were collapsed due to small cell sizes. 
Race/Ethnicity into three groups (Caucasian, African American and Other);  
Type of epilepsy into three groups (Generalized, Partial and Other);  
Type of index Antiepileptic drug into two groups (Single and Multiple actions). 
Model Fit: likelihood ratio=424.1450; df=16; p<0.0001 
Significant at p<0.05 (in bold) 
 
H2D: Patients with refractory epilepsy are more likely to switch to an alternative AED as compared 
to patients with non-refractory epilepsy. 












4.4.4 Objective 3: Healthcare Utilization and Costs 
 To compare all-cause and epilepsy-related healthcare utilization and costs between 
refractory and non-refractory patients while controlling for age, gender, race/ethnicity, type 
of epilepsy, type of index AED, baseline CCI, number of psychiatric and presence of non-
psychiatric comorbidities at follow-up, baseline pill burden, presence of baseline all-cause 
inpatient visits, baseline number of all-cause outpatient visits, and baseline all-cause total 
cost.  
4.4.4.1 Healthcare Utilization 
H3A-C: Patients with refractory epilepsy have a higher number of all-cause medical visits 
consisting of inpatient hospitalizations (H3A), ED visits (H3B), and outpatient visits (H3C) at 
follow-up as compared to patients with non-refractory epilepsy, while controlling for 
covariates. 
H3D-F: Patients with refractory epilepsy have a higher number of epilepsy-related medical 
visits consisting of inpatient hospitalizations (H3D), ED visits (H3E), and outpatient visits 
(H3F) at follow-up as compared to patients with non-refractory epilepsy, while controlling 
for covariates. 
H3G: Patients with refractory epilepsy have longer lengths of stay for all-cause 
hospitalization as compared to patients with non-refractory epilepsy, while controlling for 
covariates. 
H3H: Patients with refractory epilepsy have longer lengths of stay for epilepsy-related 







H3I-J: Patients with refractory epilepsy have a higher number of all-cause pharmacy claims 
(H3I) and epilepsy-related pharmacy claims (H3J) as compared to patients with non-refractory 
epilepsy, while controlling for covariates. 
All-cause and epilepsy-related healthcare utilization of the patients was assessed in the first 
and second year of follow-up after the index date. All-cause healthcare utilization consisted of the 
number of medical service and pharmacy claims. Epilepsy-related healthcare utilization was 
defined as the number of medical service claims associated with an epilepsy diagnosis (ICD-9-CM 
codes: 345.xx or 780.39) in the primary and/or secondary diagnoses field and pharmacy claims. 
Medical services included inpatient hospitalizations, ED visits, and outpatient visits. All-cause 
pharmacy claims consisted of the number of AEDs and non-AEDs. Epilepsy-related pharmacy 
claims consisted of the number of AEDs. Healthcare utilization was measured using McNemar’s 
test, Wilcoxon signed-rank test, and regression models. Zero-inflated Poisson regression or 
Poisson regression was used to compare and determine differences in healthcare utilization of 
patients with refractory and non-refractory epilepsy while controlling for covariates. Cox 
proportional hazards regression was used to compare and determine differences in lengths of 
hospitalization stay of patients with refractory and non-refractory epilepsy while controlling for 
covariates. The covariates included in the models were age, gender, race/ethnicity, type of 
epilepsy, type of index AED, baseline CCI, number of psychiatric comorbidities and presence of 
non-psychiatric comorbidities at follow-up, baseline pill burden, presence of baseline all-cause 








4.4.4.1.1 All-Cause Inpatient Hospitalization and ED Visits  
Of the 5,596 patients, 26.2% of the patients had at least one all-cause inpatient 
hospitalization, and 58.1% of the patients had at least one all-cause ED visit. For the present study, 
all-cause inpatient hospitalization and ED visits were combined to compare and determine 
differences in the patients with refractory and non-refractory epilepsy while controlling for 
covariates.  
4.4.4.1.1.1 All-Cause Inpatient Hospitalization and ED Visits (Unadjusted Analyses using 
Wilcoxon Signed-Rank Test and McNemar’s Test) 
 Table 4.14 presents the all-cause inpatient hospitalization and ED visits stratified by refractory 
and non-refractory status. Patients in the refractory group (3.0 [± 5.1]) had significantly higher 
(p<0.0001) mean (± SD) all-cause inpatient hospitalization and ED visits compared to patients in 
the non-refractory group (2.3 [± 4.5]). Also, a significantly higher (p<0.0001) proportion of 
patients in the refractory group (65.7%) had at least one all-cause inpatient hospitalization and ED 
visit compared to patients in the non-refractory group (56.1%). Although slightly higher numbers 
and proportions than second year of follow-up, a similar trend in the number of all-cause inpatient 









Table 4.14: Comparison of All-Cause Inpatient Hospitalization and ED Visits in the Second 
Year of Follow-Up by Refractory/Non-Refractory Status (N=5,596) 
 
All Refractory Non-refractory 
p-value 
n=5,596 n=2,798 n=2,798 
N % N % N % 
All-Cause Inpatient Hospitalization and ED Visits 
  Median 
  (Mean ± SD) 
1  
(2.7 ± 4.8) 
1  
(3.0 ± 5.1) 
1  
(2.3 ± 4.5) <0.0001a 
  Yes  3,410 60.9 1,839 65.7 1,571 56.1 
<0.0001b 
  No  2,186 39.1 959 34.3 1,227 43.9 
aWilcoxon signed-rank test 
bMcNemar’s test 









































4.4.4.1.1.2 All-Cause Inpatient Hospitalization and ED Visits (Adjusted Analysis using 
Zero-Inflated Poisson Regression) 
Table 4.15 presents the results of the zero-inflated Poisson (ZIP) regression model 
comparing the all-cause inpatient hospitalization and ED visits in the second-year of follow-up by 
refractory and non-refractory groups while controlling for covariates. The results of the overall 
model fit testing the full model without a model with predictors’ states that the model, as a whole, 
is statistically significant (p<0.05). Also, results of the Vuong test comparing ZIP model with 
standard Poisson regression indicated that the ZIP model was better (p<0.05). Note: The ZIP model 
first tests zero vs. non-zero (dichotomous) and then it tests all values > 0. Results of the 
dichotomous ZIP model indicated, patients in the refractory group had 38.0% [exp(-0.4774)] lower 
odds (p<0.0001) of being in a “certain zero” group as compared to patients in the non-refractory 
group (results not shown). Also, of all the patients with > 0 all-cause inpatient hospitalization and 
ED visits, there was no significant difference in the expected number of the visits between patients 
in the refractory and non-refractory groups, after controlling for covariates. Regarding covariates, 
increasing age, male gender, index AED with multiple actions, and increasing pill burden were 
associated with a significantly lower (p<0.05) number of all-cause inpatient hospitalization and 
ED visits. In contrast, African American race, other types of epilepsy, baseline CCI of 1 and greater 
than 1, increasing number of psychiatric comorbidities, one or more non-psychiatric comorbidities, 
one or more baseline inpatient visits, and increasing number of baseline outpatient visits were 
associated with a significantly higher (p<0.05) number of all-cause inpatient hospitalization and 






Table 4.15: Zero-Inflated Poisson Regression Comparing the All-Cause Inpatient 
Hospitalization and ED Visits in the Second Year of Follow-Up among Refractory/Non-
Refractory Patients (N=5,596) 




Refractorya 0.0233 -0.0118 - 0.0585 1.69 0.1936 
Age at index -0.0031 -0.0046 - -0.0016 16.67 <0.0001 
Malea -0.0569 -0.0924 - -0.0213 9.83 0.0017 
African American racea 0.1495 0.1043 - 0.1946 42.1 <0.0001 
Other racea -0.0281 -0.0668 - 0.0106 2.02 0.1553 
Partial type of epilepsy at first visita -0.0888 -0.1867 - 0.0092 3.15 0.0757 
Other type of epilepsy at first visita 0.1302 0.0684 - 0.192 17.05 <0.0001 
Multiple actions of index AEDa -0.1118 -0.1474 - -0.0762 37.97 <0.0001 
Baseline CCI of 1a 0.2022 0.1585 - 0.2459 82.43 <0.0001 
Baseline CCI greater than 1a 0.2014 0.1545 - 0.2483 70.82 <0.0001 
Number of psychiatric comorbidities at follow-up 0.2871 0.2754 - 0.2988 2306.27 <0.0001 
Non-psychiatric comorbidities at follow-upa 0.4629 0.4228 - 0.5030 511.15 <0.0001 
Baseline pill burden -0.0024 -0.0046 - -0.0001 4.33 0.0375 
Baseline all-cause inpatient visitsa 0.2077 0.1678 - 0.2475 104.41 <0.0001 
Number of baseline all-cause outpatient visits 0.0060 0.0049 - 0.0072 98.07 <0.0001 
Baseline total all-cause healthcare cost 0.0000 -0.0000 – 0.0000 1.52 0.2179 
CI=Confidence Interval; AED=Antiepileptic drug; CCI=Charlson Comorbidity Index 
aReference categories: Non-refractory; Female; Caucasian; Generalized type of epilepsy; Single action of   index 
AED; CCI=0; No non-psychiatric comorbidity; No baseline inpatient visit 
Note: Some variable categories were collapsed due to small cell sizes. 
Race/Ethnicity into three groups (Caucasian, African American and Other);  
Type of epilepsy into three groups (Generalized, Partial and Other);  
Type of index Antiepileptic drug into two groups (Single and Multiple actions). 
Model Fit: likelihood ratio chi-squared=4562.18; df=16; p<0.0001;  
Vuong test of ZIP vs. standard poisson: z=15.15; p<0.0001 
Significant at p<0.05 (in bold) 
H3A-B: Patients with refractory epilepsy have a higher number of all-cause medical visits consisting 
of inpatient hospitalizations and ED visits at follow-up as compared to patients with non-refractory 
epilepsy, while controlling for covariates. 










4.4.4.1.2 All-Cause Outpatient Visits  
Wilcoxon signed-rank test, McNemar’s test, and zero-inflated Poisson regression models 
were used to compare and determine differences in the all-cause outpatient visits among patients 
with refractory and non-refractory epilepsy while controlling for covariates.  
4.4.4.1.2.1 All-Cause Outpatient Visits (Unadjusted Analyses using Wilcoxon Signed-
Rank Test and McNemar’s Test) 
 Table 4.16 presents the all-cause outpatient visits stratified by refractory and non-refractory 
status. Patients in the refractory group (40.4 ± [37.1]) had significantly higher (p<0.0001) mean (± 
SD) all-cause outpatient visits compared to patients in the non-refractory group (37.0 ± [36.9]). 
However, there was no significant difference in the proportion of patients with at least one all-
cause outpatient visit among patients in the refractory and non-refractory groups. A similar trend 












Table 4.16: Comparison of All-Cause Outpatient Visits in the Second Year of Follow-Up by 
Refractory/Non-Refractory Status (N=5,596) 
 
All Refractory Non-refractory 
p-value 
n=5,596 n=2,798 n=2,798 
N % N % N % 
All-Cause Outpatient Visits 
  Median 
  (Mean ± SD) 
28  
(38.7 ± 37.0) 
30  
(40.4 ± 37.1) 
26  
(37.0± 36.9) <0.0001a 
  Yes  5,575 99.6 2,788 99.6 2,787 99.6  
0.8273b   No  21 0.4 10 0.4 11 0.4 
aWilcoxon signed-rank test 
bMcNemar’s test 





































4.4.4.1.2.2 All-Cause Outpatient Visits (Adjusted Analysis using Zero-inflated Poisson 
Regression) 
Table 4.17 presents the results of the zero-inflated Poisson regression model comparing the 
all-cause outpatient visits in the second-year of follow-up by refractory and non-refractory groups 
while controlling for covariates. The results of the overall model fit testing the full model without 
a model with predictors’ states that the model, as a whole, is statistically significant (p<0.05). Also, 
results of the Vuong test comparing ZIP model with standard Poisson regression indicates that the 
ZIP model is better (p<0.05). Results of the dichotomous ZIP model indicated, there was no 
significant difference in the odds of being in a “certain zero” group between patients in the 
refractory and non-refractory groups (results not shown). Also, of all the patients with > 0 all-
cause outpatient visits, the expected number of the visits among patients in the refractory group 
were 1.1 times [exp(0.0548)] significantly higher (95% CI=1.047-1.066; p<0.0001) than the 
expected number of the visits among patients in the non-refractory group, after controlling for 
covariates. Regarding covariates, male gender and index AED with multiple actions were 
associated with a significantly lower (p<0.05) number of all-cause outpatient visits. In contrast, 
increasing age, African American and other race, other type of epilepsy, CCI of 1 and greater than 
1, increasing number of psychiatric comorbidities, one or more non-psychiatric comorbidities, 
increasing baseline pill burden, increasing number of baseline outpatient visits, and increasing 
baseline total cost were associated with a significantly higher (p<0.05) number of all-cause 






Table 4.17: Zero-Inflated Poisson Regression Comparing the All-Cause Outpatient Visits in 
the Second Year of Follow-Up among Refractory/Non-Refractory Patients (N=5,596) 




Refractorya 0.0548 0.0462 - 0.0635 155.87 <0.0001 
Age at index 0.0033 0.003 - 0.0037 325.14 <0.0001 
Malea -0.0524 -0.0612 - -0.0436 136.25 <0.0001 
African American racea 0.1096 0.0978 - 0.1213 333.38 <0.0001 
Other racea 0.1165 0.1070 - 0.1260 578.88 <0.0001 
Partial type of epilepsy at first visita -0.0120 -0.0334 - 0.0095 1.19 0.2745 
Other type of epilepsy at first visita 0.0893 0.0750 - 0.1035 151 <0.0001 
Multiple actions of index AEDa -0.0537 -0.0625 - -0.0448 140.96 <0.0001 
Baseline CCI of 1a 0.1766 0.1655 - 0.1877 969.14 <0.0001 
Baseline CCI greater than 1a 0.1704 0.1583 - 0.1825 763.16 <0.0001 
Number of psychiatric comorbidities at follow-up 0.1158 0.1128 - 0.1188 5748.45 <0.0001 
Non-psychiatric comorbidities at follow-upa 0.2211 0.2118 - 0.2303 2191.82 <0.0001 
Baseline pill burden 0.0086 0.008 - 0.0091 859.52 <0.0001 
Baseline all-cause inpatient visitsa -0.0007 -0.0113 - 0.0098 0.02 0.8924 
Number of baseline all-cause outpatient visits 0.0160 0.0158 - 0.0163 20016.5 <0.0001 
Baseline total all-cause healthcare cost 0.0000 -0.0000 – 0.0000 475.44 <0.0001 
CI=Confidence Interval; AED=Antiepileptic drug; CCI=Charlson Comorbidity Index 
aReference categories: Non-refractory; Female; Caucasian; Generalized type of epilepsy; Single action of   index 
AED; CCI=0; No non-psychiatric comorbidity; No baseline inpatient visit 
Note: Some variable categories were collapsed due to small cell sizes. 
Race/Ethnicity into three groups (Caucasian, African American and Other);  
Type of epilepsy into three groups (Generalized, Partial and Other);  
Type of index Antiepileptic drug into two groups (Single and Multiple actions). 
Model Fit: likelihood ratio chi-squared= 62812.22; df=16; p<0.0001;  
Vuong test of ZIP vs. standard poisson: z=3.38; p=0.0004 
Significant at p<0.05 (in bold) 
H3C: Patients with refractory epilepsy have a higher number of all-cause medical visits consisting 
of outpatient visits at follow-up as compared to patients with non-refractory epilepsy, while 
controlling for covariates. 










4.4.4.1.3 Epilepsy-Related Inpatient Hospitalization and ED Visits  
Of the 5,596 patients, 15.7% of the patients had at least one epilepsy-related inpatient 
hospitalization, and 24.6% of the patients had at least one epilepsy-related ED visit in the second 
year of follow-up. For the present study, epilepsy-related inpatient hospitalization and ED visits 
were combined to compare and determine differences in the patients with refractory and non-
refractory epilepsy while controlling for covariates. 
4.4.4.1.3.1 Epilepsy-Related Inpatient Hospitalization and ED Visits (Unadjusted 
Analyses using Wilcoxon Signed-Rank Test and McNemar’s Test) 
 Table 4.18 presents the epilepsy-related inpatient hospitalization and ED visits stratified by 
refractory and non-refractory status. Patients in the refractory group (1.0 [± 2.2]) had significantly 
higher (p<0.0001) mean (± SD) epilepsy-related inpatient hospitalization and ED visits compared 
to patients in the non-refractory group (0.5 [± 1.2]). Also, a significantly higher (p<0.0001) 
proportion of patients in the refractory group (39.3%) had at least one epilepsy-related inpatient 
hospitalization and ED visit compared to patients in the non-refractory group (26.5%). Although 
higher numbers and proportions than second year of follow-up, a similar trend in the number of 
epilepsy-related inpatient hospitalization and ED visits was observed in the first year of follow-up 








Table 4.18: Comparison of Epilepsy-Related Inpatient Hospitalization and ED Visits in the 
Second Year of Follow-Up by Refractory/Non-Refractory Status (N=5,596) 
 
All Refractory Non-refractory 
p-value 
n=5,596 n=2,798 n=2,798 
N % N % N % 
Epilepsy-Related Inpatient Hospitalization and ED Visits 
  Median 
  (Mean ± SD) 
0  
(0.8 ± 1.8) 
0  
(1.0 ± 2.2) 
0  
(0.5 ± 1.2) <0.0001a 
  Yes  1,840 32.9 1,099 39.3 741 26.5 
<0.0001b 
  No  3,756 67.1 1,699 60.7 2,057 73.5 
aWilcoxon signed-rank test 
bMcNemar’s test 





































4.4.4.1.3.2 Epilepsy-Related Inpatient Hospitalization and ED Visits (Adjusted Analysis 
using Zero-inflated Poisson Regression) 
Table 4.19 presents the results of the zero-inflated Poisson regression model comparing the 
epilepsy-related inpatient hospitalization and ED visits in the second-year of follow-up by 
refractory and non-refractory groups while controlling for covariates. The results of the overall 
model fit testing the full model without a model with predictors’ states that the model, as a whole, 
is statistically significant (p<0.05). Also, results of the Vuong test comparing ZIP model with 
standard Poisson regression indicates that the ZIP model is better (p<0.05). Results of the 
dichotomous ZIP model indicated, patients in the refractory group had 30.2% [exp(-0.3598)] lower 
odds (p<0.0001) of being in a “certain zero” group as compared to patients in the non-refractory 
group (results not shown). Also, of all the patients with > 0 epilepsy-related inpatient 
hospitalization and ED visits, the expected number of the visits among patients in the refractory 
group were 1.4 times [exp(0.3568)] significantly higher (95% CI=1.316-1.551; p<0.0001) than the 
expected number of the visits among patients in the non-refractory group, after controlling for 
covariates. Regarding covariates, increasing age, CCI of 1, and baseline increasing pill burden 
were associated with a significantly lower (p<0.05) number of epilepsy-related inpatient 
hospitalization and ED visits. In contrast, African American race, increasing number of psychiatric 
comorbidities, one or more non-psychiatric comorbidities, and one or more baseline inpatient visits 
were associated with a significantly higher (p<0.05) number of epilepsy-related inpatient 






Table 4.19: Zero-Inflated Poisson Regression Comparing the Epilepsy-Related Inpatient 
Hospitalization and ED Visits in the Second Year of Follow-Up among Refractory/Non-
Refractory Patients (N=5,596) 




Refractorya 0.3568 0.2745 - 0.4391 72.26 <0.0001 
Age at index -0.0094 -0.0124 - -0.0065 38.3 <0.0001 
Malea -0.0394 -0.1097 - 0.0308 1.21 0.2712 
African American racea 0.2051 0.1127 - 0.2974 18.93 <0.0001 
Other racea 0.0638 -0.0132 - 0.1407 2.64 0.1043 
Partial type of epilepsy at first visita -0.0073 -0.1762 - 0.1615 0.01 0.9320 
Other type of epilepsy at first visita -0.0691 -0.1865 - 0.0483 1.33 0.2487 
Multiple actions of index AEDa 0.0085 -0.0614 - 0.0784 0.06 0.8110 
Baseline CCI of 1a -0.1259 -0.2163 - -0.0356 7.47 0.0063 
Baseline CCI greater than 1a 0.0043 -0.0935 - 0.1021 0.01 0.9314 
Number of psychiatric comorbidities at follow-up 0.2500 0.2265 - 0.2735 435.3 <0.0001 
Non-psychiatric comorbidities at follow-upa 0.4791 0.3999 - 0.5582 140.74 <0.0001 
Baseline pill burden -0.0073 -0.0126 - -0.0021 7.51 0.0061 
Baseline all-cause inpatient visitsa 0.2965 0.2133 - 0.3796 48.85 <0.0001 
Number of baseline all-cause outpatient visits 0.0015 -0.0012 - 0.0042 1.22 0.2690 
Baseline total all-cause healthcare cost -0.0000 -0.0000 – 0.0000 1.33 0.2487 
CI=Confidence Interval; AED=Antiepileptic drug; CCI=Charlson Comorbidity Index 
aReference categories: Non-refractory; Female; Caucasian; Generalized type of epilepsy; Single action of   index 
AED; CCI=0; No non-psychiatric comorbidity; No baseline inpatient visit 
Note: Some variable categories were collapsed due to small cell sizes. 
Race/Ethnicity into three groups (Caucasian, African American and Other);  
Type of epilepsy into three groups (Generalized, Partial and Other);  
Type of index Antiepileptic drug into two groups (Single and Multiple actions). 
Model Fit: likelihood ratio chi-squared=885.18; df=16; p<0.0001; 
Vuong test of ZIP vs. standard Poisson: z=12.48; p<0.0001 
Significant at p<0.05 (in bold) 
H3D-E: Patients with refractory epilepsy have a higher number of epilepsy-related medical visits 
consisting of inpatient hospitalization and ED visits at follow-up as compared to patients with non-
refractory epilepsy, while controlling for covariates. 










4.4.4.1.4 Epilepsy-Related Outpatient Visits  
Wilcoxon signed-rank test, McNemar’s test, and zero-inflated Poisson regression models 
were used to compare and determine differences in the epilepsy-related outpatient visits among 
patients with refractory and non-refractory epilepsy while controlling for covariates.  
4.4.4.1.4.1 Epilepsy-Related Outpatient Visits (Unadjusted Analyses using Wilcoxon 
Signed-Rank Test and McNemar’s Test) 
 Table 4.20 presents the epilepsy-related outpatient visits stratified by refractory and non-
refractory status. Patients in the refractory group (8.1 ± [11.6]) had significantly higher (p<0.0001) 
mean (± SD) epilepsy-related outpatient visits compared to patients in the non-refractory group 
(5.7 ± [9.3]). Also, a significantly higher (p<0.0001) proportion of patients in the refractory group 
(99.6%) had at least one epilepsy-related outpatient visit compared to patients in the non-refractory 
group (85.3%). Although higher numbers than second year of follow-up, a similar trend in the 











Table 4.20: Comparison of Epilepsy-Related Outpatient Visits in the Second Year of 
Follow-Up by Refractory/Non-Refractory Status (N=5,596) 
 
All Refractory Non-refractory 
p-value 
n=5,596 n=2,798 n=2,798 
N % N % N % 
Epilepsy-Related Outpatient Visits 
  Median 
  (Mean ± SD) 
4  
(6.9 ± 10.6) 
5  
(8.1 ± 11.6) 
4  
(5.7 ± 9.3) <0.0001a 
  Yes  4,935 88.2 2,788 99.6 2,388 85.3  
<0.0001b   No  661 11.8 251 9.0 410 14.7 
aWilcoxon signed-rank test 
bMcNemar’s test 

















4.4.4.1.4.2 Epilepsy-Related Outpatient Visits (Adjusted Analysis using Zero-inflated 
Poisson Regression) 
Table 4.21 presents the results of the zero-inflated Poisson regression model comparing the 
epilepsy-related outpatient visits in the second-year of follow-up by refractory and non-refractory 
groups while controlling for covariates. The results of the overall model fit testing the full model 
without a model with predictors’ states that the model, as a whole, is statistically significant 
(p<0.05). Also, results of the Vuong test comparing ZIP model with standard Poisson regression 
indicated that the ZIP model is better (p<0.05). Results of the dichotomous ZIP model indicated, 
patients in the refractory group had 41.9% [exp(-0.5426)] lower odds (p<0.0001) of being in a 
“certain zero” group as compared to patients in the non-refractory group (results not shown). Also, 
of all the patients with > 0 epilepsy-related outpatient visits, the expected number of the visits 
among patients in the refractory group were 1.3 times [exp(0.2594)] significantly higher (95% 
CI=1.270-1.323; p<0.0001) than the expected number of the visits among patients in the non-
refractory group, after controlling for covariates. Regarding covariates, increasing age, index AED 
with multiple actions, and increasing baseline pill burden were associated with a significantly 
lower (p<0.05) number of epilepsy-related outpatient visits. In contrast, male gender, African 
American and other race, CCI of 1, increasing number of psychiatric comorbidities, one or more 
non-psychiatric comorbidities, and increasing baseline outpatient visits were associated with a 







Table 4.21: Zero-Inflated Poisson Regression Comparing the Epilepsy-Related Outpatient 
Visits in the Second Year of Follow-Up among Refractory/Non-Refractory Patients 
(N=5,596) 




Refractorya 0.2594 0.2387 - 0.2800 606.12 <0.0001 
Age at index -0.0050 -0.0058 - -0.0041 128.85 <0.0001 
Malea 0.0717 0.0512 - 0.0922 46.94 <0.0001 
African American racea 0.0777 0.0492 - 0.1063 28.49 <0.0001 
Other racea 0.1186 0.0963 - 0.141 108.3 <0.0001 
Partial type of epilepsy at first visita 0.0183 -0.027 - 0.0636 0.63 0.4277 
Other type of epilepsy at first visita -0.0248 -0.0564 - 0.0067 2.39 0.1224 
Multiple actions of index AEDa -0.0775 -0.0983 - -0.0567 53.34 <0.0001 
Baseline CCI of 1a 0.0749 0.0478 - 0.1019 29.48 <0.0001 
Baseline CCI greater than 1a 0.0131 -0.0172 - 0.0435 0.72 0.3967 
Number of psychiatric comorbidities at follow-up 0.0749 0.0677 - 0.0821 413.23 <0.0001 
Non-psychiatric comorbidities at follow-upa 0.1970 0.1754 - 0.2186 319.86 <0.0001 
Baseline pill burden -0.0019 -0.0034 - -0.0003 5.54 0.0186 
Baseline all-cause inpatient visitsa 0.0155 -0.0114 - 0.0425 1.28 0.2587 
Number of baseline all-cause outpatient visits 0.0075 0.0069 - 0.0081 536.46 <0.0001 
Baseline total all-cause healthcare cost 0.0000 -0.0000 – 0.0000 2.63 0.1050 
CI=Confidence Interval; AED=Antiepileptic drug; CCI=Charlson Comorbidity Index 
aReference categories: Non-refractory; Female; Caucasian; Generalized type of epilepsy; Single action of   index 
AED; CCI=0; No non-psychiatric comorbidity; No baseline inpatient visit 
Note: Some variable categories were collapsed due to small cell sizes. 
Race/Ethnicity into three groups (Caucasian, African American and Other);  
Type of epilepsy into three groups (Generalized, Partial and Other);  
Type of index Antiepileptic drug into two groups (Single and Multiple actions). 
Model Fit: likelihood ratio chi-squared=3076.98; df=16; p<0.0001; 
Vuong test of ZIP vs. standard Poisson: z=18.11; p<0.0001 
Significant at p<0.05 (in bold) 
H3F: Patients with refractory epilepsy have a higher number of epilepsy-related medical visits 
consisting of outpatient visits at follow-up as compared to patients with non-refractory epilepsy, 
while controlling for covariates. 










4.4.4.1.5 All-Cause Length of Hospitalization Stay  
Of the 5,596 patients, only 26.2% of the patients had at least one all-cause inpatient 
hospitalization. As majority of the patients did not have an all-cause inpatient hospitalization, the 
length of hospitalization stay was not evaluated.  
H3G: Patients with refractory epilepsy have longer lengths of stay for all-cause hospitalization as 
compared to patients with non-refractory epilepsy, while controlling for covariates. 
Not evaluated 
4.4.4.1.6 Epilepsy-Related Length of Hospitalization Stay  
Of the 5,596 patients, only 15.7% of the patients had at least one epilepsy-related inpatient 
hospitalization. As majority of the patients did not have an epilepsy-related inpatient 
hospitalization, the length of hospitalization stay was not evaluated.  
H3H: Patients with refractory epilepsy have longer lengths of stay for epilepsy-related 











4.4.4.1.7 All-Cause Pharmacy Claims 
Of the 5,596 patients, 99.6% of the patients had at least one all-cause pharmacy claim (i.e., 
AED and non-AED prescriptions) in the second year of follow-up. Results of the Vuong test 
comparing ZIP model with standard Poisson regression was not significant, which indicated that 
a standard Poisson regression model was better. 
4.4.4.1.7.1 All-Cause Pharmacy Claims (Unadjusted Analyses using Wilcoxon Signed-
Rank Test and McNemar’s Test) 
 Table 4.22 presents the all-cause pharmacy claims stratified by refractory and non-refractory 
status. Patients in the refractory group (9.9 [± 6.8]) had significantly higher (p<0.0001) mean (± 
SD) all-cause pharmacy claims compared to patients in the non-refractory group (8.6 [± 6.3]). 
However, there was no significant difference in the proportion of patients with at least one all-
cause pharmacy claim among patients in the refractory and non-refractory groups. Although higher 
numbers and proportions than second year of follow-up, a similar trend in the number of all-cause 










Table 4.22: Comparison of All-Cause Pharmacy Claims in the Second Year of Follow-Up by 
Refractory/Non-Refractory Status (N=5,596) 
 
All Refractory Non-refractory 
p-value 
n=5,596 n=2,798 n=2,798 
N % N % N % 
All-Cause Pharmacy Claims 
  Median 
  (Mean ± SD) 
8  
(9.3 ± 6.6) 
8  
(9.9 ± 6.8) 
7  
(8.6 ± 6.3) <0.0001a 
  Yes  5,576 99.6 2,790 99.7 2,786 99.6  
0.3711b   No  20 0.4 8 0.3 12 0.4 
aWilcoxon signed-rank test 
bMcNemar’s test 

















4.4.4.1.7.2 All-Cause Pharmacy Claims (Adjusted Analysis using Poisson Regression) 
Table 4.23 presents the results of the Poisson regression model comparing the all-cause 
pharmacy claims in the second-year of follow-up by refractory and non-refractory groups while 
controlling for covariates. The results of the overall model fit testing the full model without a 
model with predictors’ states that the model, as a whole, is statistically significant (p<0.05). 
Results of the Poisson model indicated that the expected number of all-cause pharmacy claims 
among patients in the refractory group were 1.1 times [exp(0.0895)] significantly higher (95% 
CI=1.075-1.113; p<0.0001) than the expected number of all-cause pharmacy claims among 
patients in the non-refractory group, after controlling for covariates. Regarding covariates, male 
gender, African American and other race, index AED with multiple actions, and one or more 
inpatient visits were associated with a significantly lower (p<0.05) number of all-cause pharmacy 
claims. In contrast, CCI of 1 and greater than 1, increasing number of psychiatric comorbidities, 
one or more non-psychiatric comorbidities, increasing baseline pill burden, increasing baseline 
outpatient visits, and increasing baseline all-cause total cost were associated with a significantly 










Table 4.23: Poisson Regression Comparing the All-Cause Pharmacy Claims in the Second 
Year of Follow-Up among Refractory/Non-Refractory Patients (N=5,596) 




Refractorya 0.0895 0.0720 - 0.1071 99.73 <0.0001 
Age at index 0.0035 0.0028 - 0.0042 86.1 <0.0001 
Malea -0.0979 -0.1161 - -0.0797 111.27 <0.0001 
African American racea -0.0473 -0.0718 - -0.0229 14.4 0.0001 
Other racea -0.0202 -0.0395 - -0.0009 4.23 0.0398 
Partial type of epilepsy at first visita -0.0251 -0.0679 - 0.0176 1.33 0.2492 
Other type of epilepsy at first visita 0.0098 -0.0185 - 0.0381 0.46 0.4974 
Multiple actions of index AEDa -0.0238 -0.0418 - -0.0059 6.77 0.0093 
Baseline CCI of 1a 0.1046 0.0819 - 0.1273 81.76 <0.0001 
Baseline CCI greater than 1a 0.0462 0.0207 - 0.0716 12.64 0.0004 
Number of psychiatric comorbidities at follow-up 0.0731 0.067 - 0.0793 543.03 <0.0001 
Non-psychiatric comorbidities at follow-upa 0.1644 0.1456 - 0.1833 292.43 <0.0001 
Baseline pill burden 0.0370 0.0359 - 0.0382 4136.93 <0.0001 
Baseline all-cause inpatient visitsa -0.0243 -0.0465 - -0.0022 4.62 0.0315 
Number of baseline all-cause outpatient visits 0.0009 0.0003 - 0.0016 7.41 0.0065 
Baseline total all-cause healthcare cost 0.0000 -0.0000 – 0.0000 10.81 0.0010 
CI=Confidence Interval; AED=Antiepileptic drug; CCI=Charlson Comorbidity Index 
aReference categories: Non-refractory; Female; Caucasian; Generalized type of epilepsy; Single action of   index 
AED; CCI=0; No non-psychiatric comorbidity; No baseline inpatient visit 
Note: Some variable categories were collapsed due to small cell sizes. 
Race/Ethnicity into three groups (Caucasian, African American and Other);  
Type of epilepsy into three groups (Generalized, Partial and Other);  
Type of index Antiepileptic drug into two groups (Single and Multiple actions). 
Model Fit: likelihood ratio chi-squared=10684.29; df=16; p<0.0001 
Significant at p<0.05 (in bold) 
H3I: Patients with refractory epilepsy have a higher number of all-cause pharmacy claims as 
compared to patients with non-refractory epilepsy, while controlling for covariates. 









4.4.4.1.8 Epilepsy-Related Pharmacy Claims 
Of the 5,596 patients, 97.9% of the patients had at least one epilepsy-related pharmacy 
claim (i.e., AED prescriptions) in the second year of follow-up. Results of the Vuong test 
comparing ZIP model with standard Poisson regression was not significant, which indicated that 
a standard Poisson regression model was better. 
4.4.4.1.8.1 Epilepsy-Related Pharmacy Claims (Unadjusted Analyses using Wilcoxon 
Signed-Rank Test and McNemar’s Test) 
 Table 4.24 presents the epilepsy-related pharmacy claims stratified by refractory and non-
refractory status. Patients in the refractory group (3.1 [± 1.5]) had significantly higher (p<0.0001) 
mean (± SD) epilepsy-related pharmacy claims compared to patients in the non-refractory group 
(1.8 [± 1.1]). Also, a significantly higher (p<0.0001) proportion of patients in the refractory group 
(98.9%) had at least one epilepsy-related pharmacy claim compared to patients in the non-
refractory group (97.0%).  Although slightly higher numbers and proportions than second year of 
follow-up, a similar trend in the number of epilepsy-related pharmacy claims was observed in the 










Table 4.24: Comparison of Epilepsy-Related Pharmacy Claims in the Second Year of Follow-
Up by Refractory/Non-Refractory Status (N=5,596) 
 
All Refractory Non-refractory 
p-value 
n=5,596 n=2,798 n=2,798 
N % N % N % 
Epilepsy-Related Pharmacy Claims 
  Median 
  (Mean ± SD) 
2 
(2.4 ± 1.5) 
3 
(3.1 ± 1.5) 
2 
(1.8 ± 1.1) <0.0001a 
  Yes  5,481 97.9 2,768 98.9 2,713 97.0  
<0.0001b   No  115 2.1 30 1.1 85 3.0 
aWilcoxon signed-rank test 
bMcNemar’s test 
















4.4.4.1.8.2 Epilepsy-Related Pharmacy Claims (Adjusted Analysis using Poisson 
Regression) 
Table 4.25 presents the results of the Poisson regression model comparing the epilepsy-
related pharmacy claims in the second-year of follow-up by refractory and non-refractory groups 
while controlling for covariates. The results of the overall model fit testing the full model without 
a model with predictors’ states that the model, as a whole, is statistically significant (p<0.05). 
Results of the Poisson model indicated that the expected number of epilepsy-related pharmacy 
claims among patients in the refractory group were 1.7 times [exp(0.5179)] significantly higher 
(95% CI=1.620-1.739; p<0.0001) than the expected number of epilepsy-related pharmacy claims 
among patients in the non-refractory group, after controlling for covariates. Regarding covariates, 
increasing age was associated with a significantly lower (p<0.05) number of epilepsy-related 
pharmacy claims. In contrast, increasing number of psychiatric comorbidities, one or more non-
psychiatric comorbidities at follow-up, and increasing baseline pill burden were associated with a 











Table 4.25: Comparison of Epilepsy-Related Pharmacy Claims in the Second Year of Follow-
Up by Refractory/Non-Refractory Status (N=5,596) 




Refractorya 0.5179 0.4824 - 0.5533 820.69 <0.0001 
Age at index -0.0019 -0.0034 - -0.0005 6.82 0.0090 
Malea 0.0072 -0.0274 - 0.0418 0.17 0.6839 
African American racea -0.0462 -0.0946 - 0.0021 3.52 0.0608 
Other racea -0.0210 -0.0583 - 0.0163 1.21 0.2704 
Partial type of epilepsy at first visita 0.0357 -0.0408 - 0.1122 0.84 0.3602 
Other type of epilepsy at first visita -0.0273 -0.0807 - 0.0261 1.01 0.3157 
Multiple actions of index AEDa 0.0023 -0.0323 - 0.037 0.02 0.8944 
Baseline CCI of 1a -0.0453 -0.0921 - 0.0014 3.61 0.0575 
Baseline CCI greater than 1a -0.0316 -0.0833 - 0.0200 1.44 0.2298 
Number of psychiatric comorbidities at follow-up 0.0410 0.0289 - 0.0531 44.00 <0.0001 
Non-psychiatric comorbidities at follow-upa 0.0476 0.0113 - 0.0838 6.62 0.0101 
Baseline pill burden 0.0086 0.006 - 0.0112 41.57 <0.0001 
Baseline all-cause inpatient visitsa 0.0023 -0.0436 - 0.0481 0.01 0.9226 
Number of baseline all-cause outpatient visits 0.0001 -0.0012 - 0.0014 0.03 0.8642 
Baseline total all-cause healthcare cost 0.0000 -0.0000 – 0.0000 0.46 0.4961 
CI=Confidence Interval; AED=Antiepileptic drug; CCI=Charlson Comorbidity Index 
aReference categories: Non-refractory; Female; Caucasian; Generalized type of epilepsy; Single action of   index 
AED; CCI=0; No non-psychiatric comorbidity; No baseline inpatient visit 
Note: Some variable categories were collapsed due to small cell sizes. 
Race/Ethnicity into three groups (Caucasian, African American and Other);  
Type of epilepsy into three groups (Generalized, Partial and Other);  
Type of index Antiepileptic drug into two groups (Single and Multiple actions). 
Model Fit: likelihood ratio chi-squared=1109.55; df=16; p<0.0001;  
Significant at p<0.05 (in bold) 
H3J: Patients with refractory epilepsy have a higher number of epilepsy-related pharmacy claims 
as compared to patients with non-refractory epilepsy, while controlling for covariates. 















4.4.4.2 Healthcare Cost 
H3K-M: Patients with refractory epilepsy have a higher all-cause medical costs consisting 
of inpatient hospitalizations (H3K), ED visits (H3L), and outpatient visits (H3M) at follow-
up as compared to patients with non-refractory epilepsy, while controlling for covariates. 
H3N-P: Patients with refractory epilepsy have a higher epilepsy-related medical costs 
consisting of inpatient hospitalizations (H3N), ED visits (H3O), and outpatient visits (H3P) at 
follow-up as compared to patients with non-refractory epilepsy, while controlling for 
covariates. 
H3Q-R: Patients with refractory epilepsy have a higher cost of all-cause pharmacy claims 
(H3Q) and epilepsy-related pharmacy claims (H3R) as compared to patients with non-
refractory epilepsy, while controlling for covariates. 
All-cause and epilepsy-related healthcare cost of the patients was assessed in the first and 
second year of follow-up after the index date. All-cause healthcare cost consisted of the cost of 
medical service and pharmacy claims of the patients. Epilepsy-related healthcare cost included 
medical service claims associated with an epilepsy diagnosis (ICD-9-CM codes: 345.xx or 780.39) 
in the primary and/or secondary diagnoses field and pharmacy claims. Cost of medical services 
included inpatient hospitalizations, ED visits, and outpatient visits. All-cause pharmacy cost 
consisted of the cost of AED and non-AED claims. Epilepsy-related pharmacy cost consisted only 
of the cost of AED claims. Healthcare cost was measured using Wilcoxon signed-rank test and 
regression models. Generalized linear model was used to compare and determine differences in 






covariates. Modified Park test was used to define distribution and the functional form. The 
covariates included in the models were age, gender, race/ethnicity, type of epilepsy, type of index 
AED, baseline CCI, number of psychiatric and non-psychiatric comorbidities at follow-up, 
baseline pill burden, baseline all-cause inpatient visits, baseline number of all-cause outpatient 
visits, and baseline all-cause total cost. Overall, in the second-year of follow-up, patients in the 
refractory group ($23,136 [± $25,827]) had significantly higher (p<0.0001) mean (± SD) 
unadjusted cost of all-cause medical and pharmacy claims compared to patients in the non-
refractory group ($19,813 [± $25,907]). Similarly, patients in the refractory group ($7,811 [± 
$10,084]) had significantly higher (p<0.0001) mean (± SD) unadjusted cost of epilepsy-related 















4.4.4.2.1 All-Cause Inpatient Hospitalization and ED Visit Cost  
Of the 5,596 patients, the median cost of all-cause inpatient hospitalization was $0 in the 
second year of follow-up. For the present study, cost of all-cause inpatient hospitalization and ED 
visits were combined to compare and determine differences in patients with refractory and non-
refractory epilepsy while controlling for covariates.  
4.4.4.2.1.1 All-Cause Inpatient Hospitalization and ED Visit Cost (Unadjusted Analysis 
using Wilcoxon Signed-Rank Test) 
 Table 4.26 presents the cost of all-cause inpatient hospitalization and ED visits stratified by 
refractory and non-refractory status. Patients in the refractory group ($3,147 [± $8,343]) had 
significantly higher (p<0.0001) mean (± SD) cost of all-cause inpatient hospitalization and ED 
visits compared to patients in the non-refractory group ($2,647 [± $7,941]). Although the mean (± 
SD) and median costs were higher than second year of follow-up, a similar trend in the cost of all-
cause inpatient hospitalization and ED visits was observed in the first year of follow-up (Appendix 
VIA).  
Table 4.26: Comparison of Cost of All-Cause Inpatient Hospitalization and ED Visits in the 
Second Year of Follow-Up by Refractory/Non-Refractory Status (N=5,596) 
 
All Refractory Non-refractory 
p-value n=5,596 n=2,798 n=2,798 
All-Cause Inpatient Hospitalization and ED Visit Cost 
  Median 
  (Mean ± SD) 
$0 
($2,897 ± $8,147) 
$0 
($3,147 ± $8,343) 
$0 
($2,647 ± $7,941) <0.0001a 
aWilcoxon signed-rank test 







4.4.4.2.1.2  All-Cause Inpatient Hospitalization and ED Visit Cost (Adjusted Analysis 
using Generalized Linear Model) 
  Table 4.27 presents the results of the generalized linear model with gamma distribution and 
log-link function comparing the cost of all-cause inpatient hospitalization and ED visits in the 
second-year of follow-up by refractory and non-refractory groups while controlling for covariates. 
Results of the model indicated, there was no significant difference in the cost of all-cause inpatient 
hospitalization and ED visits of patients in the refractory and non-refractory groups, after 
controlling for covariates. Regarding covariates, baseline CCI of greater than 1, increasing number 
of psychiatric comorbidities, one or more non-psychiatric comorbidities at follow-up, increasing 
baseline pill burden, one or more baseline inpatient visits, and increasing baseline total cost were 
associated with a significantly higher (p<0.05) cost of all-cause inpatient hospitalization and ED 
visits. In the first-year of follow-up, the cost of all-cause inpatient hospitalization and ED visits of 
patients in the refractory group was significantly higher (p<0.05) than the cost of all-cause 
inpatient hospitalization and ED visits of patients in the non-refractory group, after controlling for 










Table 4.27: Generalized Linear Model Comparing the Cost of All-Cause Inpatient 
Hospitalization and ED Visits in the Second Year of Follow-Up among Refractory/Non-
Refractory Patients (N=5,596) 
 Estimate 95% CI z p-value 
Refractorya 0.0621 -0.1051 – 0.2293 0.73 0.4660 
Age at index 0.0027 -0.0041 – 0.0094 0.77 0.4390 
Malea 0.1044 -0.0651 – 0.2740 1.21 0.2270 
African American racea 0.2476 0.0157 – 0.4796 2.09 0.0360 
Other racea 0.1009 -0.0831 – 0.2850 1.07 0.2820 
Partial type of epilepsy at first visita 0.1744 -0.2070 – 0.5557 0.9 0.3700 
Other type of epilepsy at first visita -0.0204 -0.2788 – 0.2379 -0.15 0.8770 
Multiple actions of index AEDa -0.0739 -0.2452 – 0.0974 -0.85 0.3980 
Baseline CCI of 1a 0.2571 0.0348 – 0.4793 2.27 0.0230 
Baseline CCI greater than 1a 0.3190 0.0732 – 0.5648 2.54 0.0110 
Number of psychiatric comorbidities at follow-up 0.3014 0.2441 – 0.3587 10.32 <0.0001 
Non-psychiatric comorbidities at follow-upa 0.8278 0.6588 – 0.9970 9.6 <0.0001 
Baseline pill burden 0.0195 0.0059 – 0.0331 2.81 0.0050 
Baseline all-cause inpatient visitsa 0.5467 0.3257 – 0.7678 4.85 <0.0001 
Number of baseline all-cause outpatient visits 0.0025 -0.0042 – 0.0092 0.74 0.4610 
Baseline total all-cause healthcare cost 0.0000 0.0000 – 0.0000 3.14 0.0020 
CI=Confidence Interval; AED=Antiepileptic drug; CCI=Charlson Comorbidity Index 
aReference categories: Non-refractory; Female; Caucasian; Generalized type of epilepsy; Single action of   index 
AED; CCI=0; No non-psychiatric comorbidity; No baseline inpatient visit 
Note: Some variable categories were collapsed due to small cell sizes. 
Race/Ethnicity into three groups (Caucasian, African American and Other);  
Type of epilepsy into three groups (Generalized, Partial and Other);  
Type of index Antiepileptic drug into two groups (Single and Multiple actions). 
Significant at p<0.05 (in bold) 
H3K-L: Patients with refractory epilepsy have a higher all-cause medical costs consisting of 
inpatient hospitalizations and ED visits at follow-up as compared to patients with non-refractory 













4.4.4.2.2 All-Cause Outpatient Visit Cost  
 Wilcoxon signed-rank test and Generalized linear model was used to compare and determine 
differences in all-cause outpatient visit costs of patients with refractory and non-refractory epilepsy 
while controlling for covariates. 
4.4.4.2.2.1 All-Cause Outpatient Visit Cost (Unadjusted Analysis using Wilcoxon Signed-
Rank Test) 
 Table 4.28 presents the cost of all-cause outpatient visits stratified by refractory and non-
refractory status. Patients in the refractory group ($9,891 [± $18,044]) had significantly higher 
(p<0.0001) mean (± SD) cost of all-cause outpatient visits compared to patients in the non-
refractory group ($9,459 [± $18,559]). A similar trend in the cost of all-cause outpatient visits was 
observed in the first year of follow-up (Appendix VIB).  
Table 4.28: Comparison of Cost of All-Cause Outpatient Visits in the Second Year of 
Follow-Up by Refractory/Non-Refractory Status (N=5,596) 
 
All Refractory Non-refractory 
p-value n=5,596 n=2,798 n=2,798 
All-Cause Outpatient Visit Cost 
  Median 
  (Mean ± SD) 
$4,201  
($9,675 ± $18,303) 
$4,711  
($9,891 ± $18,044) 
$3,644  
($9,459 ± $18,559) <0.0001a 
aWilcoxon signed-rank test 









4.4.4.2.2.2 All-Cause Outpatient Visit Cost (Adjusted Analysis using Generalized Linear 
Model) 
 Table 4.29 presents the results of the generalized linear model with gamma distribution and log-
link function comparing the cost of all-cause outpatient visits in the second-year of follow-up by 
refractory and non-refractory groups while controlling for covariates. Results of the model 
indicated that the cost of all-cause outpatient visits of patients in the refractory group was 1.1 times 
[exp(0.0906)] significantly higher (95% CI=1.015-1.181; p=0.0190) than the cost of all-cause 
outpatient visits of patients in the non-refractory group, after controlling for covariates. Regarding 
covariates, African American and other race, baseline CCI of 1 and greater than 1, increasing 
number of psychiatric comorbidities, one or more non-psychiatric comorbidities at follow-up, 
increasing baseline outpatient visits, and increasing baseline total cost were associated with a 
significantly higher (p<0.05) cost of all-cause outpatient visits. In contrast, index AED with 
multiple actions was associated with a significantly lower (p<0.05) cost of all-cause outpatient 
visits. Similarly, in the first-year of follow-up the cost of all-cause outpatient visits of patients in 
the refractory group was significantly higher (p<0.05) than the cost of all-cause outpatient visits 









Table 4.29: Generalized Linear Model Comparing the Cost of All-Cause Outpatient in the 
Second Year of Follow-Up among Refractory/Non-Refractory Patients (N=5,596) 
 Estimate 95% CI z p-value 
Refractorya 0.0906 0.0150 – 0.1662 2.35 0.0190 
Age at index -0.0007 -0.0034 – 0.0023 -0.47 0.6350 
Malea -0.0480 -0.1237 – 0.0278 -1.24 0.2150 
African American racea 0.1833 0.0798 – 0.2869 3.47 0.0010 
Other racea 0.0877 0.0059 – 0.1695 2.1 0.0360 
Partial type of epilepsy at first visita -0.0689 -0.2386 – 0.1008 -0.8 0.4260 
Other type of epilepsy at first visita 0.0335 -0.0825 – 0.1494 0.57 0.5710 
Multiple actions of index AEDa -0.1143 -0.1914 - -0.0373 -2.91 0.0040 
Baseline CCI of 1a 0.2248 0.1237 – 0.3259 4.36 <0.0001 
Baseline CCI greater than 1a 0.2214 0.1115 – 0.3314 3.95 <0.0001 
Number of psychiatric comorbidities at follow-up 0.0867 0.0602 – 0.1132 6.42 <0.0001 
Non-psychiatric comorbidities at follow-upa 0.2854 0.2071 – 0.3637 7.14 <0.0001 
Baseline pill burden -0.0013 -0.0073 – 0.0047 -0.41 0.6830 
Baseline all-cause inpatient visitsa -0.0367 -0.1372 – 0.0638 -0.72 0.4740 
Number of baseline all-cause outpatient visits 0.0226 0.0187 – 0.0266 11.27 <0.0001 
Baseline total all-cause healthcare cost 0.0000 0.0000 – 0.0000 9.72 <0.0001 
CI=Confidence Interval; AED=Antiepileptic drug; CCI=Charlson Comorbidity Index 
aReference categories: Non-refractory; Female; Caucasian; Generalized type of epilepsy; Single action of   index 
AED; CCI=0; No non-psychiatric comorbidity; No baseline inpatient visit 
Note: Some variable categories were collapsed due to small cell sizes. 
Race/Ethnicity into three groups (Caucasian, African American and Other);  
Type of epilepsy into three groups (Generalized, Partial and Other);  
Type of index Antiepileptic drug into two groups (Single and Multiple actions). 
Significant at p<0.05 (in bold) 
H3M: Patients with refractory epilepsy have a higher all-cause medical costs consisting of 
outpatient visits (H3M) at follow-up as compared to patients with non-refractory epilepsy, while 
controlling for covariates. 














4.4.4.2.3 Epilepsy-Related Inpatient Hospitalization and ED Visit Cost  
Of the 5,596 patients, the median cost of epilepsy-related inpatient hospitalization and 
epilepsy-related ED visit was $0 in the second year of follow-up. For the present study, cost of 
epilepsy-related inpatient hospitalization and ED visits were combined to compare and determine 
differences in patients with refractory and non-refractory epilepsy while controlling for covariates.  
4.4.4.2.3.1 Epilepsy-Related Inpatient Hospitalization and ED Visit Cost (Unadjusted 
Analysis using Wilcoxon Signed-Rank Test) 
 Table 4.30 presents the cost of epilepsy-related inpatient hospitalization and ED visits stratified 
by refractory and non-refractory status. Patients in the refractory group ($1,443 [± $4,558]) had 
significantly higher (p<0.0001) mean (± SD) cost of epilepsy-related inpatient hospitalization and 
ED visits compared to patients in the non-refractory group ($872 [± $4,069]). Although the mean 
(± SD) costs were higher than second year of follow-up, a similar trend in the cost of epilepsy-
related inpatient hospitalization and ED visits was observed in the first year of follow-up 
(Appendix VIC).  
Table 4.30: Comparison of Cost of Epilepsy-Related Inpatient Hospitalization and ED Visits 
in the Second Year of Follow-Up by Refractory/Non-Refractory Status (N=5,596) 
 
All Refractory Non-refractory 
p-value n=5,596 n=2,798 n=2,798 
Epilepsy-Related Inpatient Hospitalization and ED Visit Cost 
  Median 
  (Mean ± SD) 
$0  
($1,158 ± $4,329) 
$0  
($1,443 ± $4,558) 
$0  
($872 ± $4,069) <0.0001a 








4.4.4.2.3.2 Epilepsy-Related Inpatient Hospitalization and ED Visit Cost (Adjusted 
Analysis using Generalized Linear Model) 
 Table 4.31 presents the results of the generalized linear model with gamma distribution and log-
link function comparing the cost of epilepsy-related inpatient hospitalization and ED visits in the 
second-year of follow-up by refractory and non-refractory groups while controlling for covariates. 
Results of the model indicated that the cost of epilepsy-related inpatient hospitalization and ED 
visits of patients in the refractory group was 1.5 times [exp(0.3991)] significantly higher (95% 
CI=1.215-1.828; p<0.0001) than the cost of epilepsy-related inpatient hospitalization and ED visits 
of patients in the non-refractory group, after controlling for covariates. Regarding covariates, other 
race, increasing number of psychiatric comorbidities, one or more non-psychiatric comorbidities 
at follow-up, and one or more baseline inpatient visit were associated with a significantly higher 
(p<0.05) cost of epilepsy-related inpatient hospitalization and ED visits. Similarly, in the first-year 
of follow-up the cost of epilepsy-related inpatient hospitalization and ED visits of patients in the 
refractory group was significantly higher (p<0.05) than the cost of epilepsy-related inpatient 











Table 4.31: Generalized Linear Model Comparing the Cost of Epilepsy-Related Inpatient 
Hospitalization and ED Visits in the Second Year of Follow-Up among Refractory/Non-
Refractory Patients (N=5,596) 
 Estimate 95% CI z p-value 
Refractorya 0.3991 0.1949 – 0.6032 3.83 <0.0001 
Age at index -0.0022 -0.0106 – 0.0063 -0.50 0.6160 
Malea -0.0259 -0.2371 – 0.1853 -0.24 0.8100 
African American racea 0.2500 -0.0332 – 0.5332 1.73 0.0840 
Other racea 0.3195 0.0934 – 0.5457 2.77 0.0060 
Partial type of epilepsy at first visita 0.3617 -0.1033 – 0.8268 1.52 0.1270 
Other type of epilepsy at first visita -0.2747 -0.5960 – 0.04662 -1.68 0.0940 
Multiple actions of index AEDa 0.0178 -0.1943 – 0.2300 0.16 0.8690 
Baseline CCI of 1a 0.2273 -0.0462 – 0.5009 1.63 0.1030 
Baseline CCI greater than 1a 0.1821 -0.1140 – 0.4782 1.21 0.2280 
Number of psychiatric comorbidities at follow-up 0.3041 0.2320 – 0.3762 8.26 <0.0001 
Non-psychiatric comorbidities at follow-upa 0.6966 0.4895 – 0.9037 6.59 <0.0001 
Baseline pill burden -0.0047 -0.0212 – 0.0118 -0.56 0.5790 
Baseline all-cause inpatient visitsa 0.7588 0.4809 – 1.0368 5.35 <0.0001 
Number of baseline all-cause outpatient visits -0.0039 -0.0123 – 0.0046 -0.90 0.3680 
Baseline total all-cause healthcare cost 0.0000 -0.0000 – 0.0000 0.79 0.4270 
CI=Confidence Interval; AED=Antiepileptic drug; CCI=Charlson Comorbidity Index 
aReference categories: Non-refractory; Female; Caucasian; Generalized type of epilepsy; Single action of   index 
AED; CCI=0; No non-psychiatric comorbidity; No baseline inpatient visit 
Note: Some variable categories were collapsed due to small cell sizes. 
Race/Ethnicity into three groups (Caucasian, African American and Other);  
Type of epilepsy into three groups (Generalized, Partial and Other);  
Type of index Antiepileptic drug into two groups (Single and Multiple actions). 
Significant at p<0.05 (in bold) 
H3N-O: Patients with refractory epilepsy have a higher all-cause medical costs consisting of 
epilepsy-related inpatient hospitalizations and ED visits at follow-up as compared to patients with 
non-refractory epilepsy, while controlling for covariates. 












4.4.4.2.4 Epilepsy-Related Outpatient Visit Cost  
 Wilcoxon signed-rank test and Generalized linear model was used to compare and determine 
differences in epilepsy-related outpatient visit costs of patients with refractory and non-refractory 
epilepsy while controlling for covariates. 
4.4.4.2.4.1 Epilepsy-Related Outpatient Visit Cost (Unadjusted Analysis using Wilcoxon 
Signed-Rank Test) 
 Table 4.32 presents the cost of epilepsy-related outpatient visits stratified by refractory and non-
refractory status. Patients in the refractory group ($1,767 [± $5,111]) had significantly higher 
(p<0.0001) mean (± SD) cost of epilepsy-related outpatient visits compared to patients in the non-
refractory group ($1,195 [± $4,415]). Although the mean (± SD) and median costs were higher 
than second year of follow-up, a similar trend in the cost of epilepsy-related outpatient visits was 
observed in the first year of follow-up (Appendix VID).  
Table 4.32: Comparison of Cost of Epilepsy-Related Outpatient Visits in the Second Year 
of Follow-Up by Refractory/Non-Refractory Status (N=5,596) 
 
All Refractory Non-refractory 
p-value n=5,596 n=2,798 n=2,798 
Epilepsy-Related Outpatient Visit Cost 
  Median 
  (Mean ± SD) 
$436  
($1,481 ± $4,784) 
$612  
($1,767 ± $5,111) 
$313  
($1,195 ± $4,415) <0.0001a 
aWilcoxon signed-rank test 








4.4.4.2.4.2 Epilepsy-Related Outpatient Visit Cost (Adjusted Analysis using Generalized 
Linear Model) 
 Table 4.33 presents the results of the generalized linear model with gamma distribution and log-
link function comparing the cost of epilepsy-related outpatient visits in the second-year of follow-
up by refractory and non-refractory groups while controlling for covariates. Results of the model 
indicated that the cost of epilepsy-related outpatient visits of patients in the refractory group was 
1.5 times [exp(0.4010)] significantly higher (95% CI=1.312-1.699; p<0.0001) than the cost of 
epilepsy-related outpatient visits of patients in the non-refractory group, after controlling for 
covariates. Regarding covariates, African American race, increasing number of psychiatric 
comorbidities, one or more non-psychiatric comorbidities at follow-up, increasing baseline 
outpatient visits, and increasing baseline total cost were associated with a significantly higher 
(p<0.05) cost of epilepsy-related outpatient visits. In contrast, increasing age and increasing pill 
burden were associated with a significantly lower (p<0.05) cost of epilepsy-related outpatient 
visits. Similarly, in the first-year of follow-up the cost of epilepsy-related outpatient visits of 
patients in the refractory group was significantly higher (p<0.05) than the cost of epilepsy-related 










Table 4.33: Comparison of Cost of Epilepsy-Related Outpatient Visits in the Second Year 
of Follow-Up by Refractory/Non-Refractory Status (N=5,596) 
 Estimate 95% CI z p-value 
Refractorya 0.4010 0.2717 – 0.5303 6.08 <0.0001 
Age at index -0.0091 -0.0144 - -0.0038 -3.36 0.0010 
Malea -0.0172 -0.1464 – 0.1120 -0.26 0.7940 
African American racea 0.1932 0.01556 – 0.3708 2.13 0.0330 
Other racea 0.0354 -0.1051 – 0.17585 0.49 0.6220 
Partial type of epilepsy at first visita -0.0836 -0.3750 – 0.2078 -0.56 0.5740 
Other type of epilepsy at first visita -0.1386 -0.3365 – 0.05937 -1.37 0.1700 
Multiple actions of index AEDa -0.1107 -0.2423 – 0.0210 -1.65 0.1000 
Baseline CCI of 1a 0.0528 -0.1228 – 0.2283 0.59 0.5560 
Baseline CCI greater than 1a -0.1269 -0.3171 – 0.0634 -1.31 0.1910 
Number of psychiatric comorbidities at follow-up 0.1098 0.0652 – 0.1543 4.83 <0.0001 
Non-psychiatric comorbidities at follow-upa 0.3424 0.2111 – 0.4738 5.11 <0.0001 
Baseline pill burden -0.0196 -0.0301 - -0.0091 -3.65 <0.0001 
Baseline all-cause inpatient visitsa -0.1432 -0.3129 – 0.0266 -1.65 0.0980 
Number of baseline all-cause outpatient visits 0.0146 0.0082 – 0.0209 4.5 <0.0001 
Baseline total all-cause healthcare cost 0.0000 0.0000 – 0.0000 5.47 <0.0001 
CI=Confidence Interval; AED=Antiepileptic drug; CCI=Charlson Comorbidity Index 
aReference categories: Non-refractory; Female; Caucasian; Generalized type of epilepsy; Single action of   index 
AED; CCI=0; No non-psychiatric comorbidity; No baseline inpatient visit 
Note: Some variable categories were collapsed due to small cell sizes. 
Race/Ethnicity into three groups (Caucasian, African American and Other);  
Type of epilepsy into three groups (Generalized, Partial and Other);  
Type of index Antiepileptic drug into two groups (Single and Multiple actions). 
Significant at p<0.05 (in bold) 
H3P: Patients with refractory epilepsy have a higher epilepsy-related medical costs consisting of 
outpatient visits (H3P) at follow-up as compared to patients with non-refractory epilepsy, while 
controlling for covariates. 









4.4.4.2.5 All-Cause Pharmacy Cost  
 Wilcoxon signed-rank test and Generalized linear model was used to compare and determine 
differences in all-cause pharmacy costs of patients with refractory and non-refractory epilepsy 
while controlling for covariates. 
4.4.4.2.5.1 All-Cause Pharmacy Cost (Unadjusted Analysis using Wilcoxon Signed-Rank 
Test) 
 Table 4.34 presents the cost of all-cause pharmacy stratified by refractory and non-refractory 
status. Patients in the refractory group ($9,764 [± $8,989]) had significantly higher (p<0.0001) 
mean (± SD) cost of all-cause pharmacy claims compared to patients in the non-refractory group 
(7,466 [± $11,082]). Although the mean (± SD) and median costs were higher than second year of 
follow-up, a similar trend in the cost of all-cause pharmacy claims was observed in the first year 
of follow-up (Appendix VIE).  
Table 4.34: Comparison of Cost of All-Cause Pharmacy Claims in the Second Year of 
Follow-Up by Refractory/Non-Refractory Status (N=5,596) 
 
All Refractory Non-refractory 
p-value n=5,596 n=2,798 n=2,798 
All-Cause Pharmacy Cost 
  Median 
  (Mean ± SD) 
$6,213  
($8,615 ± $10,154) 
$7,410  
($9,764 ± $8,989) 
$4,807 
($7,466 ± $11,082) <0.0001a 
aWilcoxon signed-rank test 








4.4.4.2.5.2 All-Cause Pharmacy Cost (Adjusted Analysis using Generalized Linear 
Model) 
 Table 4.35 presents the results of the generalized linear model with gamma distribution and log-
link function comparing the cost of all-cause pharmacy claims in the second-year of follow-up by 
refractory and non-refractory groups while controlling for covariates. Results of the model 
indicated that the cost of all-cause pharmacy claims of patients in the refractory group was 1.3 
times [exp(0.2958)] significantly higher (95% CI=1.280-1.411; p<0.0001) than the cost of all-
cause pharmacy claims of patients in the non-refractory group, after controlling for covariates.  
Regarding covariates, male gender, partial type of epilepsy, index AED with multiple actions, 
baseline CCI of greater than 1, increasing number of psychiatric comorbidities, increasing baseline 
pill burden, and increasing baseline total cost were associated with a significantly higher (p<0.05) 
cost of all-cause pharmacy claims. In contrast, increasing age, African Americana and other race, 
one or more baseline inpatient visits, and increasing baseline outpatient visits were associated with 
a significantly lower (p<0.05) cost of all-cause pharmacy claims. Similarly, in the first-year of 
follow-up the cost of all-cause pharmacy claims of patients in the refractory group was 
significantly higher (p<0.05) than the cost of all-cause pharmacy claims of patients in the non-









Table 4.35: Comparison of Cost of All-Cause Pharmacy Claims in the Second Year of 
Follow-Up by Refractory/Non-Refractory Status (N=5,596) 
 Estimate 95% CI z p-value 
Refractorya 0.2958 0.2471 – 0.3445 11.91 <0.0001 
Age at index -0.0028 -0.0048 - -0.0007 -2.65 0.0080 
Malea 0.0811 0.0317 – 0.1305 3.22 0.0010 
African American racea -0.1350 -0.2027 - -0.0674 -3.91 <0.0001 
Other racea -0.1276 -0.1810 - -0.0741 -4.68 <0.0001 
Partial type of epilepsy at first visita 0.1286 0.0177 – 0.2394 2.27 0.0230 
Other type of epilepsy at first visita -0.0362 -0.1122 – 0.0398 -0.93 0.3500 
Multiple actions of index AEDa 0.1189 0.0690 – 0.1688 4.67 <0.0001 
Baseline CCI of 1a 0.0107 -0.0561 – 0.0775 0.31 0.7530 
Baseline CCI greater than 1a 0.1090 0.0354 – 0.1826 2.90 0.0040 
Number of psychiatric comorbidities at follow-up 0.1003 0.0828 – 0.1179 11.20 <0.0001 
Non-psychiatric comorbidities at follow-upa -0.0119 -0.0634 – 0.0397 -0.45 0.6510 
Baseline pill burden 0.0449 0.0407 – 0.0490 21.00 <0.0001 
Baseline all-cause inpatient visitsa -0.1939 -0.2597 - -0.1281 -5.78 <0.0001 
Number of baseline all-cause outpatient visits -0.0055 -0.0073 - -0.0036 -5.84 <0.0001 
Baseline total all-cause healthcare cost 0.0000 0.0000 – 0.0000 13.87 <0.0001 
CI=Confidence Interval; AED=Antiepileptic drug; CCI=Charlson Comorbidity Index 
aReference categories: Non-refractory; Female; Caucasian; Generalized type of epilepsy; Single action of   index 
AED; CCI=0; No non-psychiatric comorbidity; No baseline inpatient visit 
Note: Some variable categories were collapsed due to small cell sizes. 
Race/Ethnicity into three groups (Caucasian, African American and Other);  
Type of epilepsy into three groups (Generalized, Partial and Other);  
Type of index Antiepileptic drug into two groups (Single and Multiple actions). 
Significant at p<0.05 (in bold) 
H3Q: Patients with refractory epilepsy have a higher cost of all-cause pharmacy claims at follow-
up as compared to patients with non-refractory epilepsy, while controlling for covariates. 
















4.4.4.2.6 Epilepsy-Related Pharmacy Cost  
 Wilcoxon signed-rank test and Generalized linear model was used to compare and determine 
differences in epilepsy-related pharmacy costs of patients with refractory and non-refractory 
epilepsy while controlling for covariates. 
4.4.4.2.6.1 Epilepsy-Related Pharmacy Cost (Unadjusted Analysis using Wilcoxon 
Signed-Rank Test) 
 Table 4.36 presents the cost of epilepsy-related pharmacy claims stratified by refractory and 
non-refractory status. Patients in the refractory group ($4,478 [± $5,971]) had significantly higher 
(p<0.0001) mean (± SD) cost of epilepsy-related pharmacy claims compared to patients in the non-
refractory group ($1,767 [± $2,835]). Although the mean (± SD) and median costs were higher 
than second year of follow-up, a similar trend in the cost of epilepsy-related pharmacy claims was 
observed in the first year of follow-up (Appendix VIF).  
Table 4.36: Comparison of Cost of Epilepsy-Related Pharmacy Claims in the Second Year 
of Follow-Up by Refractory/Non-Refractory Status (N=5,596) 
 
All Refractory Non-refractory 
p-value n=5,596 n=2,798 n=2,798 
Epilepsy-Related Pharmacy Cost 
  Median 
  (Mean ± SD) 
$1,532  
($3,122 ± $4,866) 
$2,775  
($4,478 ± $5,971) 
$803  
($1,767 ± $2,835) <0.0001a 
aWilcoxon signed-rank test 








4.4.4.2.6.2 Epilepsy-Related Pharmacy Cost (Adjusted Analysis using Generalized 
Linear Model) 
 Table 4.37 presents the results of the generalized linear model with gamma distribution and log-
link function comparing the cost of epilepsy-related pharmacy claims in the second-year of follow-
up by refractory and non-refractory groups while controlling for covariates. Results of the model 
indicated that the cost of epilepsy-related pharmacy claims of patients in the refractory group was 
2.5 times [exp(0.9038)] significantly higher (95% CI=2.308-2.641; p<0.0001) than the cost of 
epilepsy-related pharmacy claims of patients in the non-refractory group, after controlling for 
covariates.  Regarding covariates, partial type of epilepsy, index AED with multiple actions, 
increasing pill burden, and increasing baseline total cost were associated with a significantly higher 
(p<0.05) cost of epilepsy-related pharmacy visits. In contrast, increasing age, African Americans 
and other race, other type of epilepsy, baseline CCI of 1 and greater than 1, increasing number of 
psychiatric comorbidities, one or more baseline inpatient visits, and increasing baseline outpatient 
visits were associated with a significantly lower (p<0.05) cost of epilepsy-related pharmacy 
claims. Similarly, in the first-year of follow-up the cost of epilepsy-related pharmacy claims of 
patients in the refractory group was significantly higher (p<0.05) than the cost of epilepsy-related 









Table 4.37: Comparison of Cost of Epilepsy-Related Pharmacy Claims in the Second Year 
of Follow-Up by Refractory/Non-Refractory Status (N=5,596) 
 Estimate 95% CI z p-value 
Refractorya 0.9038 0.8364 – 0.9711 26.30 <0.0001 
Age at index -0.0194 -0.0222 - -0.0166 -13.42 <0.0001 
Malea 0.0151 -0.0534 – 0.0836 0.43 0.6660 
African American racea -0.2212 -0.3144 - -0.1280 -4.65 <0.0001 
Other racea -0.0678 -0.1417 – 0.0061 -1.80 0.0720 
Partial type of epilepsy at first visita 0.2035 0.0504 – 0.3566 2.61 0.0090 
Other type of epilepsy at first visita -0.1796 -0.2848 - -0.0745 -3.35 0.0010 
Multiple actions of index AEDa 0.2648 0.1963 – 0.3332 7.58 <0.0001 
Baseline CCI of 1a -0.1999 -0.2929 - -0.1069 -4.21 <0.0001 
Baseline CCI greater than 1a -0.2213 -0.3236 - -0.1189 -4.24 <0.0001 
Number of psychiatric comorbidities at follow-up -0.0929 -0.1174 - -0.0684 -7.44 <0.0001 
Non-psychiatric comorbidities at follow-upa -0.0403 -0.1118 – 0.0312 -1.10 0.2700 
Baseline pill burden 0.0147 0.0088 – 0.0207 4.85 <0.0001 
Baseline all-cause inpatient visitsa -0.1871 -0.2784 - -0.0958 -4.02 <0.0001 
Number of baseline all-cause outpatient visits -0.0032 -0.0059 - -0.0005 -2.36 0.0180 
Baseline total all-cause healthcare cost 0.0000 0.0000 – 0.0000 6.21 <0.0001 
CI=Confidence Interval; AED=Antiepileptic drug; CCI=Charlson Comorbidity Index 
aReference categories: Non-refractory; Female; Caucasian; Generalized type of epilepsy; Single action of   index 
AED; CCI=0; No non-psychiatric comorbidity; No baseline inpatient visit 
Note: Some variable categories were collapsed due to small cell sizes. 
Race/Ethnicity into three groups (Caucasian, African American and Other);  
Type of epilepsy into three groups (Generalized, Partial and Other);  
Type of index Antiepileptic drug into two groups (Single and Multiple actions). 
Significant at p<0.05 (in bold) 
H3R: Patients with refractory epilepsy have a higher cost of epilepsy-related pharmacy claims at 
follow-up as compared to patients with non-refractory epilepsy, while controlling for covariates. 
Failed to reject 
 










Table 4.38: Summary of Hypotheses Testing Results 
Hypothesis Hypothesis Statement Result 
Objective 1: To compare the demographic and clinical characteristics of patients with 
refractory and non-refractory epilepsy (Matched). 
H01A There is no significant difference in the mean age of patients 
between the refractory and non-refractory groups. 
Failed to reject 
H01B The proportion of gender categories does not differ between 
the refractory and non-refractory groups. 
Failed to reject 
H01C The proportion of race/ethnicity categories does not differ 
between the refractory and non-refractory groups. 
Rejected 
H01D The proportion of epilepsy type categories does not differ 
between the refractory and non-refractory groups. 
Rejected 
H01E There is no significant difference in the comorbidity burden 
of patients between the refractory and non-refractory groups. 
Failed to reject 
H01F The proportion of the AED type categories does not differ 
between the refractory and non-refractory groups. 
Rejected 
H01G There is no significant difference in the pill burden of 
patients between the refractory and non-refractory groups. 
Failed to reject 
Objective 2: To compare the treatment patterns of patients with refractory and non-
refractory epilepsy while controlling for covariates (Matched). 
H2A Patients with refractory epilepsy are less likely to be 
adherent to AEDs as compared to patients with non-
refractory epilepsy, while controlling for covariates. 
Rejected 
H2B Patients with refractory epilepsy are less likely to be 
persistent (i.e., duration of medication use) to AEDs as 
compared to patients with non-refractory epilepsy, while 





Patients with refractory epilepsy are more likely to add an 
alternative AED as compared to patients with non-refractory 
epilepsy. 
Failed to reject 
H2D 
(≥2 AEDs) 
Patients with refractory epilepsy are more likely to switch to 
an alternative AED as compared to patients with non-
refractory epilepsy. 

















Table 4.38: Summary of Hypotheses Testing Results (Continued) 
Hypothesis Hypothesis Statement Result 
Objective 3: To compare the all-cause and epilepsy-related healthcare utilization and costs 
between refractory and non-refractory patients while controlling for covariates (Matched). 
H3A-B Patients with refractory epilepsy have a higher number of 
all-cause medical visits consisting of inpatient 
hospitalizations and ED visits at follow-up as compared to 
patients with non-refractory epilepsy, while controlling for 
covariates. 
Note: Two-part ZIP model used 
Failed to reject 
for zero vs. non-
zero 
(dichotomous)  
Rejected for all 
values > 0 
H3C Patients with refractory epilepsy have a higher number of 
all-cause medical visits consisting of outpatient visits at 
follow-up as compared to patients with non-refractory 
epilepsy, while controlling for covariates. 





Failed to reject 
for all values > 
0 
H3D-E Patients with refractory epilepsy have a higher number of 
epilepsy-related medical visits consisting of inpatient 
hospitalization and ED visits at follow-up as compared to 
patients with non-refractory epilepsy, while controlling for 
covariates. 
Failed to reject 
H3F Patients with refractory epilepsy have a higher number of 
epilepsy-related medical visits consisting of outpatient visits 
at follow-up as compared to patients with non-refractory 
epilepsy, while controlling for covariates. 
Failed to reject 
H3G Patients with refractory epilepsy have longer lengths of stay 
for all-cause hospitalization as compared to patients with 
non-refractory epilepsy, while controlling for covariates. 
Not evaluated 
 
H3H Patients with refractory epilepsy have longer lengths of stay 
for epilepsy-related hospitalization as compared to patients 




H3I Patients with refractory epilepsy have a higher number of 
all-cause pharmacy claims as compared to patients with non-
refractory epilepsy, while controlling for covariates. 
Failed to reject 
 
H3J Patients with refractory epilepsy have a higher number of 
epilepsy-related pharmacy claims as compared to patients 
with non-refractory epilepsy, while controlling for 
covariates. 
Failed to reject 
 
H3K-L Patients with refractory epilepsy have a higher all-cause 
medical costs consisting of inpatient hospitalizations and ED 
visits at follow-up as compared to patients with non-








Table 4.38: Summary of Hypotheses Testing Results (Continued) 
Hypothesis Hypothesis Statement Result 
H3M Patients with refractory epilepsy have a higher all-cause 
medical costs consisting of outpatient visits at follow-up as 
compared to patients with non-refractory epilepsy, while 
controlling for covariates. 
Failed to reject 
H3N-O Patients with refractory epilepsy have a higher all-cause 
medical costs consisting of epilepsy-related inpatient 
hospitalizations and ED visits at follow-up as compared to 
patients with non-refractory epilepsy, while controlling for 
covariates. 
Failed to reject 
 
H3P Patients with refractory epilepsy have a higher epilepsy-
related medical costs consisting of outpatient visits at 
follow-up as compared to patients with non-refractory 
epilepsy, while controlling for covariates. 
Failed to reject 
H3Q Patients with refractory epilepsy have a higher cost of all-
cause pharmacy claims at follow-up as compared to patients 
with non-refractory epilepsy, while controlling for 
covariates. 
Failed to reject 
 
H3R Patients with refractory epilepsy have a higher cost of 
epilepsy-related pharmacy claims at follow-up as compared 
to patients with non-refractory epilepsy, while controlling 
for covariates. 



























Chapter 5 Discussion  
Chapter Overview 
This chapter includes a review of the study purpose followed by a discussion of the results 
by study objectives and possible explanations for study findings. This chapter concludes with study 
limitations and recommendations for future research. 
5.1 Study Purpose 
The purpose of the study was to characterize the demographic and clinical characteristics, 
treatment patterns, and healthcare utilization and costs associated with patients with refractory 
epilepsy and compare these characteristics to patients with non-refractory epilepsy. Treatment 
patterns included medication adherence, persistence, addition and switch to an alternative AED. 
Healthcare utilization and costs included number of all-cause and epilepsy-related services and 
costs associated with medical visits and pharmacy claims. The study used Texas Medicaid claims 
data from September 01, 2007 through December 31, 2013. The results of the study are discussed 











5.2 Study Characteristics 
The mean (± SD) age of the epileptic patients in this study was 38.7 (± 13.2), the proportion 
of females was 51.6%, and the proportion of Caucasians was 40.2%. The majority (79.8%) of 
patients had an epilepsy diagnosis classified as other convulsions (ICD-9-CM code: 780.39) at the 
first visit, and were initiated on (i.e., at index date) sodium channel blockers (40.5%). The highest 
proportion of patients were on one AED (38.5%), followed by patients on two AEDs (35.0%), and 
patients on three or more AEDs (26.5%) in the first year of follow-up (i.e., one-year identification 
period). Also, the majority of patients were on monotherapy (82.7%) on the index date (i.e., date 
of the first AED use). Personality disorder (46.1%) was the most common psychiatric comorbidity 
found in the patients in the second-year of follow-up, followed by depression (34.3%), mental 
retardation (30.2%), psychosis (26.6%), and anxiety (26.5%). The present study also found a 
higher prevalence of stroke (14.8%), followed by migraine (10.2%), sprain (9.3%), and open 
wounds (9.1%) at follow-up. At baseline, the patients had a mean (± SD) pill burden of 7.8 (±13.7) 
pills and mean (± SD) number of all-cause outpatient visits of 14.2 ± (14.9) visits. Also, 19.1% of 
the patients had one or more all-cause inpatient visits at baseline in the study cohort. These 
characteristics are similar to previous studies on epilepsy conducted using Medicaid data.29,134 
These inherent characteristics are not surprising as Medicaid includes a significant proportion of 
patients with a physical or mental disability.13 Psychiatric and non-psychiatric comorbidities have 
been commonly cited in literature among patients with epilepsy. These disorders further 









5.3 Study Objectives 
5.3.1 Objective 1: Demographic and Clinical Characteristics 
Objective 1 consisted of comparing the demographic and clinical characteristics of patients 
with refractory and non-refractory epilepsy. The present study identified 26.5% of the patients as 
refractory, which is within the range reported by previous prospective and retrospective studies 
(1.7% to 33.0%) using several working definitions to characterize refractoriness.10,11,13,19,74,75 At 
baseline, the refractory and non-refractory patients differed in the demographic characteristics of 
age, gender, and race/ethnicity, in the clinical characteristics of epilepsy type, AED type, 
comorbidity, and pill burden, and in the all-cause healthcare utilization and cost parameters of 
inpatient visits, outpatient visits, and total healthcare costs. This necessitated the use of propensity 
score matching procedure to minimize bias at baseline. After matching, the refractory and non-
refractory groups were balanced on the majority of covariates.  
Patients with refractory epilepsy had a mean (± SD) age of 38.0 (± 13.7) and were 
comprised of a higher proportion of females (55.3%), both of which are within the range of values 
reported by previous studies.10,11,13 Previous studies using retrospective administrative databases 
to evaluate refractory epilepsy among adults in the U.S. reported the range of mean (± SD) age 
from 32.8 (± 18.4) to 41.8 (± 13.7) and the proportion of females between 50.7% and 60.5%.11,13,18 
Regarding race/ethnicity, the matched cohort in the present study consisted of 41.9% patients who 
were Caucasian, 32.4% who were Hispanic, and 18.4% who were African American. Faught et al. 
reported the prevalence of Caucasians to be 53.5% and African Americans to be 20.9% among 
patients with epilepsy enrolled in the Florida, New Jersey, and Iowa Medicaid programs.29 The 






significant proportion (63%) of the non-elderly Texas Medicaid population.121 In the present study, 
patients with refractory epilepsy had a lower proportion of African Americans (15.9% vs. 20.9%) 
and higher proportion of Hispanics (34.3% vs. 30.5%) compared to patients with non-refractory 
epilepsy. Under-reporting of the condition among African Americans may be a possible 
explanation for the slightly lower proportion of African Americans with refractory epilepsy.81,135  
Regarding clinical characteristics, the matched cohort consisted of a high proportion of 
patients with other convulsions (77.2%) at first visit for both groups. A possible explanation may 
be that the first seizure (i.e., epilepsy diagnosis) observed in the study period was a single/isolated 
event that needed additional diagnostic work-up for the characterization of the seizure etiology.136  
Also, patients with refractory epilepsy consisted of a lower proportion of patients with generalized 
epilepsy (10.7% vs. 12.7%) compared to patients with non-refractory epilepsy. Earlier studies 
evaluating the impact of the type of seizure on patient outcomes have shown a high probability of 
achieving remission in patients with generalized epilepsy.82,83 This may explain the lower 
proportion of generalized epilepsy among patients with refractory epilepsy in the current study. In 
terms of AED use, a higher proportion of patients with refractory epilepsy were initiated on more 
than one type of AED (i.e., combination AEDs; 26.5% vs. 10.7%), followed by GABA analogues 
(12.0% vs. 10.2%), and calcium channel action agents (7.7% vs. 3.4%) compared to patients with 
non-refractory epilepsy. The high proportion of combination AEDs was expected among patients 
with refractory epilepsy due to the uncontrolled nature of the condition. Also, GABA analogues 
such as benzodiazepines are usually given as first-line treatment for breakthrough seizures and for 
status epilepticus in patients with refractory epilepsy.137 Conversely, in the present study a lower 
proportion of patients with refractory epilepsy were initiated on sodium channel blockers (27.6% 






2A binding agents (7.8% vs. 9.8%).  First generation sodium channel blockers such as 
carbamazepine and phenytoin are among the earliest and most efficacious drugs used as 
monotherapy in patients with epilepsy and thus may be used more commonly in patients with a 
stable form of epilepsy (i.e., non-refractory epilepsy).138 Also, phenytoin is typically not used as a 
monotherapy, but more often used as a rescue AED in combination therapy along with a chronic 
AED in patients with uncontrolled seizures, which may be a possible explanation for its lower use 
in patients with refractory epilepsy in the present study.32  
The mean (± SD) CCI of the patients with refractory epilepsy in the present study was 0.8 
(± 1.4), which is consistent with the range of 0.7 (± 1.5) to 1.1 (± 1.8) reported by previous 
studies.10,11,13 At follow-up, patients with refractory epilepsy had a higher mean (± SD) (2.1 [± 1.5] 
vs. 1.8 [± 1.4]) number of psychiatric comorbidities and a higher proportion (51.3% vs. 41.4%) of 
patients with one or more non-psychiatric comorbidity. Also, the median baseline all-cause total 
healthcare cost of the patients with refractory epilepsy was higher ($7,778 vs. $6,216) than patients 
with non-refractory epilepsy. These results are consistent with what was expected given the severe 
nature of refractory epilepsy and the resources used in the management of the condition.  
5.3.2 Objective 2: Treatment Patterns 
Objective 2 was comprised a comparison of treatment patterns of patients with refractory and non-
refractory epilepsy.  
The present study used the PDC method to measure medication adherence to AED 
monotherapy. The matched cohort had a mean (± SD) adherence of 82.8% (± 23.4%) and 74.3% 






comparable to previous studies assessing adherence in patients with epilepsy. Previous studies of 
patients with epilepsy reported a mean (± SD) adherence of 78.0 (SD not reported) to 90.3 (± 13.0) 
and 50% to 74% were adherent using a threshold of 0.8 or more to describe dichotomous 
adherence.29,102,103,105,106 Another finding was that in the present study, mean (± SD) adherence of 
the patients with refractory epilepsy (88.6 [± 19.1] vs. 77.0 [± 25.8]) was higher than the patients 
with non-refractory epilepsy. Also, patients with refractory epilepsy were more likely to adhere to 
AEDs compared to patients with non-refractory epilepsy, after adjusting for covariates. This is 
contrary to what was expected as poor medication adherence has been purported to be a cause of 
refractoriness. 107,109 As a result, it was assumed that patients with refractory epilepsy would 
continue their non-adherent behavior. However, this turned out not to be the case. Thus, as the 
present study did not evaluate medication adherence prior to identification of refractoriness, these 
results highlight the medication adherence patterns after patients are identified as refractory. As 
refractory patients are, in general, sicker and may be more symptomatic compared to non-
refractory patients, these patients may be less likely to omit taking medication(s). Nevertheless, 
among the refractory patients, the study used a liberal approach by evaluating adherence to AED 
monotherapy only. As a quarter (26.5%) of the refractory patients were initiated on polytherapy 
(i.e., on combination AEDs), adherence found in the study may have overestimated medication 
use behavior in those patients who were on multiple AEDs.  
Among the non-refractory patients, about 40% of the patients were non-adherent to AED 
regimens. A clinical explanation for lower adherence among non-refractory patients could not be 
ascertained as suboptimal effectiveness, AED intolerance, psychological fear of AEDs, and 
frequency of seizures and remission periods could not be determined from the claims dataset. 






leading to a lack of perceived benefit of AED treatment and, as a result, the patients did not feel 
the need to adhere to their AED regimens. Nonetheless, the association between non-adherent 
behavior and increased risk of hospitalization and ED visits demonstrated by previous studies in 
patients with epilepsy suggest the need to improve the medication use behavior of these 
patients.102-104 The study results also highlight that African Americans, patients with a high 
comorbidity burden (CCI), and patients who had one or more all-cause inpatient visits at baseline 
were less likely to adhere to AEDs. Disparities in access to healthcare among minorities such as 
African Americans have been previously depicted as an obstacle to medication adherence in 
patients with epilepsy.139  Moreover, as the patients were of low socioeconomic status and may 
have lacked knowledge of the condition, there may be issues with health literacy. Clinicians need 
to be aware of these barriers and develop individualized patient plans to improve the adherence to 
AEDs in patients with epilepsy. In addition, high comorbidity burden and baseline all-cause 
inpatient visits may be indicative of disease severity and associated increase in drug therapies for 
treating comorbid conditions, thus increasing the regimen complexity, which may have negatively 
impacted the adherence to AEDs.  
Similar to medication adherence, patients with refractory epilepsy (340.9 [± 194.5]) had a 
higher mean (± SD) persistence compared to patients with non-refractory epilepsy (301.3 [± 
118.1]). Also, patients with refractory epilepsy were less likely to discontinue their AED regimens 
(i.e., more likely to persist to AEDs), after controlling for covariates. Perhaps, the symptomatic 
nature of refractoriness explaining the high medication adherence in patients with refractory 
epilepsy may also explain the high persistence observed in these patients. Likewise, the covariates 
of high comorbidity burden at baseline (CCI) and all-cause inpatient visit at baseline were found 






persistence to AEDs). In addition, males had a lower likelihood of discontinuation (i.e., higher 
persistence to AEDs) compared to females. Chen et al. reported a lower prevalence of side effects 
attributable to AEDs in males compared to females, which may be a possible explanation for the 
lower discontinuation among males observed in the present study.140 
Regarding addition of an alternative AED, the majority of patients with epilepsy (90.1%) 
on dual therapy or more added an alternative AED. Adding an alternative AED to the existing 
regimen may be suggestive of a lack of seizure control and a need of greater intensity of treatment 
in patients with epilepsy.11 In contrast, a small proportion (19.6%) of the patients on dual therapy 
or more switched to an alternative AED and discontinued the existing regimen. Switching to an 
alternative AED may be suggestive of intolerance to the existing regimen leading to a change in 
the offending agent.11 In clinical practice, maintaining monotherapy with the existing regimen or 
an alternative AED is the preferable treatment paradigm in patients with epilepsy due to better 
adherence; reduction in treatment complexity especially in patients receiving other non-AEDs; 
minimization of side-effects; and containment of treatment costs.97 However, there may be high 
recurrence of seizures and associated high healthcare utilization due to AED switching as shown 
in previous studies. Thus, in clinical practice, if a patient is not responding to therapy, adding an 
AED is an alternative in patients with epilepsy, with the intent of tapering off the initial AED.21-24 
This may be a possible explanation for the high proportion of addition observed in the follow-up 
period of the present study. As, the process of tapering and switching to an alternative AED may 
take more than a year, it would be interesting to evaluate if a similar pattern of treatment exists 






Another finding of the current study was that about three-fourths (76.4% and 79.1%, 
respectively) of the patients who changed their AED regimen (addition or switch) added an 
alternative AED and/or switched to an alternative AED of a different MOA than the existing 
regimen. Use of polytherapy consisting of AEDs with different MOAs may have greater benefits 
than the effects of individual drug when given alone, i.e., use of AEDs with different MOAs may 
have supra-additive therapeutic efficacy. This approach constitutes rational polytherapy in patients 
with epilepsy.20,25-27 Yet, a lower proportion of patients with refractory epilepsy added and/or 
switched to an alternative AED of a different MOA compared to patients with non-refractory 
epilepsy. Though about one third (32.9%) of the refractory patients did not follow rational 
polytherapy, these patients may have tapered off their AED regimen at longer follow-up. In 
addition, perhaps, patients with refractory epilepsy may be less receptive to changes in chemical 
entity with a different MOA and less responsive or intolerant to a particular AED, thereby 
precluding use of AEDs based on the MOA. Nonetheless, the overall use of rational polytherapy 
by majority of patients with epilepsy (76.4% to 79.1%) in the present study is an indicator of good 
quality of care in patients enrolled in the Texas Medicaid program.  
 In the present study, compared to patients with non-refractory epilepsy (85.2%) a higher 
proportion of patients with refractory epilepsy (95.1%) added an alternative AED. Even after 
adjusting for covariates, patients with refractory epilepsy had a higher likelihood of adding an 
alternative AED compared to patients with non-refractory epilepsy. Though, patients on one AED 
were excluded, the inclusion of patients on three or more AEDs in the refractory group as opposed 
to patients with two AEDs in the non-refractory group, may have increased the likelihood of adding 
an alternative AED by patients with refractory epilepsy. Regarding covariates, not surprisingly, 






AED. In contrast, patients who had higher comorbidity burden at baseline (measured using CCI) 
and at follow-up (psychiatric and non-psychiatric comorbidities) were less likely to add an 
alternative AED. As discussed previously, patients with higher comorbidity burden may have a 
high medication load associated with the comorbidity, which may make clinicians more prudent 
in adding medications. Medications used in the treatment of comorbid conditions may also exert 
anti-seizure effects (i.e., additive effect), thus complicating epilepsy management.141 Likewise, 
AEDs may be associated with psychiatric adverse events such as psychosis and mania, and may 
be associated with detrimental effects on cognition functioning, motor speed, and attention, further 
complicating the management of epilepsy, especially among patients with psychiatric 
comorbidities.114,115 
 A similar trend was observed in the proportion of patients switching to an alternative AED; 
a higher proportion of patients with refractory epilepsy (28.7%) compared to patients with non-
refractory epilepsy (10.6%) switched to an alternative AED. This relationship persisted even after 
adjusting for covariates. Patients with higher comorbidity burden at baseline (measured using CCI) 
and at follow-up (psychiatric and non-psychiatric comorbidities), and with a high pill burden at 
baseline were more likely to switch to an alternative AED. As discussed previously, managing 
medications may be complicated in patients with several comorbid conditions. As a result 
switching to an alternative AED, as opposed to adding an AED, may be an option to minimize pill 
burden and to prevent potential drug-drug interactions. Conversely, the covariates of increasing 
age, male gender, partial type of epilepsy, other convulsions, and AEDs with multiple actions were 
associated with a lower likelihood of switching in patients with epilepsy. Reasons for these 
associations are not very clear. However, associations between male gender and lower 






association with lower switch rates and lower discontinuation of existing regimen in this group of 
patients. This result is consistent to a study by Cunnington et al. where patients with epilepsy 
reported a higher likelihood of regimen change among females compared to males.32 
5.3.3 Objective 3: Healthcare Utilization and Cost 
Objective 3 compared healthcare utilization and cost between patients with refractory and 
non-refractory epilepsy. A higher proportion of patients with refractory epilepsy had at least one 
epilepsy-related inpatient hospitalization visit (19.5% vs. 11.8%) and at least one epilepsy-related 
ED visit (29.7% vs. 19.5%) compared to patients with non-refractory epilepsy. This finding was 
slightly higher than the proportions reported by Cramer et al. among privately insured patients. 
Cramer et al. reported the proportion of patients with refractory and non-refractory epilepsy with 
at least one epilepsy-related inpatient hospitalization visit to be 15.7% and 7.0%, respectively, and 
those with at least one epilepsy-related ED visit to be 21.2% and 12.0%, respectively.11 A possible 
explanation may be due to the inherent differences in the patient populations.  A higher proportion 
of patients in Medicaid may be more severe and have more physical or cognitive limitations, which 
may explain the higher number of visits in the present study.13  
Furthermore, the combined mean (± SD) epilepsy-related inpatient hospitalization and ED 
visits of patients with refractory epilepsy (1.0 [± 2.2] vs. 0.5 [± 1.2]) was higher than that observed 
in patients with non-refractory epilepsy. Also, a higher proportion of patients with refractory 
epilepsy (39.3% vs. 26.5%) had at least one epilepsy-related inpatient hospitalization and ED visit 
compared to patients with non-refractory epilepsy, and this trend existed even after controlling for 
covariates. Also, African Americans, patients with higher comorbidity burden (psychiatric and 






baseline were associated with a higher number of epilepsy-related inpatient hospitalizations and 
ED visits. The negative association between African Americans and medication adherence and 
persistence found in the present study may explain the higher number of epilepsy-related inpatient 
hospitalizations and ED visits. Furthermore, other race, higher comorbidity burden, and baseline 
all-cause inpatient visits were associated with a higher cost of epilepsy-related inpatient 
hospitalizations and ED visits. Psychiatric and non-psychiatric comorbidities may be: a cause of 
seizures (e.g., stroke); a complication of having a seizure (e.g., fractures, sprains); or intensified 
by epilepsy (e.g., depression, anxiety). All of these may explain the positive association between 
comorbidity burden and epilepsy-related inpatient hospitalizations and ED visits and costs. 
Previous studies have reported that patients with comorbidities are more likely to have an inpatient 
admission and are more likely to be referred by epileptologists to inpatient settings for diagnostic 
evaluations of psychogenic non-epileptic events, thereby increasing the healthcare costs.117,118 
These results highlight the importance of better management of epilepsy and associated 
comorbidities, which may significantly decrease the utilization of healthcare resources by patients 
with epilepsy. 
In the present study, mean (± SD) all-cause and epilepsy-related outpatient visits of patients 
with refractory epilepsy (40.4 ± [37.1]; 8.1 ± [11.6]) was higher than visits among patients with 
non-refractory epilepsy (37.0 ± [36.9]); 5.7 ± [9.3]) and was significantly higher even after 
controlling for covariates. Similar to inpatient hospitalization and ED visits, African American and 
other race/ethnicity, high comorbidity burden at baseline and follow-up, and increasing baseline 
all-cause outpatient visits were positively associated with increasing all-cause and epilepsy-related 
outpatient visits in patients with epilepsy. In addition, increasing baseline pill burden was 






provider visits for comorbid conditions associated with epilepsy may have led to higher all-cause 
outpatient visits.  
Regarding all-cause and epilepsy-related pharmacy claims (i.e., number of prescriptions), 
patients with refractory epilepsy (9.9 [± 6.8]; 3.1 [± 1.5]) had higher mean number of prescriptions 
compared to patients with non-refractory epilepsy (8.6 [± 6.3]; 1.8 [± 1.1]). Moreover, after 
adjusting for covariates, the all-cause and epilepsy-related pharmacy costs of patients with 
refractory epilepsy were 1.3 to 2.5 fold higher than the respective costs of patients with non-
refractory epilepsy. Similar to medical visits and costs, the all-cause and epilepsy-related 
pharmacy claims were positively associated with increasing comorbidity burden at baseline and 
follow-up and increasing pill burden at baseline. Another notable finding is the negative 
association between other race/ethnicity and all-cause pharmacy visits and costs and epilepsy-
related pharmacy costs in the present study.  
Overall, in the present study (2013 dollars) the mean all-cause cost of medical visits and 
pharmacy claims for patients with refractory epilepsy was $23,136 (± $25,827) and for patients 
with non-refractory epilepsy was $19,813 (± $25,907). Also, the mean epilepsy-related cost of 
medical visits and pharmacy claims for patients with refractory epilepsy was $7,811 (± $10,084) 
and for patients with non-refractory epilepsy was $3,893 (± $7,047). These findings are similar to 
the cost estimates reported by Cramer et al. (2009 dollars) among privately insured patients. 
Cramer et al. estimated the mean all-cause cost of medical visits and pharmacy claims at $23,238 
(± 42,894) for patients with refractory epilepsy and $13,839 (± $6,789) for patients with non-
refractory epilepsy. Also, their study estimated the mean epilepsy-related cost of medical and 






for patients with non-refractory epilepsy.11 Similar estimates found in the present study (2013 
dollars) suggest that the healthcare utilization and costs have remained unchanged after the 
introduction of newer AEDs in the U.S. 
The cost estimates in the present study differ from the estimates reported by Manjunath et al. 
in a sample of Medicaid enrollees from the states of Florida, Iowa, Kansas, Missouri and New 
Jersey. The study estimated the mean all-cause cost of medical and pharmacy visits (2009 dollars) 
of refractory epilepsy at $38,708 (±$114,904) and of non-refractory epilepsy at $29,635 
(±$105,644).13 The state Medicaid program of Texas differs from the other states included by 
Manjunath et al. in the demographic characteristics of the populations served, services covered, 
and different structures of benefits and payments. The Medicaid program in the state of Texas has 
the highest proportion of Hispanics (63%).121 Also, the study by Manjunath et al. used a restrictive 
identification criterion to define refractory epilepsy. The inclusion criterion required an epilepsy-
related ED visit or hospitalization following two or more AED changes that restricted the study to 
patients with severe epilepsy.13 This combination of the patient population served and the strict 
identification criteria may explain the higher cost estimates compared to the present study.  
In summary, though all the individual cost categories were higher in patients with refractory 
epilepsy compared to patients with non-refractory epilepsy in the present study, the highest cost 
differences were found in epilepsy-related medical and pharmacy costs. Pharmacy costs of the 
patients with refractory epilepsy accounted for more than twice the costs of non-refractory patients, 
followed by differences in inpatient hospitalization and ED costs, and finally outpatient visit costs 
in comparison to patients with non-refractory epilepsy. Considerably higher cost of epilepsy-






AEDs to achieve satisfactory seizure control.10 Also, use of urgent care for the treatment of 
breakthrough seizures and status epilepticus as well as surgical procedures may have increased the 
cost associated with hospitalization and ED visits.137 Moreover, patients with refractory epilepsy 
may have had higher diagnostic work-up, which resulted in increased cost of outpatient visits. 
Another related finding was that epilepsy-related total costs were one-third of the all-cause total 
costs in patients with refractory epilepsy and 20% in patients with non-refractory epilepsy. This 
suggests the impact of comorbid conditions on the additional healthcare medical and pharmacy 
costs of patients with epilepsy. Thus, management of epilepsy extends beyond the control of 






5.4 Limitations  
 The present study has several limitations that must be noted when interpreting the results. 
First, confirmation of the onset of seizures could not be validated in the Texas Medicaid 
administrative and claims dataset, without access to laboratory or other diagnostic reports. The 
study used a combination of ICD-9-CM diagnoses codes and AED prescriptions to identify 
patients with epilepsy. This may have led to misclassification of the patients with epilepsy. A 
systematic review of studies assessing the validity of epilepsy algorithms in claims datasets 
reported that the best model to identify epilepsy cases was an algorithm that required an ICD-9-
CM code in addition to a pharmacy fill for an AED. This model showed a positive predictive value 
of 83.9% and a sensitivity of 81.8%. Also, algorithms that had inpatient hospitalizations, had 
higher positive predictive values compared to those that relied only on outpatient visits.142 
Consequently, the present study used a more restrictive criterion for identifying outpatient visits 
that required patients to have two or more outpatient visits at least a month apart. This ensured that 
the outpatient visits were not to rule-out the diagnosis of epilepsy.11  Moreover, the indication of 
each AED prescription could not be confirmed from the pharmacy claims. AEDs may have been 
used prophylactically for the treatment of neuropathic or chronic pain, fibromyalgia, bipolar 
disorder, migraine, stroke, trauma or brain tumor. However, based on clinical expert opinion, the 
present study required patients to have fills for AEDs for at least 90 days without a gap of more 
than 60 days to ensure use of AEDs in the treatment of epilepsy as opposed to their use in 
prophylaxis. 
Second, as clinical determination of inefficacy or intolerance to AEDs to identify failure 






not be precise. The present study employed clinical expert opinion to identify patients with 
potential refractoriness. The study used an operational definition of the use of at least three AEDs 
in a one-year identification period. Using this definition, 26.5% of the patients with epilepsy were 
identified as refractory, which is within the range (1.7% to 33.0%) reported in the literature. Of 
the 26.5% of the patients with refractory epilepsy, 9% had partial seizures, which is similar to the 
prevalence of 11% for patients with refractory epilepsy reported by Chen et al. among 
commercially insured patients with partial epilepsy.10 Although, Chen et al. used a similar 
operational definition to characterize refractoriness in patients with partial epilepsy, the study 
followed patients for a longer period of time (i.e., four years of data collection period), which may 
explain the slightly higher prevalence.  
Third, the use of PDC to measure adherence, may not reflect actual adherence, as patients 
may not have taken the filled prescriptions. In addition, a hospitalization may have disrupted the 
continuity of prescription claims, underestimating the adherence and persistence patterns. Also, 
the study used a liberal approach by evaluating medication adherence to AED monotherapy only 
to account for the change in AED(s). This may have overestimated adherence and persistence 
patterns among the patients. Fourth, the study used a baseline period in which patients did not have 
an AED fill; however, this does not guarantee newly diagnosed epilepsy. Fifth, though propensity 
score matching was used to balance the refractory and non-refractory groups at baseline, there may 
be differences in matched cohorts due to unobservable clinical characteristics. Also, there were 
differences in race/ethnicity, type of epilepsy, and baseline all-cause total cost, even after 
matching. However, these differences were small and not practically significant. Sixth, the cost 
analyses were based on the costs to the Texas Medicaid program, which may not reflect the actual 






burden; however, indirect costs could not be evaluated using insurance claims. In addition, the 
study excluded about one quarter (24.1%) of patients who were dual eligible for Medicare and 
Medicaid. Thus, the cost estimates may not be representative of the entire Texas Medicaid 
population. Seventh, the external validity of the study results may be limited by the characteristics 
of the study population and the results may be generalizable to the Texas Medicaid non-dual 
eligible adult epilepsy population only. Lastly, as this study uses prescription and medical claims 
data, which have been collected for the purpose of payment and not for research.  Therefore, any 













5.5 Conclusions, Recommendations for Future Research 
The main aim of the study was to characterize and compare the treatment patterns (consisting 
of medication adherence and persistence, and adding and switching to alternative therapy), and 
healthcare utilization and costs associated with patients who have refractory and non-refractory 
epilepsy. The results of the study suggest that patients with refractory epilepsy were significantly 
more likely to adhere and persist to AED regimen, and were significantly more likely to add and 
switch to an alternative AED than patients with non-refractory epilepsy. Also, patients with 
refractory epilepsy had a significantly higher number of all-cause outpatient visits and pharmacy 
claims, and epilepsy-related inpatient hospitalization and ED visits, outpatient visits, and 
pharmacy claims. Consequently, these patients incurred higher costs of all-cause outpatient visits 
and pharmacy claims, and higher costs of epilepsy-related inpatient hospitalization and ED visits, 
outpatient visits, and pharmacy claims. In addition, these analyses confirm that patients with 
refractory epilepsy have higher nonepilepsy-related service costs than patients with non-refractory 
epilepsy.  
In conclusion, findings from this study provide evidence on the dynamic patterns of AED 
use in clinical practice. Medication profiles of African Americans, patients with a high pill burden 
as well as those with a high comorbidity burden need to be explored to improve medication use 
behavior and reduce healthcare utilization and costs of these patients.  Also, the high adherence 
and persistence patterns and the overall use of rational polytherapy by a significant proportion of 
patients with epilepsy is an indicator of good quality of care in patients enrolled in the Texas 
Medicaid program. In addition, the present study provides current estimates of the resource 






These results highlight the importance of better management of epilepsy and associated 
comorbidities, which may significantly decrease the utilization of healthcare resources by patients 
with epilepsy and as a result improve the overall burden of the disease. Patients failing three or 
more AEDs may trigger referral to comprehensive epilepsy centers for confirming accuracy of the 
etiology of epilepsy and determining potential refractoriness. This timely identification of patients 
with refractory epilepsy and early treatment optimization may help prevent long-term clinical and 
psychosocial consequences associated with the condition. 
Future research needs to validate the claims-based refractory epilepsy identification 
algorithm in a different patient population. Also, the use of a hybrid study design that includes 
clinical information from medical charts in addition to claims-based records would help validate 
the definition used in the present study. Future studies also need to evaluate the medication use 
patterns and economic outcomes over a longer follow-up period and assess differences in patients 













Patient 1: This patient was identified as refractory as the patient is dispensed 3 chronic AEDs in 
the 1 year identification period.  
 
Antiepileptic drug Start date Days of supply 
KEPPRA 500 MG TABLET 17-Mar-08 30 
NEURONTIN 600 MG TABLET 17-Mar-08 30 
PHENOBARBITAL 64.8 MG TABLET 17-Mar-08 30 
KEPPRA 500 MG TABLET 16-Apr-08 30 
PHENOBARBITAL 32.4 MG TABLET 16-Apr-08 30 
KEPPRA 500 MG TABLET 14-May-08 30 
PHENOBARBITAL 32.4 MG TABLET 14-May-08 30 
KEPPRA 500 MG TABLET 13-Jun-08 30 
PHENOBARBITAL 32.4 MG TABLET 13-Jun-08 30 
NEURONTIN 600 MG TABLET 27-Jun-08 30 
KEPPRA 500 MG TABLET 11-Jul-08 30 
PHENOBARBITAL 32.4 MG TABLET 11-Jul-08 30 
NEURONTIN 600 MG TABLET 12-Aug-08 30 
KEPPRA 500 MG TABLET 12-Aug-08 30 
PHENOBARBITAL 32.4 MG TABLET 12-Aug-08 30 
NEURONTIN 600 MG TABLET 12-Sep-08 30 
KEPPRA 500 MG TABLET 12-Sep-08 30 
PHENOBARBITAL 32.4 MG TABLET 12-Sep-08 30 
KEPPRA 500 MG TABLET 10-Oct-08 30 
PHENOBARBITAL 32.4 MG TABLET 10-Oct-08 30 
KEPPRA 500 MG TABLET 5-Nov-08 30 
NEURONTIN 600 MG TABLET 5-Nov-08 30 
PHENOBARBITAL 32.4 MG TABLET 5-Nov-08 30 
KEPPRA 500 MG TABLET 9-Dec-08 30 
NEURONTIN 600 MG TABLET 9-Dec-08 30 
PHENOBARBITAL 32.4 MG TABLET 9-Dec-08 30 
KEPPRA 500 MG TABLET 9-Jan-09 30 
NEURONTIN 600 MG TABLET 9-Jan-09 30 
PHENOBARBITAL 32.4 MG TABLET 9-Jan-09 30 
KEPPRA 500 MG TABLET 2-Feb-09 30 
GABAPENTIN 600 MG TABLET 2-Feb-09 30 
PHENOBARBITAL 32.4 MG TABLET 5-Feb-09 30 







Patient 2: This patient was identified as refractory as the patient is dispensed 3 chronic AEDs in 
the 1 year identification period.  
 
Antiepileptic drug Start date Days of supply 
DIAZEPAM 10 MG TABLET 21-Feb-11 1 
PHENYTOIN SOD EXT 100 MG CAP 25-Feb-11 30 
PHENYTOIN SOD EXT 100 MG CAP 30-Mar-11 30 
DIAZEPAM 10 MG TABLET 25-Apr-11 4 
PHENYTOIN SOD EXT 100 MG CAP 8-May-11 30 
ZONISAMIDE 50 MG CAPSULE 1-Jun-11 21 
ZONISAMIDE 100 MG CAPSULE 18-Jun-11 35 
ZONISAMIDE 100 MG CAPSULE 14-Aug-11 30 
GABAPENTIN 400 MG CAPSULE 2-Sep-11 90 
GABAPENTIN 300 MG CAPSULE 3-Oct-11 30 
GABAPENTIN 300 MG CAPSULE 17-Nov-11 30 
GABAPENTIN 300 MG CAPSULE 16-Dec-11 30 
GABAPENTIN 300 MG CAPSULE 14-Jan-12 30 




















Patient 3: This patient was identified as non-refractory as the patient is dispensed 2 chronic AEDs 
in the 1 year identification period.  
 
Antiepileptic drug Start date Days of supply 
PHENYTOIN SOD EXT 100 MG CAP 21-Oct-09 90 
DIAZEPAM 5 MG TABLET 25-Nov-09 5 
PHENYTOIN SOD EXT 100 MG CAP 4-Jan-10 30 
PHENYTOIN SOD EXT 100 MG CAP 29-Jan-10 30 
LEVETIRACETAM 500 MG TABLET 29-Jan-10 30 
PHENYTOIN SOD EXT 100 MG CAP 25-Feb-10 30 
LEVETIRACETAM 500 MG TABLET 25-Feb-10 30 
LEVETIRACETAM 500 MG TABLET 20-Mar-10 15 
LEVETIRACETAM 500 MG TABLET 5-Apr-10 15 
PHENYTOIN SOD EXT 100 MG CAP 5-Apr-10 30 
PHENYTOIN SOD EXT 100 MG CAP 4-May-10 30 
LEVETIRACETAM 500 MG TABLET 7-May-10 30 
LEVETIRACETAM 500 MG TABLET 1-Jun-10 30 
PHENYTOIN SOD EXT 100 MG CAP 1-Jun-10 30 
PHENYTOIN SOD EXT 100 MG CAP 2-Jul-10 30 
LEVETIRACETAM 500 MG TABLET 12-Jul-10 30 
PHENYTOIN SOD EXT 100 MG CAP 28-Jul-10 30 
LEVETIRACETAM 500 MG TABLET 11-Aug-10 30 
PHENYTOIN SOD EXT 100 MG CAP 24-Aug-10 30 
LEVETIRACETAM 500 MG TABLET 9-Sep-10 30 
PHENYTOIN SOD EXT 100 MG CAP 17-Sep-10 30 
LEVETIRACETAM 500 MG TABLET 14-Oct-10 30 














Patient 4: This patient was identified as refractory as the patient is dispensed 6 chronic AEDs in 
the 1 year identification period.  
 
Antiepileptic drug Start date Days of supply 
KEPPRA 100 MG/ML ORAL SOLN 5-Mar-08 100 
OXCARBAZEPINE 600 MG TABLET 27-Mar-08 30 
KEPPRA 100 MG/ML ORAL SOLN 3-Apr-08 30 
OXCARBAZEPINE 600 MG TABLET 28-Apr-08 30 
PHENYTEK 300 MG CAPSULE 30-Apr-08 30 
DEPAKOTE ER 500 MG TABLET 12-May-08 30 
KEPPRA 750 MG TABLET 12-May-08 30 
CLONAZEPAM 1 MG TABLET 26-May-08 30 
DEPAKOTE ER 500 MG TABLET 2-Jun-08 30 
CLONAZEPAM 1 MG TABLET 27-Jun-08 30 
DEPAKOTE ER 500 MG TABLET 19-Jul-08 15 
CLONAZEPAM 1 MG TABLET 21-Jul-08 60 
DEPAKOTE ER 500 MG TABLET 20-Aug-08 30 
CLONAZEPAM 1 MG TABLET 4-Sep-08 30 
DEPAKOTE ER 500 MG TABLET 18-Sep-08 30 
DEPAKOTE ER 500 MG TABLET 20-Oct-08 30 
LAMICTAL 25 MG TABLET 30-Oct-08 30 
DEPAKOTE ER 500 MG TABLET 1-Dec-08 30 
DEPAKOTE ER 500 MG TABLET 28-Dec-08 30 
DEPAKOTE ER 500 MG TABLET 29-Jan-09 30 



























Anxiety disorders 292.8x, 293.8x, 300.0x, 300.2x, 308.0x, 309.2x 
Bipolar disorder 296.0x, 296.1x, 296.4x-296.9x 
Depression 296.2x, 296.3x, 298.0x, 300.4x, 309.0x, 309.1x, 311.xx, V79.0x 
Psychosis 290.xx-299.xx (except 292.8x, 293.8x, 298.0x, and 296.xx) 
Personality disorder 300.xx-316.xx (except 300.0x, 300.2x, 300.4x, 308.0x, 309.0x, 309.1x, 309.2x, 
and 311.x), V17.0x, V71.0x 
Mental retardation 317.xx-319.xx 
Alzheimer’s disease 290.0x-290.3x, 294.10, 294.11, 331.0x, 331.82 
Brain tumor 191.xx, 198.3x, 237.5x, 239.6x,  
Head injury 854.x 
Meningitis 047.xx, 094.2x, 320.xx-322.xx 
Migraine 346.xx 
Stroke 434.xx-436.xx 
Multiple Sclerosis 340.xx 
Fracture 800.xx-829.xx 
Dislocation 830.xx-839.xx 
Sprains and strains 840.xx-849.xx 
Open wounds 870.xx-897.xx 
Burns 940.xx-943.xx 

























Comparison of Medication Adherence (Sensitivity Analyses) in the Second Year of Follow-
Up by Refractory/Non-Refractory Status (N=5,596) 
Medication Adherence 
All Refractory Non-refractory 
p-value 
n=5,596 n=2,798 n=2,798 
N % N % N % 
Adherence cut-off 70%  
  Adherent (PDC≥70%) 4,578 81.8 2,518 90.0 2,060 73.6 
<0.0001 
  Non-Adherent (PDC<70%) 1,018 18.2 280 10.0 738 26.4 
Adherence cut-off 90%  
  Adherent (PDC≥90%) 3,426   61.2 2,125 76.0 1,301 46.5 
<0.0001 
  Non-Adherent (PDC<90%) 2,170 38.8 673 24.1 1,497 53.5 
PDC=Proportion of days covered 
 
Comparison of Medication Adherence in the First Year of Follow-Up by Refractory/Non-
Refractory Status (N=5,596) 
Medication Adherence 
All Refractory Non-refractory 
p-value 
n=5,596 n=2,798 n=2,798 
N % N % N % 
PDC  
  Mean ± SD 91.6 ± 15.9 96.7 ± 10.4 86.5 ± 18.7 <0.0001 
  Adherent (PDC≥80%) 4,702 84.0 2,627 93.9 2,075 74.2 
<0.0001 
  Non-Adherent (PDC<80%) 894 16.0 171 6.1 723 25.8 













Conditional Logistic Regression Analysis (Sensitivity Analyses) Comparing the Likelihood 
of being Adherent (PDC≥70) in the Second Year of Follow-Up among Refractory/Non-




95% CI Wald X2 p-value 
Refractorya 3.378 2.846 - 4.010 193.73 <0.0001 
Age at index 1.010 0.993 - 1.028 1.38 0.2400 
Malea 1.738 1.213 - 2.490 9.07 0.0026 
African American racea 0.718 0.527 - 0.976 4.46 0.0347 
Other racea 0.997 0.757 - 1.313 0.00 0.9832 
Partial type of epilepsy at first visita 1.670 0.884 - 3.157 2.49 0.1143 
Other type of epilepsy at first visita 1.537 0.819 - 2.885 1.79 0.1804 
Multiple actions of index AEDa 1.243 0.971 - 1.591 2.98 0.0843 
Baseline CCI of 1a 0.830 0.592 - 1.163 1.17 0.2790 
Baseline CCI greater than 1a 1.130 0.669 - 1.908 0.21 0.6474 
Number of psychiatric comorbidities at follow-up 0.876 0.803 - 0.956 8.79 0.0030 
Non-psychiatric comorbidities at follow-upa 0.933 0.732 - 1.189 0.32 0.5743 
Baseline pill burden 0.946 0.858 - 1.043 1.24 0.2661 
Baseline all-cause inpatient visitsa 0.853 0.622 - 1.168 0.99 0.3208 
Number of baseline all-cause outpatient visits 0.998 0.988 - 1.007 0.22 0.6416 
Baseline total all-cause healthcare cost 1.000 1.000 - 1.000 1.33 0.2493 
CI=Confidence Interval; AED=Antiepileptic drug; CCI=Charlson Comorbidity Index 
aReference categories: Non-refractory; Female; Caucasian; Generalized type of epilepsy; Single action of   index 
AED; CCI=0; No non-psychiatric comorbidity; No baseline inpatient visit 
Note: Some variable categories were collapsed due to small cell sizes. 
Race/Ethnicity into three groups (Caucasian, African American and Other);  
Type of epilepsy into three groups (Generalized, Partial and Other);  
Type of index Antiepileptic drug into two groups (Single and Multiple actions). 
Model Fit: likelihood ratio=297.3227; df=16; p<0.0001 


















Conditional Logistic Regression Analysis (Sensitivity Analyses) Comparing the Likelihood 
of being Adherent (PDC≥90) in the Second Year of Follow-Up among Refractory/Non-




95% CI Wald X2 p-value 
Refractorya 3.649 3.192 - 4.172 359.77 <0.0001 
Age at index 0.993 0.978 - 1.009 0.78 0.3783 
Malea 1.204 0.886 - 1.637 1.40 0.2361 
African American racea 0.827 0.646 - 1.060 2.26 0.1332 
Other racea 0.755 0.61 - 0.936 6.58 0.0103 
Partial type of epilepsy at first visita 1.686 1.050 - 2.706 4.68 0.0305 
Other type of epilepsy at first visita 1.150 0.679 - 1.949 0.27 0.6027 
Multiple actions of index AEDa 1.291 1.067 - 1.562 6.87 0.0088 
Baseline CCI of 1a 0.642 0.485 - 0.850 9.59 0.0020 
Baseline CCI greater than 1a 0.777 0.49 - 1.231 1.16 0.2819 
Number of psychiatric comorbidities at follow-up 0.971 0.908 - 1.038 0.75 0.3876 
Non-psychiatric comorbidities at follow-upa 1.008 0.826 - 1.23 0.01 0.9389 
Baseline pill burden 1.029 0.938 - 1.127 0.36 0.5476 
Baseline all-cause inpatient visitsa 0.678 0.528 - 0.871 9.22 0.0024 
Number of baseline all-cause outpatient visits 0.998 0.991 - 1.006 0.27 0.6048 
Baseline total all-cause healthcare cost 1.000 1.000 – 1.000 0.92 0.3377 
CI=Confidence Interval; AED=Antiepileptic drug; CCI=Charlson Comorbidity Index 
aReference categories: Non-refractory; Female; Caucasian; Generalized type of epilepsy; Single action of   index 
AED; CCI=0; No non-psychiatric comorbidity; No baseline inpatient visit 
Note: Some variable categories were collapsed due to small cell sizes. 
Race/Ethnicity into three groups (Caucasian, African American and Other);  
Type of epilepsy into three groups (Generalized, Partial and Other);  
Type of index Antiepileptic drug into two groups (Single and Multiple actions). 
Model Fit: likelihood ratio=559.4323; df=16; p<0.0001 


















Conditional Logistic Regression Analysis Comparing the Likelihood of being Adherent 





95% CI Wald X2 p-value 
Refractorya 6.513 5.126-8.276 235.02 <0.0001 
Age at index 1.030 1.007-1.053 6.44 0.0112 
Malea 2.571 1.614-4.097 15.78 <0.0001 
African American racea 0.494 0.336-0.726 12.90 0.0003 
Other racea 0.775 0.551-1.089 2.16 0.1416 
Partial type of epilepsy at first visita 3.162 1.404-7.12 7.72 0.0054 
Other type of epilepsy at first visita 2.008 0.919-4.387 3.05 0.0806 
Multiple actions of index AEDa 1.415 1.021-1.962 4.34 0.0373 
Baseline CCI of 1a 0.806 0.516-1.258 0.90 0.3423 
Baseline CCI greater than 1a 1.555 0.794-3.048 1.65 0.1983 
Number of psychiatric comorbidities at follow-up 0.824 0.736-0.922 11.31 0.0008 
Non-psychiatric comorbidities at follow-upa 0.848 0.619-1.163 1.05 0.3060 
Baseline pill burden 0.863 0.762-0.977 5.41 0.0200 
Baseline all-cause inpatient visitsa 0.567 0.377-0.851 7.49 0.0062 
Number of baseline all-cause outpatient visits 1.002 0.99-1.015 0.14 0.7115 
Baseline total all-cause healthcare cost 1.000 1.000-1.000 2.25 0.1339 
CI=Confidence Interval; AED=Antiepileptic drug; CCI=Charlson Comorbidity Index 
aReference categories: Non-refractory; Female; Caucasian; Generalized type of epilepsy; Single action of   index 
AED; CCI=0; No non-psychiatric comorbidity; No baseline inpatient visit 
Note: Some variable categories were collapsed due to small cell sizes. 
Race/Ethnicity into three groups (Caucasian, African American and Other);  
Type of epilepsy into three groups (Generalized, Partial and Other);  
Type of index Antiepileptic drug into two groups (Single and Multiple actions). 
Model Fit: likelihood ratio=505.2191; df=16; p<0.0001 



















Comparison of Medication Persistence (Sensitivity Analyses) in the Second Year of Follow-
Up by Refractory/ Non-Refractory Status (N=5,596) 
Medication Persistence 
All Refractory Non-refractory 
p-value 
n=5,596 n=2,798 n=2,798 
N % N % N % 
Persistence Gap of 30 days  
  Mean ± SD  283.7 ± 121.6 308.6 ± 105.9 258.8 ± 130.9 <0.0001 
Persistence Gap of 90 days  
  Mean ± SD  322.7 ± 90.6 335.3 ± 77.2 310.0 ± 100.6 <0.0001 
 
 
Comparison of Medication Persistence in the First Year of Follow-Up by Refractory/ Non-
Refractory Status (N=5,596) 
Medication Persistence 
All Refractory Non-refractory 
p-value 
n=5,596 n=2,798 n=2,798 
N % N % N % 
Persistence Gap of 60 days  



















Cox Proportional Hazard Regression Analysis Comparing the Likelihood of Discontinuation 
(Persistence 30 Day Gap) in the Second Year of Follow-Up among Refractory/ Non-




95% CI Wald X2 p-value 
Refractorya 0.612 0.568 - 0.659 171.41 <0.0001 
Age at index 0.998 0.99 - 1.006 0.19 0.6598 
Malea 0.855 0.727 - 1.005 3.60 0.0578 
African American racea 1.083 0.940 - 1.246 1.22 0.2695 
Other racea 1.037 0.925 - 1.162 0.38 0.5375 
Partial type of epilepsy at first visita 0.870 0.677 - 1.117 1.19 0.2746 
Other type of epilepsy at first visita 0.847 0.64 - 1.121 1.35 0.2452 
Multiple actions of index AEDa 0.928 0.836 - 1.031 1.94 0.1632 
Baseline CCI of 1a 1.232 1.059 - 1.434 7.28 0.0070 
Baseline CCI greater than 1a 1.032 0.804 - 1.325 0.06 0.8057 
Number of psychiatric comorbidities at follow-up 1.022 0.985 - 1.06 1.30 0.2544 
Non-psychiatric comorbidities at follow-upa 0.998 0.894 - 1.113 0.00 0.9670 
Baseline pill burden 1.019 0.972 - 1.069 0.64 0.4252 
Baseline all-cause inpatient visitsa 1.146 0.999 - 1.315 3.79 0.0516 
Number of baseline all-cause outpatient visits 0.999 0.995 - 1.003 0.20 0.6535 
Baseline total all-cause healthcare cost 1.000 1.000 – 1.000 0.42 0.5188 
CI=Confidence Interval; AED=Antiepileptic drug; CCI=Charlson Comorbidity Index 
aReference categories: Non-refractory; Female; Caucasian; Generalized type of epilepsy; Single action of   index 
AED; CCI=0; No non-psychiatric comorbidity; No baseline inpatient visit 
Note: Some variable categories were collapsed due to small cell sizes. 
Race/Ethnicity into three groups (Caucasian, African American and Other);  
Type of epilepsy into three groups (Generalized, Partial and Other);  
Type of index Antiepileptic drug into two groups (Single and Multiple actions). 
Model Fit: likelihood ratio=228.9262; df=16; p<0.0001 























Cox Proportional Hazard Regression Analysis Comparing the Likelihood of Discontinuation 
(Persistence 90 Day Gap) in the Second Year of Follow-Up among Refractory/Non-




95% CI Wald X2 p-value 
Refractorya 0.675 0.629 - 0.725 117.25 <0.0001 
Age at index 0.995 0.987 - 1.003 1.44 0.2308 
Malea 0.841 0.718 - 0.984 4.65 0.0311 
African American racea 1.086 0.948 - 1.245 1.41 0.2350 
Other racea 1.021 0.915 - 1.141 0.14 0.7066 
Partial type of epilepsy at first visita 0.855 0.671 - 1.089 1.61 0.2049 
Other type of epilepsy at first visita 0.821 0.626 - 1.078 2.02 0.1553 
Multiple actions of index AEDa 0.943 0.852 - 1.043 1.31 0.2526 
Baseline CCI of 1a 1.122 0.969 - 1.299 2.35 0.1253 
Baseline CCI greater than 1a 1.01 0.792 - 1.288 0.01 0.9372 
Number of psychiatric comorbidities at follow-up 1.022 0.986 - 1.059 1.37 0.2421 
Non-psychiatric comorbidities at follow-upa 0.979 0.88 - 1.088 0.16 0.6894 
Baseline pill burden 1.027 0.981 - 1.076 1.29 0.2567 
Baseline all-cause inpatient visitsa 1.145 1.002 - 1.309 3.97 0.0464 
Number of baseline all-cause outpatient visits 0.999 0.996 - 1.003 0.12 0.7335 
Baseline total all-cause healthcare cost 1.000 1.000 – 1.000 0.81 0.3690 
CI=Confidence Interval; AED=Antiepileptic drug; CCI=Charlson Comorbidity Index 
aReference categories: Non-refractory; Female; Caucasian; Generalized type of epilepsy; Single action of   index 
AED; CCI=0; No non-psychiatric comorbidity; No baseline inpatient visit 
Note: Some variable categories were collapsed due to small cell sizes. 
Race/Ethnicity into three groups (Caucasian, African American and Other);  
Type of epilepsy into three groups (Generalized, Partial and Other);  
Type of index Antiepileptic drug into two groups (Single and Multiple actions). 
Model Fit: likelihood ratio=158.7666; df=16; p<0.0001 























Cox Proportional Hazard Regression Analysis Comparing the Likelihood of Discontinuation 





95% CI Wald X2 p-value 
Refractorya 0.792 0.744 - 0.844 51.92 <0.0001 
Age at index 0.993 0.986 - 1.001 3.23 0.0724 
Malea 0.827 0.717 - 0.953 6.87 0.0088 
African American racea 1.170 1.035 - 1.323 6.29 0.0122 
Other racea 1.057 0.958 - 1.167 1.22 0.2684 
Partial type of epilepsy at first visita 0.855 0.688 - 1.063 1.98 0.1595 
Other type of epilepsy at first visita 0.811 0.637 - 1.034 2.85 0.0913 
Multiple actions of index AEDa 0.953 0.871 - 1.043 1.08 0.2986 
Baseline CCI of 1a 1.052 0.922 - 1.200 0.70 0.4514 
Baseline CCI greater than 1a 0.901 0.725 - 1.120 0.88 0.3484 
Number of psychiatric comorbidities at follow-up 1.015 0.980 - 1.051 0.71 0.4008 
Non-psychiatric comorbidities at follow-upa 1.002 0.913 - 1.100 0.00 0.9639 
Baseline pill burden 1.034 0.992 - 1.078 2.54 0.1111 
Baseline all-cause inpatient visitsa 1.075 0.953 - 1.213 1.39 0.2378 
Number of baseline all-cause outpatient visits 0.999 0.996 - 1.003 0.15 0.7014 
Baseline total all-cause healthcare cost 1.000 1.000 – 1.000 1.63 0.2013 
CI=Confidence Interval; AED=Antiepileptic drug; CCI=Charlson Comorbidity Index 
aReference categories: Non-refractory; Female; Caucasian; Generalized type of epilepsy; Single action of   index 
AED; CCI=0; No non-psychiatric comorbidity; No baseline inpatient visit 
Note: Some variable categories were collapsed due to small cell sizes. 
Race/Ethnicity into three groups (Caucasian, African American and Other);  
Type of epilepsy into three groups (Generalized, Partial and Other);  
Type of index Antiepileptic drug into two groups (Single and Multiple actions). 
Model Fit: likelihood ratio=80.9658; df=16; p<0.0001 














Comparison of Patient Characteristics by Refractory/Non-Refractory Status (Excluding 






n=5,414 n=2,707 n=2,707 
N % N % N % 
Demographics 
Age at index datea,e 
  Mean ± SD, year 37.9 ± 12.9 37.9 ± 12.6 37.8 ± 13.2 0.7823 
Genderb,e   
Male 2,431 44.9 1,217 45.0 1,214 44.8 
0.9342 
Female 2,983 55.1 1,490 55.0 1,493 55.2 
Race/Ethnicityb,e   
Caucasian 2,241 41.4 1,149 42.4 1,092 40.3 0.1185 
African American 974 18.0 435 16.1 539 19.9 0.0003 
Hispanic 1,819 33.6 936 34.6 883 32.6 0.1293 
Other/Unknown 380 7.0 187 6.9 193 7.1 0.3200 
Clinical Characteristics 
Type of epilepsy at first visitb,e  
Generalized 589 10.9 284 10.5 305 11.3 0.3621 
Partial 450 8.3 235 8.7 215 7.9 0.3221 
Other convulsions 4,193 77.4 2,090 77.2 2,103 77.7 0.6704 
Multiple types 182 3.4 98 3.6 84 3.1 0.2885 
Type of index Antiepileptic drugb  
Sodium channel blockers  1,724 31.8 758 28.0 966 35.7 <0.0001 
GABA analogues 617 11.4 320 11.8 297 11.0 0.3298 
Calcium channel actions 322 5.9 199 7.4 123 4.5 <0.0001 
Multiple actions 1,026 19.0 491 18.1 535 19.8 0.1294 
Synaptic vesicle protein 2A binding 450 8.3 211 7.8 239 8.8 0.1605 
Combination 1,275 23.6 728 26.9 547 20.2 <0.0001 
Baseline Charlson Comorbidity Indexa,b   
Mean ± SDe 0.7 ± 1.4  0.7 ± 1.4 0.8 ± 1.4 0.7740  
0 3,452 63.8 1,744 64.4 1,708 63.1 0.2897 
1 1,009 18.6 500 18.5 509 18.8 0.7468 










Comparison of Patient Characteristics by Refractory/Non-Refractory Status (Excluding 






n=5,414 n=2,707 n=2,707 
N % N % N % 
Number of psychiatric comorbidities (First year)a,d  
  Mean ± SD 1.5 ± 1.3 1.6 ± 1.4 1.4 ± 1.3  <0.0001 
Clinical Characteristics 
Non-psychiatric comorbidities (First year)b,d 
Yes 2,306 42.6 1,261 46.6 1,045 38.6 
<0.0001 
No 3,108 57.4 1,446 53.4 1,662 61.4 
Number of psychiatric comorbidities (Second year)a,d 
  Mean ± SD 1.9  ± 1.4 2.0  ± 1.5  1.8  ± 1.4 <0.0001 
Non-psychiatric comorbidities (Second year)b,d  
Yes 2,550 47.1 1,370 50.6 1,180 43.6 
<0.0001 
No 2,864 52.9 1,337 49.4 1,527 56.4 
Baseline pill burdenc,e 
Median  7 7 8 
0.5581  
(Mean ± SD) (9.0 ± 6.8) (9.1 ± 6.9)  (9.0 ± 6.7) 
Baseline Healthcare Utilization and Cost 
Baseline all-cause inpatient visitb  
Yes 1,092 20.2 551 20.4 541 20.0 
0.7243 
No 4,322 79.8 2,156 79.6 2,166 80.0 
Baseline all-cause outpatient visitc 
Median  11 11 11 
0.5835 
(Mean ± SD) (15.4 ± 15.2) (15.1 ± 14.5) (15.6 ± 15.8) 
Baseline all-cause total healthcare costc,e,f  
Median  7,134 7,557 6,674 
<0.0001 









cWilcoxon signed-rank test 
dMeasured in the follow-up period 
eUsed as predictors of selection in refractory or non-refractory group with caliper set at 0.05(matching) 
fAdjusted to 2013 US dollars 











Comparison of All-Cause Inpatient Hospitalization and ED Visits in the First Year of Follow-
Up by Refractory/Non-Refractory Status (N=5,596) 
 
All Refractory Non-refractory 
p-value 
n=5,596 n=2,798 n=2,798 
N % N % N % 
  Median 
  (Mean ± SD) 
1  
(2.9 ± 5.3) 
2  
(3.5 ± 5.5) 
1  
(2.4 ± 5.0) <0.0001a 
  Yes  3,550 63.4 1,950 69.7 1,600 57.2 
<0.0001b 
  No  2,046 36.6 848 30.3 1,198 42.8 
aWilcoxon signed-rank test 
bMcNemar’s test 

















Zero-Inflated Poisson Regression Comparing the All-Cause Inpatient Hospitalization and 
ED Visits in the First Year of Follow-Up among Refractory/ Non-Refractory Patients 
(N=5,596) 




Refractorya 0.1262 0.0924 - 0.1599 53.59 <0.0001 
Age at index -0.0014 -0.0028 – 0.0000 3.78 0.0519 
Malea -0.0983 -0.132 - -0.0645 32.62 <0.0001 
African American racea 0.2248 0.1826 - 0.2669 109.17 <0.0001 
Other racea -0.0333 -0.0703 - 0.0038 3.10 0.0784 
Partial type of epilepsy at first visita -0.2535 -0.3546 - -0.1524 24.16 <0.0001 
Other type of epilepsy at first visita 0.1387 0.0784 - 0.1991 20.29 <0.0001 
Multiple actions of index AEDa -0.1034 -0.1375 - -0.0693 35.37 <0.0001 
Baseline CCI of 1a 0.1183 0.0763 - 0.1604 30.42 <0.0001 
Baseline CCI greater than 1a 0.2100 0.1655 - 0.2545 85.6 <0.0001 
Number of psychiatric comorbidities at follow-up 0.2807 0.2694 - 0.2921 2356.46 <0.0001 
Non-psychiatric comorbidities at follow-upa 0.4600 0.4228 - 0.4972 588.28 <0.0001 
Baseline pill burden 0.0008 -0.0013 - 0.0029 0.60 0.4383 
Baseline all-cause inpatient visitsa 0.2340 0.1967 - 0.2714 150.79 <0.0001 
Number of baseline all-cause outpatient visits 0.0079 0.0068 - 0.0090 199.98 <0.0001 
Baseline total all-cause healthcare cost 0.0000 -0.0000 – 0.0000 15.40 <0.0001 
CI=Confidence Interval; AED=Antiepileptic drug; CCI=Charlson Comorbidity Index 
aReference categories: Non-refractory; Female; Caucasian; Generalized type of epilepsy; Single action of   index 
AED; CCI=0; No non-psychiatric comorbidity; No baseline inpatient visit 
Note: Some variable categories were collapsed due to small cell sizes. 
Race/Ethnicity into three groups (Caucasian, African American and Other);  
Type of epilepsy into three groups (Generalized, Partial and Other);  
Type of index Antiepileptic drug into two groups (Single and Multiple actions). 
Model Fit: likelihood ratio chi-squared=5573.18; df=16; p<0.0001;  
Vuong test of ZIP vs. standard Poisson: z=12.70; p<0.0001; 



















Comparison of All-Cause Outpatient Visits in the First Year of Follow-Up by 
Refractory/Non-Refractory Status (N=5,596) 
 
All Refractory Non-refractory 
p-value 
n=5,596 n=2,798 n=2,798 
N % N % N % 
  Median 
  (Mean ± SD) 
28  
(39.1 ± 37.2) 
31  
(41.5 ± 37.5) 
26  
(36.6 ± 36.7) <0.0001a 
  Yes  5,588 99.9 2,793 99.8 2,795 99.9 
0.4795b 
  No  8 0.1 5 0.2 3 0.1 
aWilcoxon signed-rank test 
bMcNemar’s test 








































Zero-Inflated Poisson Regression Comparing the All-Cause Outpatient Visits in the First 
Year of Follow-Up among Refractory/ Non-Refractory Patients (N=5,596) 




Refractorya 0.1107 0.1021 - 0.1193 639.06 <0.0001 
Age at index 0.0019 0.0015 - 0.0022 102.67 <0.0001 
Malea -0.0549 -0.0636 - -0.0462 151.72 <0.0001 
African American racea 0.0782 0.0664 - 0.09 168.63 <0.0001 
Other racea 0.0871 0.0777 - 0.0965 330.31 <0.0001 
Partial type of epilepsy at first visita -0.0671 -0.0882 - -0.0459 38.64 <0.0001 
Other type of epilepsy at first visita 0.0472 0.0333 - 0.0612 44.23 <0.0001 
Multiple actions of index AEDa -0.0574 -0.0662 - -0.0486 162.5 <0.0001 
Baseline CCI of 1a 0.1631 0.152 - 0.1741 834.67 <0.0001 
Baseline CCI greater than 1a 0.1708 0.1588 - 0.1828 776.28 <0.0001 
Number of psychiatric comorbidities at follow-up 0.1213 0.1181 - 0.1244 5731.1 <0.0001 
Non-psychiatric comorbidities at follow-upa 0.1938 0.1847 - 0.2029 1746.22 <0.0001 
Baseline pill burden 0.0056 0.005 - 0.0062 372.42 <0.0001 
Baseline all-cause inpatient visitsa 0.0090 -0.0015 - 0.0194 2.84 0.0921 
Number of baseline all-cause outpatient visits 0.0203 0.0201 - 0.0205 42732.1 <0.0001 
Baseline total all-cause healthcare cost 0.0000 -0.0000 – 0.0000 334.33 <0.0001 
CI=Confidence Interval; AED=Antiepileptic drug; CCI=Charlson Comorbidity Index 
aReference categories: Non-refractory; Female; Caucasian; Generalized type of epilepsy; Single action of   index 
AED; CCI=0; No non-psychiatric comorbidity; No baseline inpatient visit 
Note: Some variable categories were collapsed due to small cell sizes. 
Race/Ethnicity into three groups (Caucasian, African American and Other);  
Type of epilepsy into three groups (Generalized, Partial and Other);  
Type of index Antiepileptic drug into two groups (Single and Multiple actions). 
Model Fit: likelihood ratio chi-squared= 81743.18; df=16; p<0.0001;  
Vuong test of ZIP vs. standard Poisson: z=2.38; p=0.0086  ; 


















Comparison of Epilepsy-Related Inpatient Hospitalization and ED Visits in the First Year 
of Follow-Up by Refractory/ Non-Refractory Status (N=5,596) 
 
All Refractory Non-refractory 
p-value 
n=5,596 n=2,798 n=2,798 
N % N % N % 
  Median 
  (Mean ± SD) 
0  
(0.9 ± 2.1) 
0  
(1.3 ± 2.6) 
0  
(0.6 ± 1.3) <0.0001a 
  Yes  2,226 39.8 1,360 48.6 866 31.0 
<0.0001b 
  No  3,370 60.2 1,438 51.4 1,932 69.1 
aWilcoxon signed-rank test 
bMcNemar’s test 

















Zero-Inflated Poisson Regression Comparing the Epilepsy-Related Inpatient Hospitalization 
and ED Visits in the First Year of Follow-Up among Refractory/ Non-Refractory Patients 
(N=5,596) 




Refractorya 0.3688 0.2946 - 0.4431 94.73 <0.0001 
Age at index -0.0060 -0.0086 - -0.0033 19.17 <0.0001 
Malea 0.0354 -0.0267 - 0.0975 1.25 0.2641 
African American racea 0.2410 0.1597 - 0.3224 33.73 <0.0001 
Other racea 0.0873 0.0188 - 0.1558 6.24 0.0125 
Partial type of epilepsy at first visita -0.1140 -0.2767 - 0.0487 1.89 0.1697 
Other type of epilepsy at first visita 0.0994 -0.0081 - 0.2069 3.28 0.0700 
Multiple actions of index AEDa 0.0333 -0.0291 - 0.0956 1.09 0.2954 
Baseline CCI of 1a 0.0331 -0.0474 - 0.1135 0.65 0.4204 
Baseline CCI greater than 1a 0.0218 -0.0680 - 0.1117 0.23 0.6336 
Number of psychiatric comorbidities at follow-up 0.2357 0.2143 - 0.2572 465.37 <0.0001 
Non-psychiatric comorbidities at follow-upa 0.4626 0.3945 - 0.5306 177.34 <0.0001 
Baseline pill burden -0.0191 -0.0238 - -0.0144 63.34 <0.0001 
Baseline all-cause inpatient visitsa 0.2879 0.2139 - 0.3619 58.11 <0.0001 
Number of baseline all-cause outpatient visits 0.0038 0.0014 - 0.0062 9.61 0.0019 
Baseline total all-cause healthcare cost 0.0000 -0.0000 – 0.0000 0.29 0.5880 
CI=Confidence Interval; AED=Antiepileptic drug; CCI=Charlson Comorbidity Index 
aReference categories: Non-refractory; Female; Caucasian; Generalized type of epilepsy; Single action of   index 
AED; CCI=0; No non-psychiatric comorbidity; No baseline inpatient visit 
Note: Some variable categories were collapsed due to small cell sizes. 
Race/Ethnicity into three groups (Caucasian, African American and Other);  
Type of epilepsy into three groups (Generalized, Partial and Other);  
Type of index Antiepileptic drug into two groups (Single and Multiple actions). 
Model Fit: likelihood ratio chi-squared=1096.18; df=16; p<0.0001; 
Vuong test of ZIP vs. standard Poisson: z=10.51; p<0.0001; 











Comparison of Epilepsy-Related Outpatient Visits in the First Year of Follow-Up by 
Refractory/ Non-Refractory Status (N=5,596) 
 
All Refractory Non-refractory 
p-value 
n=5,596 n=2,798 n=2,798 
N % N % N % 
  Median 
  (Mean ± SD) 
5  
(7.7 ± 11.6) 
6  
(9.1 ± 12.2) 
4  
(6.4 ± 10.8) <0.0001a 
  Yes  5,352 95.6 2,713 97.0 2,639 94.3 
<0.0001b 
  No  244 4.4 85 3.0 159 5.7 
aWilcoxon signed-rank test 
bMcNemar’s test 

















Zero-Inflated Poisson Regression Comparing the Epilepsy-Related Outpatient Visits in the 
First Year of Follow-Up among Refractory/Non-Refractory Patients (N=5,596) 




Refractorya 0.3187 0.2991 - 0.3383 1018.13 <0.0001 
Age at index -0.0063 -0.0072 - -0.0055 235.9 <0.0001 
Malea 0.0388 0.0194 - 0.0582 15.36 <0.0001 
African American racea 0.0220 -0.0054 - 0.0494 2.47 0.1157 
Other racea 0.1187 0.0977 - 0.1397 122.66 <0.0001 
Partial type of epilepsy at first visita -0.2425 -0.2881 - -0.197 108.95 <0.0001 
Other type of epilepsy at first visita -0.0438 -0.0733 - -0.0144 8.51 0.0035 
Multiple actions of index AEDa -0.0630 -0.0828 - -0.0433 39.22 <0.0001 
Baseline CCI of 1a 0.0989 0.0734 - 0.1243 58.1 <0.0001 
Baseline CCI greater than 1a 0.0245 -0.0042 - 0.0532 2.81 0.0939 
Number of psychiatric comorbidities at follow-up 0.0623 0.0551 - 0.0696 283.65 <0.0001 
Non-psychiatric comorbidities at follow-upa 0.1684 0.1480 - 0.1888 261.52 <0.0001 
Baseline pill burden -0.0115 -0.0130 - -0.0100 229.75 <0.0001 
Baseline all-cause inpatient visitsa 0.0383 0.0131 - 0.0635 8.85 0.0029 
Number of baseline all-cause outpatient visits 0.0134 0.0128 - 0.0139 2597.89 <0.0001 
Baseline total all-cause healthcare cost -0.0000 -0.0000 – 0.0000 0.000 0.9854 
CI=Confidence Interval; AED=Antiepileptic drug; CCI=Charlson Comorbidity Index 
aReference categories: Non-refractory; Female; Caucasian; Generalized type of epilepsy; Single action of   index 
AED; CCI=0; No non-psychiatric comorbidity; No baseline inpatient visit 
Note: Some variable categories were collapsed due to small cell sizes. 
Race/Ethnicity into three groups (Caucasian, African American and Other);  
Type of epilepsy into three groups (Generalized, Partial and Other);  
Type of index Antiepileptic drug into two groups (Single and Multiple actions). 
Model Fit: likelihood ratio chi-squared=5744.05; df=16; p<0.0001; 
Vuong test of ZIP vs. standard Poisson: z=9.68; p<0.0001; 












Comparison of All-Cause Pharmacy Visits in the First Year of Follow-Up by Refractory/ 
Non-Refractory Status (N=5,596) 
 
All Refractory Non-refractory 
p-value 
n=5,596 n=2,798 n=2,798 
N % N % N % 
  Median 
  (Mean ± SD) 
8  
(9.7 ± 6.4) 
9  
(10.6 ± 6.7) 
8  
(8.8 ± 6.0) <0.0001a 
  Yes  5,596 100.0 2,798 100.0 2,798 100.0 
 
  No  0 0.0 0 0.0 0 0.0 
aWilcoxon signed-rank test 























Poisson Regression Comparing the All-Cause Pharmacy Claims in the First Year of Follow-
Up among Refractory/ Non-Refractory Patients (N=5,596) 




Refractorya 0.1470 0.1298 - 0.1642 280.38 <0.0001 
Age at index 0.0027 0.002 - 0.0034 53.31 <0.0001 
Malea -0.0838 -0.1015 - -0.0661 86.09 <0.0001 
African American racea -0.0328 -0.0565 - -0.0091 7.36 0.0067 
Other racea -0.037 -0.0559 - -0.0182 14.83 0.0001 
Partial type of epilepsy at first visita -0.0599 -0.1026 - -0.0172 7.56 0.0060 
Other type of epilepsy at first visita 0.0302 0.0023 - 0.0581 4.49 0.0342 
Multiple actions of index AEDa -0.0728 -0.0905 - -0.0552 65.32 <0.0001 
Baseline CCI of 1a 0.1354 0.1132 - 0.1576 142.81 <0.0001 
Baseline CCI greater than 1a 0.1255 0.1009 - 0.1501 99.80 <0.0001 
Number of psychiatric comorbidities at follow-up 0.0786 0.0722 - 0.085 579.39 <0.0001 
Non-psychiatric comorbidities at follow-upa 0.1407 0.1226 - 0.1589 231.20 <0.0001 
Baseline pill burden 0.0353 0.0342 - 0.0364 3982.91 <0.0001 
Baseline all-cause inpatient visitsa 0.0162 -0.0052 - 0.0376 2.21 0.1368 
Number of baseline all-cause outpatient visits 0.0012 0.0005 - 0.0018 12.79 0.0003 
Baseline total all-cause healthcare cost 0.0000 0.0000 – 0.0000 17.34 <0.0001 
CI=Confidence Interval; AED=Antiepileptic drug; CCI=Charlson Comorbidity Index 
aReference categories: Non-refractory; Female; Caucasian; Generalized type of epilepsy; Single action of   index 
AED; CCI=0; No non-psychiatric comorbidity; No baseline inpatient visit 
Note: Some variable categories were collapsed due to small cell sizes. 
Race/Ethnicity into three groups (Caucasian, African American and Other);  
Type of epilepsy into three groups (Generalized, Partial and Other);  
Type of index Antiepileptic drug into two groups (Single and Multiple actions). 
Model Fit: likelihood ratio chi-squared=11338.26; df=16; p<0.0001; 


















Comparison of Epilepsy-Related Pharmacy Claims in the First Year of Follow-Up by 
Refractory/ Non-Refractory Status (N=5,596) 
 
All Refractory Non-refractory 
p-value 
n=5,596 n=2,798 n=2,798 
N % N % N % 
  Median 
  (Mean ± SD) 
2  
(2.7 ± 1.5) 
3 
(3.6 ± 1.4) 
2  
(1.7 ± 0.9) <0.0001a 
  Yes  5,596 100.0 2,798 100.0 2,798 100.0 
 
  No  0 0.0 0 0.0 0 0.0 
aWilcoxon signed-rank test 


















Poisson Regression Comparing the Epilepsy-Related Pharmacy Claims in the First Year of 
Follow-Up among Refractory/ Non-Refractory Patients (N=5,596) 




Refractorya 0.7341 0.6993 - 0.7688 1714.56 <0.0001 
Age at index -0.0024 -0.0037 - -0.001 11.32 0.0008 
Malea -0.0085 -0.0414 - 0.0245 0.25 0.6147 
African American racea -0.0272 -0.073 - 0.0186 1.35 0.2451 
Other racea -0.0222 -0.0577 - 0.0133 1.50 0.2200 
Partial type of epilepsy at first visita -0.0138 -0.0883 - 0.0608 0.13 0.7171 
Other type of epilepsy at first visita -0.0087 -0.0602 - 0.0427 0.11 0.7387 
Multiple actions of index AEDa -0.1476 -0.181 - -0.1142 74.99 <0.0001 
Baseline CCI of 1a -0.0218 -0.0662 - 0.0225 0.93 0.3343 
Baseline CCI greater than 1a -0.0004 -0.0491 - 0.0484 0.00 0.9879 
Number of psychiatric comorbidities at follow-up 0.0522 0.0399 - 0.0645 69.32 <0.0001 
Non-psychiatric comorbidities at follow-upa 0.0585 0.0241 - 0.0929 11.10 0.0009 
Baseline pill burden 0.0058 0.0033 - 0.0083 21.05 <0.0001 
Baseline all-cause inpatient visitsa 0.0470 0.0038 - 0.0902 4.55 0.0329 
Number of baseline all-cause outpatient visits 0.0000 -0.0013 - 0.0012 0.01 0.9424 
Baseline total all-cause healthcare cost -0.0000 -0.0000 – 0.0000 0.00 0.9673 
CI=Confidence Interval; AED=Antiepileptic drug; CCI=Charlson Comorbidity Index 
aReference categories: Non-refractory; Female; Caucasian; Generalized type of epilepsy; Single action of   index 
AED; CCI=0; No non-psychiatric comorbidity; No baseline inpatient visit 
Note: Some variable categories were collapsed due to small cell sizes. 
Race/Ethnicity into three groups (Caucasian, African American and Other);  
Type of epilepsy into three groups (Generalized, Partial and Other);  
Type of index Antiepileptic drug into two groups (Single and Multiple actions). 
Model Fit: likelihood ratio chi-squared=2182.72; df=16; p<0.0001  ;  


















Comparison of Cost of All-Cause Inpatient Hospitalization and ED Visits in the First Year 
of Follow-Up by Refractory/ Non-Refractory Status (N=5,596) 
 
All Refractory Non-refractory 
p-value n=5,596 n=2,798 n=2,798 
  Median 
  (Mean ± SD) 
$118 
($3,680 ± $10,824) 
$239 
($4,136 ± $9,663) 
$65 
($3,224 ± $11,858) <0.0001a 
aWilcoxon signed-rank test 


















Generalized Linear Model Comparing the Cost of All-Cause Inpatient Hospitalization and 
ED Visits in the First Year of Follow-Up among Refractory/ Non-Refractory Patients 
(N=5,596) 
 Estimate 95% CI z p-value 
Refractorya 0.3756 0.2136 - 0.5375 4.55 <0.0001 
Age at index -0.0012 -0.0075 - 0.0051 -0.36 0.7190 
Malea 0.0320 -0.1288 - 0.1928 0.39 0.6960 
African American racea 0.1836 -0.0382 - 0.4054 1.62 0.1050 
Other racea -0.0402 -0.2154 - 0.1350 -0.45 0.6530 
Partial type of epilepsy at first visita 0.1485 -0.2155 - 0.51253 0.80 0.4240 
Other type of epilepsy at first visita 0.2263 -0.0193 - 0.4719 1.81 0.0710 
Multiple actions of index AEDa -0.1906 -0.3538 - -0.0274 -2.29 0.0220 
Baseline CCI of 1a 0.3051 0.0908 - 0.5194 2.79 0.0050 
Baseline CCI greater than 1a 0.4297 0.1948 - 0.6647 3.58 <0.0001 
Number of psychiatric comorbidities at follow-up 0.3421 0.2815 - 0.4028 11.06 <0.0001 
Non-psychiatric comorbidities at follow-upa 0.5796 0.4136 - 0.7455 6.85 <0.0001 
Baseline pill burden 0.0115 -0.0009 - 0.0239 1.82 0.0680 
Baseline all-cause inpatient visitsa 0.6045 0.3939 - 0.8151 5.63 <0.0001 
Number of baseline all-cause outpatient visits 0.0019 -0.0050 - 0.0088 0.54 0.5900 
Baseline total all-cause healthcare cost 0.0000 0.0000 - 0.0000 4.26 <0.0001 
CI=Confidence Interval; AED=Antiepileptic drug; CCI=Charlson Comorbidity Index 
aReference categories: Non-refractory; Female; Caucasian; Generalized type of epilepsy; Single action of   index 
AED; CCI=0; No non-psychiatric comorbidity; No baseline inpatient visit 
Note: Some variable categories were collapsed due to small cell sizes. 
Race/Ethnicity into three groups (Caucasian, African American and Other);  
Type of epilepsy into three groups (Generalized, Partial and Other);  
Type of index Antiepileptic drug into two groups (Single and Multiple actions). 





















Comparison of Cost of All-Cause Outpatient Visits in the First Year of Follow-Up by 
Refractory/ Non-Refractory Status (N=5,596) 
 
All Refractory Non-refractory 
p-value n=5,596 n=2,798 n=2,798 
  Median 
  (Mean ± SD) 
$4,260  
($9,705 ± $19,095) 
$4,925  
($10,025 ± $17,760) 
$3,682  
($9,384 ± $20,341) <0.0001a 
aWilcoxon signed-rank test 


















Generalized Linear Model Comparing the Cost of All-Cause Outpatient Visits in the First 
Year of Follow-Up among Refractory/ Non-Refractory Patients (N=5,596) 
 Estimate 95% CI z p-value 
Refractorya 0.1685 0.0962 - 0.2408 4.57 <0.0001 
Age at index -0.0013 -0.0042 - 0.0016 -0.86 0.3900 
Malea -0.0642 -0.1368 - 0.0085 -1.73 0.0830 
African American racea 0.1525 0.0534 - 0.2515 3.02 <0.0001 
Other racea 0.0716 -0.0066 - 0.1499 1.79 0.0730 
Partial type of epilepsy at first visita -0.1005 -0.2626 - 0.0616 -1.22 0.2240 
Other type of epilepsy at first visita 0.1139 0.0028 - 0.2249 2.01 0.0440 
Multiple actions of index AEDa -0.0926 -0.1662 - -0.0190 -2.47 0.0140 
Baseline CCI of 1a 0.2014 0.1046 - 0.2981 4.08 <0.0001 
Baseline CCI greater than 1a 0.2237 0.1180 - 0.3293 4.15 <0.0001 
Number of psychiatric comorbidities at follow-up 0.0884 0.0606 - 0.1162 6.23 <0.0001 
Non-psychiatric comorbidities at follow-upa 0.2544 0.1784 - 0.3305 6.56 <0.0001 
Baseline pill burden -0.0064 -0.01201 - -0.0007 -2.21 0.0270 
Baseline all-cause inpatient visitsa -0.0840 -0.1801 - 0.0122 -1.71 0.0870 
Number of baseline all-cause outpatient visits 0.0274 0.0235 - 0.0313 13.7 <0.0001 
Baseline total all-cause healthcare cost 0.0000 0.0000 - 0.0000 11.38 <0.0001 
CI=Confidence Interval; AED=Antiepileptic drug; CCI=Charlson Comorbidity Index 
aReference categories: Non-refractory; Female; Caucasian; Generalized type of epilepsy; Single action of   index 
AED; CCI=0; No non-psychiatric comorbidity; No baseline inpatient visit 
Note: Some variable categories were collapsed due to small cell sizes. 
Race/Ethnicity into three groups (Caucasian, African American and Other);  
Type of epilepsy into three groups (Generalized, Partial and Other);  
Type of index Antiepileptic drug into two groups (Single and Multiple actions). 

























Comparison of Cost of Epilepsy-Related Inpatient Hospitalization and ED Visits in the First 
Year of Follow-Up by Refractory/ Non-Refractory Status (N=5,596) 
 
All Refractory Non-refractory 
p-value n=5,596 n=2,798 n=2,798 
  Median 
  (Mean ± SD) 
$0  
($1,583 ± $5,409) 
$0  
($2,077 ± $6,156) 
$0  
($1,091 ± $4,488) <0.0001a 
aWilcoxon signed-rank test 


















Generalized Linear Model Comparing the Cost of Epilepsy-Related Inpatient 
Hospitalization and ED Visits in the First Year of Follow-Up among Refractory/ Non-
Refractory Patients (N=5,596) 
 Estimate 95% CI z p-value 
Refractorya 0.6104 0.4260 - 0.7947 6.49 <0.0001 
Age at index 0.0012 -0.0059 - 0.0084 0.33 0.7380 
Malea 0.0874 -0.0966 - 0.2715 0.93 0.3520 
African American racea 0.0068 -0.2420 - 0.2557 0.05 0.9570 
Other racea -0.0217 -0.2177 - 0.1744 -0.22 0.8290 
Partial type of epilepsy at first visita 0.1422 -0.2691 - 0.5534 0.68 0.4980 
Other type of epilepsy at first visita 0.1187 -0.1587 - 0.3961 0.84 0.4020 
Multiple actions of index AEDa -0.1353 -0.3210 - 0.0505 -1.43 0.1540 
Baseline CCI of 1a -0.0298 -0.2740 - 0.2143 -0.24 0.8110 
Baseline CCI greater than 1a -0.0116 -0.2750 - 0.2518 -0.09 0.9310 
Number of psychiatric comorbidities at follow-up 0.3255 0.2562 - 0.3948 9.21 <0.0001 
Non-psychiatric comorbidities at follow-upa 0.5313 0.3439 - 0.71869 5.56 <0.0001 
Baseline pill burden -0.0068 -0.02079 - 0.00729 -0.95 0.3430 
Baseline all-cause inpatient visitsa 0.7032 0.4662 - 0.9403 5.81 <0.0001 
Number of baseline all-cause outpatient visits -0.0025 -0.0096 - 0.0047 -0.67 0.5020 
Baseline total all-cause healthcare cost 0.0000 0.0000 - 0.0000 3.70 <0.0001 
CI=Confidence Interval; AED=Antiepileptic drug; CCI=Charlson Comorbidity Index 
aReference categories: Non-refractory; Female; Caucasian; Generalized type of epilepsy; Single action of   index 
AED; CCI=0; No non-psychiatric comorbidity; No baseline inpatient visit 
Note: Some variable categories were collapsed due to small cell sizes. 
Race/Ethnicity into three groups (Caucasian, African American and Other);  
Type of epilepsy into three groups (Generalized, Partial and Other);  
Type of index Antiepileptic drug into two groups (Single and Multiple actions). 





















Comparison of Cost of Epilepsy-Related Outpatient Visits in the First Year of Follow-Up by 
Refractory/ Non-Refractory Status (N=5,596) 
 
All Refractory Non-refractory 
p-value n=5,596 n=2,798 n=2,798 
  Median 
  (Mean ± SD) 
$577  
($1,741 ± $6,418) 
$821  
($1,980 ± $5,716) 
$400  
($1,503 ± $7,044) <0.0001a 
aWilcoxon signed-rank test 


















Generalized Linear Model Comparing the Cost of Epilepsy-Related Outpatient Visits in the 
First Year of Follow-Up among Refractory/ Non-Refractory Patients (N=5,596) 
 Estimate 95% CI z p-value 
Refractorya 0.3900 0.2882 - 0.4918 7.51 <0.0001 
Age at index -0.0107 -0.0149 - -0.0066 -5.05 <0.0001 
Malea -0.0488 -0.1517 - 0.0542 -0.93 0.3530 
African American racea 0.1634 0.0235 - 0.3032 2.29 0.0220 
Other racea 0.0534 -0.0575 - 0.1643 0.94 0.3450 
Partial type of epilepsy at first visita -0.1608 -0.3903 - 0.0688 -1.37 0.1700 
Other type of epilepsy at first visita 0.0650 -0.0915 - 0.2216 0.81 0.4150 
Multiple actions of index AEDa -0.0716 -0.1753 - 0.03212 -1.35 0.1760 
Baseline CCI of 1a 0.1726 0.03604 - 0.3093 2.48 0.0130 
Baseline CCI greater than 1a 0.1239 -0.02481 - 0.2726 1.63 0.1020 
Number of psychiatric comorbidities at follow-up 0.0878 0.0476 - 0.1279 4.29 <0.0001 
Non-psychiatric comorbidities at follow-upa 0.3027 0.1961 - 0.4094 5.56 <0.0001 
Baseline pill burden -0.0209 -0.0288 - -0.0130 -5.21 <0.0001 
Baseline all-cause inpatient visitsa -0.2088 -0.3403 - -0.0772 -3.11 0.0020 
Number of baseline all-cause outpatient visits 0.0111 0.0064 - 0.0158 4.66 <0.0001 
Baseline total all-cause healthcare cost 0.0000 0.0000 - 0.0000 10.19 <0.0001 
CI=Confidence Interval; AED=Antiepileptic drug; CCI=Charlson Comorbidity Index 
aReference categories: Non-refractory; Female; Caucasian; Generalized type of epilepsy; Single action of   index 
AED; CCI=0; No non-psychiatric comorbidity; No baseline inpatient visit 
Note: Some variable categories were collapsed due to small cell sizes. 
Race/Ethnicity into three groups (Caucasian, African American and Other);  
Type of epilepsy into three groups (Generalized, Partial and Other);  
Type of index Antiepileptic drug into two groups (Single and Multiple actions). 






















Comparison of Cost of All-Cause Pharmacy Claims in the First Year of Follow-Up by 
Refractory/ Non-Refractory Status (N=5,596) 
 
All Refractory Non-refractory 
p-value n=5,596 n=2,798 n=2,798 
  Median 
  (Mean ± SD) 
$7,875  
($10,190 ± $12,267) 
$9,998  
($11,857 ± $9,058) 
$5,780  
($8,525 ± $14,607) <0.0001a 
aWilcoxon signed-rank test 


















Generalized Linear Model Comparing the Cost of All-Cause Pharmacy Claims in the First 
Year of Follow-Up among Refractory/ Non-Refractory Patients (N=5,596) 
 Estimate 95% CI z p-value 
Refractorya 0.3646 0.3205 - 0.4086 16.23 <0.0001 
Age at index -0.0043 -0.0061 - -0.0024 -4.48 <0.0001 
Malea 0.0537 0.0090 - 0.0983 2.35 0.0190 
African American racea -0.1621 -0.2232 - -0.1011 -5.20 <0.0001 
Other racea -0.0859 -0.1343 - -0.0375 -3.48 0.0010 
Partial type of epilepsy at first visita 0.0969 -0.0036 - 0.1974 1.89 0.0590 
Other type of epilepsy at first visita -0.1309 -0.1997 - -0.0620 -3.73 <0.0001 
Multiple actions of index AEDa 0.2149 0.1698 - 0.2600 9.34 <0.0001 
Baseline CCI of 1a -0.0448 -0.1054 - 0.0158 -1.45 0.1480 
Baseline CCI greater than 1a 0.0137 -0.0531 - 0.0804 0.40 0.6880 
Number of psychiatric comorbidities at follow-up 0.0768 0.0593 - 0.0943 8.60 <0.0001 
Non-psychiatric comorbidities at follow-upa -0.0139 -0.0608 - 0.0330 -0.58 0.5610 
Baseline pill burden 0.0430 0.0392 - 0.0469 22.08 <0.0001 
Baseline all-cause inpatient visitsa -0.2224 -0.2825 - -0.1624 -7.26 <0.0001 
Number of baseline all-cause outpatient visits -0.0058 -0.0074 - -0.0041 -6.92 <0.0001 
Baseline total all-cause healthcare cost 0.0000 0.0000 - 0.0000 16.49 <0.0001 
CI=Confidence Interval; AED=Antiepileptic drug; CCI=Charlson Comorbidity Index 
aReference categories: Non-refractory; Female; Caucasian; Generalized type of epilepsy; Single action of   index 
AED; CCI=0; No non-psychiatric comorbidity; No baseline inpatient visit 
Note: Some variable categories were collapsed due to small cell sizes. 
Race/Ethnicity into three groups (Caucasian, African American and Other);  
Type of epilepsy into three groups (Generalized, Partial and Other);  
Type of index Antiepileptic drug into two groups (Single and Multiple actions). 


























Comparison of Cost of Epilepsy-Related Pharmacy Claims in the First Year of Follow-Up 
by Refractory/ Non-Refractory Status (N=5,596) 
 
All Refractory Non-refractory 
p-value n=5,596 n=2,798 n=2,798 
  Median 
  (Mean ± SD) 
$2,904  
($4,783 ± $5,634) 
$5,094  
($6,810 ± $6,499) 
$1,422  
($2,756 ± $3,610) <0.0001a 
aWilcoxon signed-rank test 


















Generalized Linear Model Comparing the Cost of Epilepsy-Related Pharmacy Claims in the 
First Year of Follow-Up among Refractory/Non-Refractory Patients (N=5,596) 
 Estimate 95% CI z p-value 
Refractorya 0.8967 0.8403 - 0.9531 31.17 <0.0001 
Age at index -0.0157 -0.0181 - -0.0133 -12.96 <0.0001 
Malea -0.0226 -0.0799 - 0.0345 -0.78 0.4380 
African American racea -0.2301 -0.3082- -0.1520 -5.77 <0.0001 
Other racea -0.0661 -0.1281 - -0.0040 -2.09 0.0370 
Partial type of epilepsy at first visita 0.1352 0.0068 - 0.2637 2.06 0.0390 
Other type of epilepsy at first visita -0.2279 -0.31606 - -0.1398 -5.07 <0.0001 
Multiple actions of index AEDa 0.3903 0.3330 - 0.4477 13.34 <0.0001 
Baseline CCI of 1a -0.1948 -0.2726- -0.1171 -4.91 <0.0001 
Baseline CCI greater than 1a -0.2420 -0.3281 - -0.1559 -5.51 <0.0001 
Number of psychiatric comorbidities at follow-up -0.0740 -0.0967 - -0.0512 -6.38 <0.0001 
Non-psychiatric comorbidities at follow-upa -0.0501 -0.1101 - 0.0099 -1.64 0.1020 
Baseline pill burden 0.0176 0.0126 - 0.0227 6.84 <0.0001 
Baseline all-cause inpatient visitsa -0.1992 -0.2763 - -0.1221 -5.06 <0.0001 
Number of baseline all-cause outpatient visits -0.0031 -0.0053 - -0.0009 -2.73 <0.0001 
Baseline total all-cause healthcare cost 0.0000 0.0000 - 0.0000 7.14 <0.0001 
CI=Confidence Interval; AED=Antiepileptic drug; CCI=Charlson Comorbidity Index 
aReference categories: Non-refractory; Female; Caucasian; Generalized type of epilepsy; Single action of   index 
AED; CCI=0; No non-psychiatric comorbidity; No baseline inpatient visit 
Note: Some variable categories were collapsed due to small cell sizes. 
Race/Ethnicity into three groups (Caucasian, African American and Other);  
Type of epilepsy into three groups (Generalized, Partial and Other);  
Type of index Antiepileptic drug into two groups (Single and Multiple actions). 
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